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ABSTRACT 
For regenerative medicine applications, a common limitation to biomaterial cultures and 
implants is nutrient transport. Unlike native tissue which contains a dense vascular network to 
provide nutrients and eliminate waste, biomaterials rely solely on diffusive transport which is 
often insufficient at maintaining cellular behavior of implants, diminishing their efficacy. Many 
strategies seek to prevascularize these de novo tissue constructs using traditional tissue 
engineering techniques such as including cocultures of pro-angiogenic cells or the delivery of 
angiogenic factors within the biomaterials to direct cellular behavior. These methods have not 
shown the capacity to recreate the complexity of neovascular processes. The work described in 
this thesis develops an angiogenic tissue model to improve general understanding of how native 
vascular processes translate to vascularization in an in vitro environment and to develop new 
techniques to efficiently pre-vascularize biomaterials. The intent of this model is to incorporate 
biological cues inspired by a physiological vascularization process that occurs within the 
endometrium, the lining of the uterus.  Since endometrial vascularization is orchestrated by 
changes in sex hormones estradiol and progesterone in vivo, we chose to develop an endometrial 
inspired 3D vasculogenic culture in vitro. We culture endometrial epithelial and stromal cells 
with non-endometrial endothelial cells in both porous collagen scaffolds and gelatin hydrogel 
biomaterial environments in order to monitor pro-angiogenic processes. Additionally, we explore 
how traditional tissue engineering and nature-inspired methods can be combined to present not 
only traditional angiogenic driving cues (i.e. vascular endothelial growth factor) but additional 
pro-angiogenic cues such as estradiol within these biomaterial constructs to promote pro-
angiogenic events.  
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CHAPTER 1: INTRODUCTION AND BACKGROUND: DEVELOPMENT OF 
ANGIOGENIC ENDOMETRIAL MODELS IN VITRO 
In this dissertation I describe the development of three-dimensional biomaterial models of 
endometrial cell activity to explore physiologically inspired vascular processes in vitro. These 
processes associated with vascular growth and remodeling in the endometrium provide a rich set 
of data regarding temporal and spatial changes in pro-angiogenic cues to motivate efforts to 
efficiently pre-vascularize biomaterial constructs for regenerative medicine purposes. To this 
end, this thesis first describes the culture of non-endometrial endothelial cells with endometrial 
epithelial and/or stromal cells within two distinct biomaterials previously used for tissue 
engineering applications, a porous collagen glycosaminoglycan scaffold and a gelatin 
methacrylate hydrogel. This work then evaluates the effect of sex hormones on these cultures for 
their ability to induce a vascularizing response which could tune vascularization within these 
cocultures.  
1.1 Significance 
Tissue engineering is stinted by our inability to develop biomaterials that adequately exchange 
nutrients and cellular waste. Over the past few decades, researchers have sought to resolve this 
issue by developing methods to introduce vascularization, the formation of blood vessels, in 
materials used for regeneration in vitro. While these methods have become more complex by 
adding  multiple biological factors, tuning material properties, and incorporating additional 
supporting cell types, these endeavors lack a strong physiological, especially non-pathological, 
basis. This thesis therefore hopes to exploit the robust angiogenic properties of the endometrium 
and explore these physiological dynamics within three-dimensional cultures. These models will 
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use cocultures of endometrial cells with biomaterials and additionally seek methods to 
incorporate hormones and angiogenic cues. 
1.2 Perspective 
The endometrium undergoes rapid, robust growth every menstrual cycle in order to prepare a 
dense network of vessels to support embryo implantation. This rapid development and 
remodeling of vascular networks mirrors an acute need in tissue engineering to rapidly increase 
biotransport capabilities to support the growth of functional tissues for regenerating damaged or 
diseased tissue. Therefore, I see an opportunity to develop physiologically inspired techniques 
for overcoming existing tissue engineering limitations. While endometrial models have been 
used to explore implantation physiology and uterine pathology, their use for tissue engineering 
efforts to date has primarily been confined to research as a potential cell source. I see more 
opportunity to use endometrial physiology within the field to develop strategies to address key 
challenges including tissue growth, immune response regulation, and vascularization. I am 
particularly interested in neovascularization as nutrient transport continues to be a major 
roadblock in tissue engineering while the endometrium is effective at vascular remodeling to 
accommodate endometrial growth. Additionally, the regulation of endometrial vascularization 
provides a hormone-based signaling axis that is fundamentally distinct from the majority of 
tissue engineering strategies to date that rely on growth factors delivery. So in addition to 
demonstrating the capacity of endometrial derived cells to support angiogenic events in tissue 
engineering biomaterial, this work also explores the possibility of estradiol and progesterone as 
regulators of pro-angiogenic events within a biomaterial. 
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1.3 Chapter overview 
The need to vascularize biomaterials arises from the poor intrinsic mass transport properties 
limiting their regenerative efficacy. Physiologically, capillary networks with spacing on the order 
of 200 µm facilitate the exchange of nutrients and waste in tissues [1, 2]. However, 
vascularization is no simple matter. This chapter offers a brief background on the field of tissue 
engineering and biomaterials before discussing the complexity of native vasculature and 
associated vascularization processes, previous biomaterial vascularization work, and the 
endometrium as a potential tissue that can be studied to better understand the intricacies of 
angiogenic signaling. I also review previously developed in vitro models of the endometrium.  
1.4 Engineering biomaterials 
Since its rise in the 1970s and 1980s, tissue engineering has been an interdisciplinary effort to 
generate biological products for treatment of diseased and damaged organs [3, 4]. Early 
approaches focused on cells with or without biomaterials as well as biological factors (molecules 
that can alter the behavior of cells within the biomaterial). By the 1990’s, several tissue 
engineered products were approved by the FDA and commercialized including Integra’s Dermal 
Regeneration Template, similar to collagen glycosaminoglycan scaffolds used in the research 
herein [4-8].  The field has since evolved, incorporating both biological factors, i.e. chemical and 
physical cues, into cell/biomaterial systems in order to not only replace tissues, but for use as 
medical diagnostic platforms as well [4]. In recent years, the tissue engineering field has begun 
to see promise. In 2011, tissue engineering industry sales nearly matched spending for the first 
time since the market was analyzed, with nearly $3.5 billion in sales generated mostly in 
orthopedic and wound healing products [9]. As of that time, nearly 14,000 employees worked for 
200 companies in the Tissue Engineering and Stem Cell Therapeutics industry.  
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Since the field’s conception, many biomaterials have been created to address requirements for 
specific tissue engineering applications. Multiple considerations must be taken into account in 
the design of biomaterials for tissue engineering [10, 11]. On the macroscale, biomaterials 
provide the overall structure for the tissue they are to replace and therefore must be 
biocompatible and have desirable degradation rates and mechanical properties. Additionally, 
biomaterials must also be able to support cell life. This requires additional architectural features, 
such as pore size and surface properties.  
Biomaterials are produced from a diversity of materials. In general, these materials can be 
categorized as either natural (e.g. decellularized extracellular matrix, collagen, gelatin, silk, 
fibrin, chitosan) or synthetic (e.g. poly(ι-lactide), poly(lactide-co-glycolide), polycaprolactone) 
[12-14]. While natural biomaterials are inherently better mimics of in vivo cellular environment, 
synthetic polymers are also advantageous, being easier to produce and having more tunable 
mechanical properties [10, 15]. Additionally, like natural biomaterials, these materials can and 
have been modified to be more bioactive. Porous biomaterial constructs are produced using a 
variety of methods, including sintering, electrospinning, lyophilization, and leaching [16, 17].  
1.5 Biotransport limitations to current generation biomaterials 
To date, biomaterials application for regenerating tissues naturally dense with cells has been 
limited to thin tissues (less than 1-2 mm) such as skin [10]. The dimensions of successful tissue 
constructs are dependent on the ability of nutrient diffusion necessary to maintain cellular 
activity and viability throughout the material. Without diffusive capabilities, cell viability is 
restricted to regions of a biomaterial where nutrients are readily available, near the perimeter of 
the material. While existing host vasculature can infiltrate into the biomaterial, the angiogenic 
processes take time, during which cells within the construct are without proper nutrients.  This 
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can diminish the implant’s efficacy [10].  Therefore, nutrient transport remains a key design 
criterion in tissue engineering. 
Many strategies have been devised to circumvent the inherent diffusion limitations of 
biomaterials. Cells can be cultured as monolayers to eliminate the diffusion limitations of thicker 
tissues, then layered into cell sheets for use [1].  Endothelial networks can also be incorporated 
into sheets [18]. However, the cell sheets lack the stimulus provided by 3D culture environment 
and could adversely affect the tissue viability and performance. Another alternative is to use host 
vasculature to induce angiogenesis into a biomaterial. In this method, the biomaterial is placed 
within an arteriovenous loop inside a chamber in vivo or placed inside a vascular bed to allow the 
host vasculature to penetrate into the construct, then harvested [1, 18, 19].  This method, 
however, requires surgical implantation, which can lead to infection and a second healing site. 
Alternatively, biomaterials can be vascularized to ameliorate nutrient diffusive limitations which 
better mimics nature’s approach. In vivo, capillaries with a maximal spacing of 200 μm facilitate 
the necessary nutrient and waste transport [1, 2]. To develop vasculature, endothelial cells have 
been seeded into microchannels into which media is perfused [20]. Using traditional tissue 
engineering techniques, the formation of vascular networks can also be induced within 
biomaterials using a combination of pro-angiogenic signals and supporting cell types, as 
discussed in more detail in Section 1.7 [10, 15, 20]. We used this approach, as described in the 
following chapters, to develop a vascularizing endometrial coculture in vitro.  
Vascularization is an intricate process physiologically, requiring coordinated actions of many 
cell types during the multi-step process. To replicate the full complexity of this process 
completely in vitro is a difficult endeavor. Exploration of cells from vascularizing tissues within 
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a biomaterial environment could aid in identifying which conditions observed in vivo are 
necessary to induce vascularization in vitro. 
1.6 Native vascularization processes  
Engineered vasculature has a variety of physiological functions which require different cell types 
and structural characteristics. For simple nutrient transport, the development of a capillary 
network that can be incorporated into existing vasculature networks upon implantation is logical. 
Capillaries, the most abundant vessel type, are also the simplest and smallest (besides nascent 
vessels) with diameters around 0.5 μm.  Capillaries are responsible for nutrient and waste 
exchange at the tissue level, which requires low blood flow velocity (regulated by the arteries) 
with high diffusive properties. To allow for diffusion, the capillary wall is thin, the endothelium 
lined only with a basement membrane and pericytes [21, 22]. Thus, when engineering capillaries, 
both endothelial cells and vascular supporting cells that can act as pericytes are required. In our 
endometrial model, we investigate non-endometrial endothelial cells (HUVECs) and endometrial 
stromal cells for their ability to form simple capillaries or vessel structures. 
Vascularization occurs through three distinct processes: angiogenesis, vasculogenesis, and 
arteriogenesis (Figure 1.1) – that can provide inspiration for tissue engineering efforts [10, 23-
25]. During angiogenesis, new vessels form from existing vasculature through sprouting (the 
formation of new vascular branches from existing vasculature) or intussusception (the splitting of 
one vessel into two vessels). Vasculogenesis, which occurs mainly during embryogenesis, is the 
formation of new vessels from circulating progenitor cells [20]. The expansion of the vascular 
network through widening and remodeling of the existing vasculature network is referred to as 
arteriogenesis. To improve diffusion for tissue engineering purposes, we leverage angiogenic and 
vasculogenic processes. However, angiogenesis requires existing vasculature. Thus, in the case 
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of pre-vascularizing biomaterials in vitro, vasculogenesis makes the most sense. However, there 
is much overlap in angiogenic cues between native angiogenesis and vasculogenesis, and we 
hypothesize both sets can be leveraged to direct vasculogenic vessel formation.    
Angiogenesis 
Angiogenesis is a complex multi-step/multi-factor process. One chief initiator of angiogenesis is 
hypoxia. A decrease in available oxygen within a tissue results in an upregulation of hypoxia 
induced factor (HIF-1α). In response, angiogenic factors are produced. These factors form a 
gradient towards the hypoxic region which is sensed by endothelial cells in neighboring vessels, 
initiating sprouting angiogenesis [25-27]. The existing vasculature is destabilized as the 
endothelial cells detach from mural cells (cells lining the endothelial tubes) and degrade the 
basement membrane surrounding the vessel. The endothelial cells then migrate along the 
gradient. Endothelial cells proliferate in order to form the new vessel branches and restore 
nutrient levels in the tissue. These nascent vessels are remodeled and integrated. Once formed, 
the vessel then undergoes maturation. A new basement membrane is formed, and mural cells are 
recruited. These stages of angiogenesis must be addressed to develop a biomaterial with a mature 
and functional vasculature. 
Angiogenic Factors 
Biological factors are essential regulators of angiogenic and vasculogenic processes. Vascular 
Endothelial Growth Factor (VEGF) initiates the neovascularization process and is one of many 
biological factors whose role in neovascularization processes has been studied [21].  During 
physiological angiogenesis, VEGF as well as other angiogenic factors are transcribed due to 
increases in HIF-1α [23]. VEGF has a variety of functions including aiding in endothelial cell 
proliferation and survival as well as inducing vascular permeability and dilation [28]. VEGF is a 
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significant element in the angiogenic process, but when unaccompanied by other factors, leads to 
the formation of immature vasculature [21, 29, 30]. For instance, when unsupported by platelet-
derived growth factor (PDGF), VEGF signaling results in a leaky, malformed vascular network 
[31]. Hence, temporal presentations of multiple angiogenic factors are necessary to direct the 
organization and stabilization of the structure.  
Various angiogenic factors have been implicated in facilitating the different stages of 
angiogenesis. During vessel destabilization, in the presence of VEGF, angiopoietin 2 (Ang2) 
induces sprouting, while during stabilization in the absence of VEGF, Ang2 counteracts 
angiopoietin 1 (Ang1)-mediated decrease in vessel permeability [21, 27]. Among other 
functions, PDGFs and fibroblast growth factors (FGFs) are important in the recruitment of mural 
cells for vessel stabilization [21, 23, 25, 27]. While the mechanisms for sprouting angiogenesis 
are well-characterized, less is known about elongation and intussusception. The formation of 
mature, functional vasculature, therefore, is a concerted effort of multiple cell types and temporal 
expressions of angiogenic factors.  
In addition to secreted cytokines and factors, the composition as well as remodeling of 
extracellular matrix (ECM) is crucial to regulation of angiogenesis [32]. The ECM serves 
multiple functions, sequestering angiogenic factors to direct vessel growth, providing adhesion 
of endothelial sprouts, as well as supporting endothelial survival and proliferation [21].  
At a minimum, prevascularized biomaterials should have an adequate network of capillaries that 
can transport nutrients throughout the construct and should integrate into existing vasculature 
when implanted. Physiologically, neovascularization is a complex multi-step process that 
requires multiple factors in a temporal presentation and necessitates both endothelial cells as well 
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as at least one mural cell type. Thus, the design of a vascularized tissue analog will require an 
instructive biomaterial that promotes the various phases of angiogenesis or vasculogenesis 
temporally. 
1.7 Balancing vascularization and tissue specialization needs in biomaterial design 
Tissue engineering has been applied in many studies for vascularizing biomaterials, with 
considerations to material composition and properties, choice of cell types, and incorporation of 
biological signals. A key challenge in developing vascularized biomaterials is leaving the tissue 
construct pliable to further development/for specialized tissues applications while providing an 
environment conducive to vessel formation. Consequently, the choices of biomaterial, cell types, 
and angiogenic signals for the design of vascularized biomaterial are constrained. While these 
studies have demonstrated that vascular networks can be incorporated in biomaterials, most have 
used only a few specific physiological characteristics of angiogenesis or vasculature in their 
design. The following sections will highlight how the different parts of the tissue engineering 
triad have addressed the balance between vascularization and end use. A few specific studies of 
vascularization within collagen scaffolds will be explored in more detail.  
Selection of biomaterial composition  
Specific ECM components have been identified as promoters or attenuators of 
neovascularization. Components of provisional matrix such as vitronectin, fibronectin, type I 
collagen (Col I), and thrombin promote pro-angiogenic processes including endothelial 
proliferation and migration as well as tube formation [15, 33-35]. Constituents of vascular 
basement membranes (e.g. laminin), on the other hand, support stability and quiescence. Some 
researchers have exploited these angiogenic properties in developing vascularized biomimetic 
constructs by opting for biomaterials constructed from angiogenic ECM components [10, 15, 
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19], including hydrogels of collagen [36, 37] and fibrin [29, 38-43] that mimic the environment 
endothelial cells encounter during sprouting angiogenesis [33]. While these native ECM 
components support neo-vascularization, certain inherent properties diminish their usefulness for 
general tissue engineering applications. Specifically, collagen lacks mechanical strength, 
whereas fibrin is a main element of scar tissue. Still, vascularized fibrin constructs have been 
pursued for a variety of tissues [10]. While angiogenic ECM components have been incorporated 
into vascularizing cultures, these components may not be used to their full potential without 
signaling cells to degrade the matrix via matrix metalloproteinase (MMP) secretion to reveal 
hidden integrins [34].  
Rather than using biomaterials that promote vascularization, some researchers use alternative 
biomaterials due to their physical properties. Synthetic polymer biomaterials allow for greater 
uniformity in manufacturing and tunable mechanical properties for different applications, despite 
their lack of bioactivity [10, 15]. These materials may be more amenable for certain engineered 
tissue mimetics such as bone [44, 45]. Again, the choice of material comes down to balancing 
angiogenic and other properties. In our work on developing a vascularizing endometrial culture, 
we have chosen to pro-angiogenic ECM components, using Col I with heparin scaffolds and 
gelatin hydrogels. 
Choice of cell population 
Many studies have used monocultures of endothelial cells to determine early vasculogenic 
responses from combinations of biomaterials and vascular cues [20, 46-49]. These cultures, 
however, are incapable of realizing mature vascular networks in vitro. As previously discussed in 
Section 1.5, the simplest vessel, the capillary, consists of an inner endothelial tube with basement 
membrane and outer layer of pericytes. Furthermore, tissue regenerative processes such as 
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vascularization require what Kirkpatrick et al. refer to as “cellular crosstalk” [50]. Therefore, the 
main question is not whether to choose a monoculture or coculture, but rather which cell types to 
use in the coculture.  
Kirkpatrick et al. suggests that while endothelial cells are more or less the same, it might be 
desirable to choose the supporting vascular type based on application and specific tissue, 
highlighting such vascular cultures for tissues such as skin, liver, and bone [50]. Other research 
has used a broader approach utilizing generic cocultures of endothelial cells with cells known to 
aid in vascularization such as fibroblasts [38, 42, 51, 52] and mesenchymal stem cells (MSCs) 
[37, 53-55]. These cells secrete angiogenic factors to induce endothelial proliferation and 
migration and act as pericytes [38, 56].We have chosen to use Human Umbilical Vein 
Endothelial Cells (HUVECs) and endometrial stromal cells that, like MSCs, have been shown to 
promote pro-angiogenic signaling with non-endometrial endothelial cells [57].  
Incorporating pro-angiogenic signals 
While biomaterial and cell selection are largely motivated by end use, angiogenic signals have 
mainly been selected for their angiogenic potential. For example, one commonly-employed 
neovascularizing strategy is to incorporate VEGF, a key regulator of angiogenesis, within these 
cultures facilitate vessel formation [15, 20, 50, 58].  
A significant issue with VEGF is that it regulates only part of the complex angiogenic process. 
As discussed in Section 1.5, VEGF alone, while a superior initiator of angiogenesis, is incapable 
of supporting mature vessel formation without the aid of additional angiogenic cytokines. Hence, 
researchers have turned to physiological angiogenesis (Figure 1 in [29]) to select combinations 
of growth factors that can be supplemented or temporally released with VEGF supplementation. 
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For example, biomaterial systems have been designed for rapid release of VEGF to initiate 
vessel formation, followed by a slower and/or delayed release of PDGF to recruit supporting 
cells to stabilize the endothelial structures [20, 59]. Other factors added in conjunction with 
VEGF include Ang1, Ang2, FGF, IGF, and SDF [20, 29, 55, 60, 61].  
Additionally, Brudno et al. varied temporal pro-sprouting (VEGF and Ang2) and pro-maturation 
factor (PDGF and Ang1) profiles to mimic the angiogenic processes within cocultures of 
endothelial cells and pericytes within fibrin gels to look at the early angiogenic response [29]. 
Using PLG mircospheres embedded into PLG porous scaffolds and implanted subcutaneously 
into mice to regulate release kinetics of these factors, they found that the microvessel density was 
highest with rapid VEGF and Ang2 release with or without delayed release of PDGF and 
Ang1[29]. Davies et al. found that the combination of rapid release of VEGF and prolonged 
release of PDGF from heparinized collagen scaffolds resulted in higher arteriole ingrowth when 
implanted into rats [59]. Additionally, delayed PDGF with or without Ang1 led to the highest 
number of vessels with smooth muscle cells following rapid release of VEGF and Ang2.  
One final consideration of physiological angiogenesis in the design of a vascular construct is the 
spatial presentation of cell signals that occur due to hypoxia in vivo. Odedra et al. observed that 
an immobilized gradient of VEGF led to increased migration of endothelial cells within a porous 
collagen scaffold [62]. In addition to looking at spatial effects of VEGF supplementation in vivo, 
Silva and Mooney found a high initial dosage followed by a decreasing concentration of VEGF 
within in vitro fibrin gel cultures led to the best sprouting [47]. 
While a handful of angiogenic factors were used to improve vascularization within biomaterials, 
these studies significantly simplified the vascular cell signal complexities. Although cultures that 
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used VEGF in combination with factors that recruit supporting cells were able to develop mature 
vessels, the vascularization could be further optimized by determining how levels of angiogenic 
factor expression are altered using cells that support vascularization are altered in vitro and the 
corresponding effect on vascularization.  
Vascularizing collagen scaffolds 
Recently, many studies have surfaced that explore the vascularization potential of porous 
collagen scaffolds using tissue engineering. The scaffold’s angiogenic potential was evaluated by 
implanting the constructs directly without the addition of cells or biological factors [63]. A study 
on rat brain lesions found that addition of the collagen scaffold led to increased proliferative 
endothelial cells and smooth muscle cells that formed arterioles and also led to increases of 
angiogenesis at the lesion site. By subcutaneously implanting the collagen scaffolds into mice, 
Chan et al. also observed vessel infiltration [64]. The addition of fibrinogen gel (a component of 
provisional matrix) to these scaffolds led to increased vascularization within rats, but constructs 
completely degraded by week 4.  While these experiments demonstrate that modified collagen 
scaffolds have the potential to undergo vessel infiltration in vivo, the process takes weeks,  
Other experiments used cell seeded scaffolds to improve vascularization as well as to explore 
cell-matrix and cell-cell interactions in inducing vascularization. In addition to the implanted 
scaffold experiments, Chan et al. found that microvascular networks formed within the collagen 
scaffolds within 3 days of culturing endothelial cells in vitro [64]. The study, however, did not 
determine whether these structures would persist or regress overtime. The group also implanted 
scaffolds seeded with adipose derived stromal cells into rats and found improved vascularization 
when compared to the scaffold alone. Similarly, O’Loughlin et al. loaded collagen scaffolds with 
MSCs and showed improved vascularization within diabetic rabbit ulcers [65].  
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Two papers that are more relevant to prevascularizing scaffolds focused specifically on cell-cell 
interactions in vivo and in vitro. These studies explored how combinations of endothelial cells, 
MSCs, and smooth muscle cells (SMCs) could be cocultured in collagen glycosaminoglycan 
scaffolds [58, 66]. In the first, MSCs not only altered vascularization in cocultures with 
endothelial cells in a time and dose-dependent manner, but also formed vessel-like structures 
when mono-cultured in endothelial medium [58]. Furthermore, SMCs altered vessel size in 
coculture with endothelial cells while having no effect on vascularization with MSCs. The latter 
paper illustrated the significance of temporal angiogenic processes by demonstrating that PDGF 
secretion by ECs is diminished upon addition of MSCs, while VEGF increased [66]. Further, the 
delayed introduction of MSCs to EC cultures led to the best vessel formation in vitro. These 
studies excelled at exploring vascular cell-cell interactions and demonstrated successful 
anastomosis upon implantation in rats. However, these studies could be further optimized to 
improve vascularization in vitro by optimizing factor supplementation.  
Finally, additional collagen scaffold studies have focused on controlling the presentation of 
angiogenic factors within the collagen scaffold to promote vascularization. VEGF has been 
incorporated covalently by many groups, including ours, to support vascularization [46, 62, 67]. 
Scaffolds incorporating conjugated VEGF increased vessel infiltration in rats [67]. In in vitro 
studies, scaffolds covalently bound with VEGF and seeded with HUVECs showed improved cell 
infiltration as well as evidence of early vasculogenesis over scaffolds without VEGF [46]. 
Further D4T cells were shown to migrate across a gradient of crosslinked VEGF [62]. These in 
vitro experiments focused solely on the early stage of vascularization (endothelial organization). 
Chiu and Radisic not only looked at promoting early endothelial response but also maturation by 
crosslinking both VEGF and Ang1 into the collagen prior to addition of H5V cells, leading to 
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increased proliferation and lactate production with Ang1 and VEGF individually or in 
combination. This led to tube formation by 3 and 7 days, though the stability of the vessels 
wasn’t evaluated [61]. This is particularly important as the study didn’t include a vascular 
supporting cell type. Additionally, Chiu and Radisic found the combination of VEGF with Ang1 
improved hemoglobin concentration in a Chick Chorioallantoic Membrane assay, suggesting 
improved angiogenesis [61]. Alternatively to VEGF, bFGF was explored as a potential regulator 
of angiogenesis within the collagen scaffold. The release of bFGF from the scaffolds was 
improved by the addition of heparan sulfate cross-linked into the constructs and led to increased 
capillaries and cell infiltration in subcutaneous rat implants [68].  
Need for a more physiologically regulated neovascularization 
Studies in vascularizing collagen scaffolds demonstrate that prevascularizing these constructs are 
feasible. However, these studies require further development to better recapitulate the processes 
necessary to form stable vascular networks. Future work needs to be conducted in order to 
optimize both the types of cells as well as the use of factors (concentrations and timing of 
factors) to improve pre-vascularization in vitro. An in vitro culture that recapitulates an 
angiogenic tissue could be created to learn how to better control the vascular processes in vitro. 
This model could be used to observe the variations in angiogenic regulators that are present at 
different stages of vascular development.  
1.8 The endometrium as a rapidly vascularizing tissue 
With the aim of developing prevascularization strategies for biomaterials in mind, a better 
understanding of how native vascular processes translate in vitro is required. Although much is 
known about the pro- and anti-angiogenic factors and the steps involved in hypoxia-driven 
sprouting, other angiogenic and vasculogenic processes exist. Further, how these signals and 
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processes are altered in a simple in vitro environment is not clear. Therefore, the development of 
a highly vascular tissue, specifically one that undergoes regular vascular development, would 
provide useful information on how cells involved in regular angiogenesis behave and how this 
affects vessel formation. 
 Few non-pathological angiogenic processes outside of fetal development exist. Due to the 
complexity and robustness of the angiogenesis, the endometrium has previously been proposed 
as an angiogenic model [69].  One of the advantages of the endometrium as an angiogenic model 
is that the endometrium undergoes vascularization regularly, and various different angiogenic 
processes have been identified at different times during the menstrual cycle. Therefore, exploring 
how endometrial cells direct vasculogenesis with a non-endometrial endothelial cell could 
provide much needed insight into how prevascularization can be regulated.  
Endometrial cycle and structural organization 
As the mucosal lining of the uterus, the endometrium serves a vital role in human reproduction. 
The endometrium facilitates blastocyst implantation by providing an environment dense with 
adhesion molecules and cytokines. Following implantation, the endometrium provides nutrients 
to the blastocyst until placentation occurs [70, 71].  
The human endometrial cycle consists of three distinct phases — proliferative, secretory and 
menstrual—which are regulated by fluctuations in the sex steroid hormones associated with 
ovarian follicular development, Figure 1.2 [70-72]. The proliferative phase is characterized by 
rapid growth as a result of increasing estradiol (E2). Following ovulation, during the secretory 
phase, progesterone (P4) levels rise as the endometrial stromal cells begin to decidualize in 
preparation to receive the fertilized ovum. If implantation does not occur, the menstrual phase 
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begins: P4 and E2 levels drop and the functional layer of the endometrium is shed. Simultaneous 
to the tissue breakdown, the endometrium repairs and angiogenesis takes place [73, 74].  
The human endometrium consists of two distinct regions called the functional and basal zones, 
Figure 1.2 [71]. The luminal side of the functional zone consists of a simple cuboidal-columnar 
epithelium containing mucosal glands that stretch into the depth of the endometrium. Stromal 
cells and spiral arteries reside beneath the epithelium. The basal zone located next to the 
myometrium differs from the functional zone in both structure and purpose. The basal zone is 
supplied by straight arteries and maintains all endometrial cell types necessary to give rise to 
new functional zones which are shed during cyclical menstruation. 
Complex development of endometrial vascular network, a crucial feature for reproduction  
Endometrial vasculature not only provides nutrients to the local endometrial cell population, but 
also to the implanted embryo.  Following implantation, the vasculature remodels further to 
support the blastocyst through early pregnancy [75]. Therefore vascular dysfunction can be 
detrimental to reproduction. Vascular issues can lead to fertility issues including recurrent 
miscarriages and implantation failures [76]. Due to the highly sensitive nature of endometrial 
vascularization, angiogenesis must be highly regulated. By examining how the endometrium is 
able to rapidly and efficiently vascularize, we can shed light on how pre-vascularized 
biomaterials can be achieved as well as provide insight into causes of female infertility. 
Development of endometrial vascularization, i.e. the spiral arteries, during the endometrial cycle 
and pregnancy is regulated in part by the actions of sex steroid hormones and hypoxia [69, 77, 
78]. These hormones act dynamically on endometrial cells including stromal, epithelial, and 
immune cells, as well as endothelial cells themselves [69, 79-83].  
18 
 
The site of angiogenesis changes through the endometrial cycle. During menstruation, 
angiogenesis occurs within the vascular bed of the basal layer, while during the proliferative and 
secretory phases it occurs in the functional layer [81].  Distinct angiogenic processes, namely 
elongation, intussusception, sprouting and circulating endothelial cell incorporation also 
correspond with different periods of the endometrial cycle [69]. During the proliferative stage 
when the endometrium undergoes rapid growth, an increase in circulating E2 results in vessel 
permeability and an influx of proliferative factors into the endometrial tissue [84]. Vessel 
elongation is dominant during this stage [69, 79]. In vitro, epithelial cell signaling promoted 
endothelial tubule formation which is further ameliorated by E2 supplementation [85]. The 
angiogenic benefits (endothelial proliferation) of E2 treatment were also observed in 
ovariectomized mice [82, 86]. However, vessel maturation, the recruitment of mural cells, was 
not observed.  The spiral arteries undergo growth and coiling during the secretory phase among 
humans and other catarrhine primates [81]. During this phase, characterized by high levels of P4, 
increased vascular branching occurs which is attributed to sprouting or intussusception [69, 79]. 
Unlike E2, both endothelial proliferation and vessel maturation were observed with progesterone 
treatment of ovariectomized mice with progesterone [82, 87]. Changes in vascularization 
coincide with changes in sex steroid hormones. Sex steroids initiate and complete these 
processes through the activation of signaling cascades as well as cytokine production. 
Biochemical factors that contribute to endometrial angiogenesis 
Pro- and anti-angiogenic factor expressions have been linked to changes in sex steroid hormone 
levels and are produced in varying degrees by different endometrial cell types [76, 77]. VEGF 
levels increase when the endometrium is hypoxic (menstruation) or when estradiol levels are 
high (proliferative phase) [74, 77]. Both endometrial epithelial and stromal cells contribute to 
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this increase in VEGF production, with epithelial cells producing more than stromal cells [74, 
88, 89]. Hypoxic driven VEGF production has been shown to be dependent on HIF-1α. During 
the proliferative phase, VEGF expression has been observed within endometrial stromal cells, 
and similarly to under hypoxic conditions, more so in endometrial epithelial cells [76, 80, 90].  
Another family of important angiogenic growth factors in the endometrium is the angiopoietins. 
Although Ang1 is observed mainly in the endothelium in both the secretory and proliferative 
phases, ANG1 is expressed in HESCs [91]. ANG2, however, was found to be expressed mainly 
by human endometrial endothelial cells, with some expression in the epithelial cells [91]. Ang1 
secretion by HESCs was higher when treated with P4 rather than E2. This corresponds with 
findings from Tsuzuki et al. whose experiments also found that ANG2 decreased with 
medroxyprogesterone acetate (MPA) treatment as well as the ratio of ANG2/ANG1 was high 
under hypoxia and estradiol treatment [92]. These results suggest that Ang1 expression is 
expected to be highest during the secretory phase (high P4) and the ratio Ang2/Ang1 should be 
higher during menstruation and the proliferative phase.   
Lash et al. found that endothelial cells and vascular smooth muscle cells from endometrial 
explants stained positive for PDGF by varying degrees throughout the endometrial cycle [76]. 
Endometrial epithelial, stromal, endothelial, and smooth muscle cells stained positive for TGF-β 
which decreased between the proliferative and early secretory, then increased to a greater extent 
in the mid-late secretory phase. In addition to the angiogenic factors described above, SDF-1, 
interleukin 8, and angiogenin have also been shown to change under different endometrial 
conditions [77]. It may be possible to achieve a better understanding of the regulation of 
endometrial angiogenesis through monitoring changes in pro-angiogenic factor expression of 
endometrial cells in response to sex steroid hormones in vitro. This knowledge could then be 
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applied to developing a temporally- and spatially-regulated angiogenic environment in vitro to 
pre-vascularize biomaterials. 
1.9 Existing in vitro endometrial models 
In vitro models have been suggested and used for observing single endometrial cell types under 
controlled conditions. The usefulness of these models, however, is limited due to their simplicity 
[73, 93]. By the mid-1920’s, endometrial explants were being cultured in vitro to study 
endometriosis [94]. Endometrial explants have been used to probe the angiogenic environment 
[95].  Contributions of leukocytes to spiral artery remodeling during pregnancy have been 
explored with matched placental-decidual explant cocultures [96]. Explants, however, maintain 
certain drawbacks such as viability and changes within the tissue during cultures [97].  
Alternatively to explants, individual endometrial cell types have been isolated and used for in 
vitro cultures, particularly to study implantation [98]. A diversity of in vitro endometrial models 
incorporating different endometrial cells and culture conditions has been employed in the last 
decade to explore endometrial phenomena (APPENDIX A).  A large portion of these studies 
focus on implantation (see Weimar et al. for a review [99]) as well as exploration of endometrial 
pathologies [100-104]. One culture system of special interest, seen repeatedly across multiple 
studies with different biomaterial platforms, attempts to reconstruct part of the endometrial 
architecture by creating a three-dimensional stromal compartment with an epithelial monolayer 
[105-109]. More simply, endometrial epithelial and stromal cells have been cultured directly 
together within a Col I/matrigel hydrogel [110]. In a similar fashion, an in vitro culture of 
endometrial cells could be probed with endometrial-inspired cues, namely sex hormones, to 
evaluate changes in key angiogenic regulators as well as monitor how these changes affect non-
endometrial endothelial cells using tissue engineering. 
21 
 
To date, few studies have explored models of endometrial angiogenesis in vitro [85, 95, 111-
114]. Three of these studies explored therapeutic targets for endometrial pathologies [112-114]. 
The remaining studies have sought to explore the effects of sex steroid hormones on vascular 
cellular behavior and are discussed below. While many of these cultures were carried out using 
ECM components, most of these relied on complex materials (i.e. matrigel or ECMatrix) that are 
known to alter cellular behavior, and were also generally two-dimensional coated substrates, 
lacking the three-dimensional environment.  
Two of these studies focused on a specific behavior of one endometrial cell type involved in the 
vascular process. The first sought to explore hormone contributions to early angiogenic response 
of endothelial cells within the endometrium. Human endometrial endothelial cells were found to 
improve vascular ratings when treated with E2, P4, or combination thereof in cultures performed 
either with an angiogenesis assay (ECMatrix) or on type I collagen coated wells [111]. The study 
also demonstrated that endometrial endothelial cells form vessel-like networks, but did not 
attempt to mature the vascular networks beyond nascent vessels. A separate study focusing on 
the maturation of vasculature found the migration of vascular SMCs through  fibrin coated 
transwell inserts was increased when treated with media conditioned by endometrial explants 
from the proliferative phase over control media [95]. The researchers also found that while sex 
steroid-supplemented control media had no effect on migration, explant conditioned media 
containing E2 led to greater increases when compared to similarly conditioned media with no 
supplementation, supplementation with P4 only, or a combination of E2 and P4.  
A separate study by Albrecht et al. sought to explore how secreted biomolecules from indirect 
co-cultures of human endometrial glandular epithelial cells or stromal cells with Human 
Myometrial Microvascular Endothelial Cells (HMMECs) demonstrated that endometrial 
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epithelial cells with or without E2 were better vascular promoters, while stromal cells were not 
[85]. The study did not specify any significant increase in either vessel formation with E2 
supplementation or in angiogenic factor (VEGF) production. These experiments also 
demonstrated the cell-cell interactions mediated by soluble angiogenic factors while eliminating 
cell-cell signals from direct contact.  
Together, this collection of studies suggest that endometrial cells can respond to hormones in 
culture, suggesting that hormones could be used to promote pro-angiogenic processes in 
biomaterial constructs in vitro to overcome current diffusion limitations. However, the 
experimental designs used in these studies, while employing ECM components, cells, and 
angiogenic signals, were mostly in three-dimensional culture environments. How these cells will 
respond in a true three-dimensional environment remains to be determined [115, 116]. Further, it 
will be important to explore both endothelial tube formation and vessel stabilization in the same 
system simultaneously, because both processes are necessary to develop a mature vascular 
network.  
1.10 Conclusion 
The background in conjunction with both the vascularizing biomaterial and endometrial research 
reviews above highlights that: [1] the formation of vascular networks is not one but many 
complex processes that involve multiple cells and biological signals; [2] tissue engineering has 
been used to develop vascularizing tissue in vitro and in vivo using just a few characteristic 
elements of native angiogenesis; [3] treatment of endothelial cells with VEGF alone can induce 
tube formation, but does not support vessel maturation. While these experiments show promise 
for pre-vascularizing biomaterial constructs, the methods used to cultivate desired vessel 
networks are somewhat underdeveloped, having less-than-ideal physiological justification. By 
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developing a natively angiogenic-inspired tissue culture in vitro, researchers could compare how 
physiological changes in vivo compare to the recapitulated tissue in vitro and optimize 
angiogenic cue profiles to be used in development of pre-vascularized biomaterials. We therefore 
propose using the endometrium, which undergoes rapid vascularization, as a model system. By 
mimicking changes in hormone profiles, we hope to be able to observe changes in angiogenic 
factor production and vessel formation in vitro as depicted in Figure 1.2.  
1.11 Chapter Progression 
Chapter 1 provided a brief introduction into neovascularization and previous in vitro angiogenic 
cultures.  I then introduced endometrial physiology with a short overview of what is known 
about angiogenesis. The chapter concluded with a summary of in vitro endometrial models. 
Chapter 2 explores the angiogenic contributions of endometrial epithelial cells treated with 
estradiol on early angiogenic response with a model biomaterial, a collagen-glycosaminoglycan 
(CG) scaffold. Chapter 3 builds upon the findings in Chapter 2 to develop a new model with a 
different biomaterial platform methacrylamide-functionalized gelatin (GelMA) hydrogel. 
Endometrial stromal cells are introduced as a mural cell. Sex steroid hormones as drivers of 
angiogenesis are pursued further with both estradiol and progesterone supplementation. Chapter 
4 is devoted to the incorporation of angiogenic biomolecules into the biomaterials for tissue 
engineering applications. The thesis concludes with Chapter 5 with a summary of the findings 
and proposed future directions. 
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1.12 Figures  
 
 
Figure 1.1 Mechanisms of vascular growth. The three major vascular processes: 
Vasculogenesis (vasculature formed directly from endothelial cells and their precursors), 
Angiogenesis (vessels arising from existing vasculature), and Arteriogenesis (remodeling of 
arteries) Reproduced from [117] with permission from The Royal Society of Chemistry. 
http://dx.doi.org/10.1039/B921869F 
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Figure 1.2 Project overview. Sex steroid hormones produced by the ovaries regulate 
vascularization in the endometrium. We will explore how cultures of endometrial cells in the 
presence of hormones can alter vascularization of non-endometrial endothelial cells within our 
biomaterial constructs in vitro. 
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CHAPTER 2: ANGIOGENIC CONTRIBUTIONS OF ENDOMETRIAL EPITHELIAL 
CELLS
1
 
2.1 Chapter overview 
In this chapter, the angiogenic potential of endometrial epithelial cells under the influence of sex 
steroid hormone E2 is explored in vivo using CG scaffolds. These studies focus on the mid-late 
proliferative phase of the endometrial cycle, driven by high circulating levels of E2 around 670 
pM [118]. 
2.2 Introduction 
Nutrient transport remains a major limitation in the design of biomaterials for tissue engineering 
application. Dense capillary networks, often with vessel-to-vessel spacing of order 200 µm, are 
required to convey oxygen and nutrients as well as eliminate waste in vivo [1, 2]. However, 
while some recent success has been reported regarding development of perfused microvascular 
networks, the in vitro analog of capillaries, using microfluidic platforms [119, 120], such 
networks remain difficult to replicate in most macroscale biomaterial constructs. As a result, cell 
viability is often restricted to regions of a biomaterial with minor diffusive limitations such as 
immediately adjacent to the surface. One approach to overcome this constraint is to incorporate 
pro-angiogenic signals within the biomaterial to promote vascular network formation [10, 15]. 
Vascular endothelial growth factor (VEGF), a pro-angiogenic signal, is often used to promote 
angiogenic processes. VEGF is commonly incorporated with cultures of endothelial cells or 
cocultures of endothelial cells with stromal cells to facilitate vessel formation [15, 20, 50, 58]. 
Previous research has shown that the use of VEGF alone can often lead to rapid growth of 
                                                 
1
 This chapter has been adapted from the following publication: Pence, J.C., K.B. Clancy, et al. (2015) “The 
induction of pro-angiogenic process within a collagen scaffold via exogenous estradiol and endometrial epithelial 
cells.” 
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immature vessels [29, 30]. These results have in turn suggested physiological angiogenesis 
requires temporal presentation of both pro- and anti-angiogenic factors to achieve stable, mature 
vascular networks [21, 29, 50, 59]. 
The endometrium, the lining of the uterus and site of embryo implantation, is one potential 
model that could be used in the design of a vascularized biomaterial. During the menstrual cycle, 
the endometrium exhibits rapid growth characterized by the development of dense networks of 
mature blood vessels which are shed during menstruation. Endometrial angiogenic events are 
thought to be orchestrated throughout the female reproductive cycle and following implantation 
by sex steroid hormones [69]. These hormones act dynamically on a host of endometrial cells 
including, endothelial, stromal, epithelial, and immune cells [69, 79-83]. The reproductive cycle 
consists of three distinct phases – proliferative, secretory and menstrual – each characterized by 
distinct hormone profiles and angiogenic processes [70]. The proliferative phase is characterized 
by rapid tissue proliferation mediated by increasing estradiol (E2) levels. Following ovulation, 
progesterone levels begin to rise as the endometrium prepares for implantation, resulting in 
stromal cell decidualization, the formation of a mucous membrane. If implantation fails to occur, 
progesterone and E2 levels drop rapidly, leading to shedding of the functional layer of the 
endometrium. Should implantation occurs, E2 and progesterone levels remain elevated, and the 
endometrium continues to remodel in order to support the trophoblast during the first trimester of 
pregnancy.  
Given a need to develop biomaterial platforms able to support the formation of dense, mature 
vascular networks, our efforts have focused on the mid-late proliferative phase of the 
endometrial cycle, driven by high circulating levels of E2 around 670 pM [118]. During this 
period, endometrial angiogenesis occurs mainly through vessel elongation [79]. Elevated levels 
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of circulating E2 are a primary signal responsible for the initial local production of proliferative 
factors involved in vessel formation (Figure 2.1) [84]. VEGF expression has been detected 
within endometrial stromal cells, and more so in endometrial epithelial cells during this period 
[76, 80, 90]. Though in vivo endometrial epithelial cells are believed to secrete VEGF and other 
pro-angiogenic factors more readily to the uterine lumen where implantation occurs rather than 
to the vascularized stromal region[121], recent in vitro efforts have suggested endometrial 
epithelial cells may be important sources of pro-angiogenic. Transwell cultures of human 
endometrial glandular epithelial cells or stromal cells with human myometrial microvascular 
endothelial cells (HMMECs) showed epithelial cells promoted vascular endothelial tube 
formation in vitro while stromal cells did not [85]. The addition of exogenous E2 to these 
cultures containing epithelial cells further stimulated pro-angiogenic processes [85]. While many 
previous in vitro endometrial studies have focused on characteristics other than angiogenesis 
(i.e., receptivity, decidualization) [99, 122-124], those that have examined angiogenic processes 
relied heavily on coated two-dimensional culture substrates [85, 111] that are unable to recreate 
cell-cell and cell-ECM interactions present in three-dimensional endometrial tissue. Notably, 
none of these studies examined whether endometrial-inspired signals may be of value in the 
design of biomaterial constructs able to promote pro-angiogenic processes to overcome current 
biotransport concerns. 
This study examines the potential for endometrial-inspired signals for supporting pro-angiogenic 
processes within a collagen-GAG scaffold platform under development for a range of soft tissue 
engineering applications. The scaffold microstructure (99% porosity; 100µm pores) is defined by 
individual CG fibers, termed struts, which provide alignment, compositional, and stiffness cues 
to cells within the network. Scaffolds support significant cell invasion and metabolite 
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biotransport [125, 126] and have previously been used as a model system to examine the impact 
of structural and mechanical properties on cell behavior [125, 127, 128]. Recently, methods have 
been described to incorporate exogenous biomolecular signals in soluble [129], covalently-bound 
[46, 130, 131], or transiently sequestered [132, 133] forms in order to further instruct cell 
behaviors. In this study we examined the impact of exogenous E2 on separate and combined 
cultures of endometrial epithelial cells (Ishikawa 3-H-12 cells) and an endothelial cells line 
(human umbilical vein endothelial cells, HUVECs) commonly used in many investigations of 
angiogenesis. Given the known mechanism of action of E2 on the endometrium, we anticipated 
that E2 would activate cellular pathways associated with the estrogen receptor (ERα) within 
endometrial epithelial cells, resulting in endogenous VEGF production. We hypothesized that 
addition of exogenous E2 would not directly impact non-endometrial endothelial cells 
significantly, but rather would drive endogenous VEGF production by endometrial epithelial 
cells to upregulate pro-angiogenic processes in the endothelial cell population. Using this 
approach we asked whether exogenous E2 could promote endometrial-inspired crosstalk between 
epithelial and endothelial cells within a fully three-dimensional collagen biomaterial. 
2.3 Materials and methods 
CG scaffold fabrication 
CG scaffolds were fabricated as previously described [125, 134]. A CG slurry was prepared by 
homogenizing fibrillar collagen (Collagen Matrix, Franklin Lakes, NJ; Sigma Aldrich, St. Louis, 
MO) and heparin from porcine intestinal mucosa (Sigma Aldrich) in 0.05 M acetic acid (Acros 
Organic, NJ) [6]. The 0.5 wt% CG suspension was stored at 4˚C and degassed prior to use. The 
suspension was lyophilized in an aluminum mold by first cooling at a constant freezing rate (1 
˚C/min) to -40⁰C followed by subsequent sublimation of ice crystals (0˚C, 200 mTorr).  
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CG scaffold crosslinking 
Dry scaffold sheets were crosslinked and sterilized via a dehydrothermal crosslinking (105˚C, 24 
hours, 0.5 mmHg) [6]. Experimental specimens (6 mm dia.; 3 mm thick) were cut from the sheet 
using a biopsy punch (Integra-Miltex, York, PA), then hydrated prior to use in first ethanol and 
subsequently water. Scaffolds underwent further crosslinking via carbodiimide chemistry. 
Briefly, scaffolds were crosslinked (room temperature, 1.5 hrs) in a solution of 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (EDC) (Sigma Aldrich) and N-
hydroxysulfosuccinimide (NHS) (Sigma Aldrich) at a molar ratio of 5:2:1 EDC:NHS:COOH. 
For immobilized estradiol experiments, BSA-E2 (0-1000 nM; Sigma Aldrich) was immobilized 
into the scaffolds during crosslinking at a molar ratio of 5:12.5:1 EDC:NHS:COOH using a 
previously described stepwise reaction [133, 135]. The scaffolds were then washed in PBS and 
stored at 4˚C until use. 
Cell Culture  
Endometrial epithelial cells, Ishikawa 3-H-12 cells, were cultured in epithelial growth medium 
consisting of DMEM/F-12 medium supplemented with 5% in-house carbon stripped FBS 
(Invitrogen, Carlsbad, CA), 100 U/mL: 100 μg/mL penicillin/streptomycin (Invitrogen), 2 mM 
L-glutamine (Invitrogen) at 37˚C in a 5% CO2 enriched environment. Cells were trypsinized 
when they reached confluence and were subsequently passaged (1.5x10
6
 cells per T 75 flask), 
cryopreserved, or seeded into scaffolds. Human Umbilical Vein Endothelial Cells (HUVECs) 
(Invitrogen) were seeded at 2.5x10
5
 cells per T 75 flask pre-coated with gelatin (Sigma Aldrich) 
and fibronectin (Sigma Aldrich) in endothelial growth medium consisting of Medium 200 
(Invitrogen) supplemented with Low Serum Growth Supplement (LSGS) (Invitrogen) and 100 
U/mL: 100 μg/mL penicillin/streptomycin (Invitrogen) at 37˚C in a 5% CO2 enriched 
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environment. HUVECs were used at passage 4 for experiments. Cells were seeded into hydrated 
scaffold discs (6 mm dia.; 3 mm thick) using previously described static seeding methods [127, 
136]. Cell seeded scaffolds were then incubated at 37C and 5% CO2 for up to 14 days with 
media replacement on days 3, 6, 10, and 13. Culture media was supplemented for some 
experiments with soluble E2 (1-1000 μM; Sigma) or VEGF (100 ng/mL; ProSpec). For studies 
examining the impact of factors secreted by epithelial cells, condition media was collected from 
epithelial cell-seeded scaffolds and applied to endothelial cell-seeded scaffolds. 
Cell number and metabolic activity quantification  
The total number of cells within each scaffold was determined via DNA quantification [136]. 
DNA was tagged with Hoechst 33528 (Invitrogen) following scaffold and cellular digestion in a 
papain solution (Sigma Aldrich) (60˚C, 24 hours). Normalized fluorescent intensity was 
measured using a F200 spectrophotometer (Tecan) 360(35)/465(35) nm (excitation/emission) to 
determine cell number with a standard curve of known cell numbers and normalized fluorescent 
intensities. The total metabolic activity of cell seeded scaffolds was monitored via a non-
destructive AlamarBlue assay [136, 137]. Scaffolds were rinsed in PBS and incubated at 37˚C in 
AlamarBlue (Invitrogen,) under mild shaking. The metabolic reduction of resazurin to the 
fluorescent byproduct resorufin by cells was measured on a F200 spectrophotometer (Tecan) at 
540(52)/580(20) nm (excitation/emission). Relative metabolic activity was then determined by 
comparing the resulting normalized fluorescent intensities with a prepared standard curve of 
known cell numbers and normalized fluorescent intensities.  
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VEGF quantification in conditioned media 
Conditioned media was collected from epithelial cell-seeded scaffolds after 24 or 48 hours, 
aliquoted, then frozen (-20 ˚C). The concentration of secreted VEGF was determined via the 
ELISA duoset kit (R&D systems, Minneapolis, MN) per manufacturer’s instructions. 
Western blot analysis of receptor and signaling pathway activation 
For analysis of receptor and signaling pathway activation, cells were first transferred to 
unsupplemented DMEM/F-12 media for 20 hours to create a baseline. Epithelial cells were then 
seeded into the scaffold and maintained for 4 hours in unsupplemented DMEM/F-12 media to 
allow for sufficient cell attachment within the matrix. Cell-seeded scaffolds were then transferred 
to 1.8 mL microcentrifuge tubes. Scaffolds were stimulated with 25 μL of desired E2 
supplemented media for a set reaction time (3-20 min). Immediately at the end of the reaction 
time, 100 μL of cold RIPA buffer was added to each tube. Scaffold specimens were vortexed for 
20 minutes then frozen (-20˚C) for subsequent analysis. Protein concentration was determined by 
BCA assay (Bio-Rad) to ensure equal loading of samples. For analysis, samples were diluted in 
equal volumes of Laemmli buffer 2x with 2% β-mercaptoethanol (BioRad), heat-treated for 10 
minutes at 95˚C, and loaded onto SDS-PAGE (10% separating) (1 hour, 150 V). Protein was 
transferred onto nitrocellulose membranes via a Trans-Blot SD (BioRad) (15 minutes, 15 V). 
The membranes were blocked with 5% milk in 0.1% Tween-20 in TBS for 30 minutes at room 
temperature before overnight incubation with primary antibodies β-actin, (p44/42 MAPK, P-
p44/42 MAPK (T202/Y204), Estrogen Receptor α (D8H8), and Phospho-Estrogen Receptor α 
(S104/106) (Cell Signaling, Beverly, MA). Blots were imaged using ImageQuant LAS 4010 (GE 
Healthcare Life Sciences, Pittsburgh, PA). Protein bands were quantified using ImageJ software. 
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Analysis of epithelial/endothelial cell cultures in scaffolds via fluorescence microscopy 
Prior to seeding into scaffolds, flasks containing endothelial cells (Cell Tracker Green CMFDA, 
Invitrogen) and endometrial epithelial cells (Call Tracker Red CMTPX, Invitrogen) were 
incubated with fluorescent dyes and for 30 min. Scaffold specimens (6 mm diameter; 1 mm 
thick) were seeded as previously described with either 100,000 endothelial cells on their own or 
1:1 mixture of 50,000 endothelial: cells and 50,000 epithelial cells. Cell-seeded scaffolds were 
cultured in the absence of light for 48 hours at 37˚C. Scaffolds (n=3) were then fixed in 10% 
formalin in neutral phosphate buffer (Polyscience), rinsed in PBS, soaked in a 20% sucrose 
solution, then flash frozen at -80 ˚C in Optimal Cutting Temperature (OCT, Tissue-Tek, 
Torrance, CA). Cell-seeded scaffolds were then sectioned (25 μm slices) transversely using a 
Leica CM3050 S cryostat. Sections were imaged via fluorescence microscopy (Leica DMI4000B 
fluorescence microscope, Qimaging camera). Images were generated by merging fluorescent and 
brightfield channels using ImageJ. 
Statistical methods  
Statistical analyses were performed using SPSS software (IBM). Statistical significance was 
assumed at p < 0.05 unless otherwise stated. For analysis of proliferation and cell number during 
2-week cultures of epithelial cells with E2 (n = 6) and following 48 hour cultures of endothelial 
cells with E2 or VEGF treatment (n = 6) as well as 48 hour VEGF production by epithelial cells 
(n=6), ANOVAs with Bonferroni post hoc tests were used. E2 dose effects on ERα 
phosphorylation (n = 4), ERK 1/2 phosphorylation (n = 4), were assessed with ANOVAs. We 
examined the effect of E2 in Ishikawa conditioned media on HUVEC metabolism and cell 
number via independent t-tests (n = 6). Carbodiimide immobilization of E2-BSA was evaluated 
by linear correlation. The effect of soluble versus EDC immobilized BSA-E2 conjugates on 
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epithelial cell metabolic activity and VEGF production was evaluated via ANOVA (n = 6). Error 
bars are reported as standard error of the mean unless otherwise noted. 
2.4 Results 
Exogenous E2 epithelial cell metabolic activity and VEGF production.  
The total number and metabolic activity of endometrial epithelial cells (100,000 cells) in CG 
scaffolds were quantified in the presence and absence of 10 nM E2 for up to 14 days in culture 
(Figure 2.2). Endometrial epithelial cells remained viable up to 14 days and showed significant 
increases in metabolic activity and cell number through day 7 (p ≤ 0.001). Collapsed across all 
time points, epithelial cell seeded scaffolds cultured with 10 nM E2 were more metabolically 
active (p = 0.015). However, there was no effect of E2 supplementation on epithelial cell 
proliferation (p = 0.5).  
To determine whether E2 was acting on endometrial epithelial cells (300,000 cells) in scaffolds 
via activation of estrogen receptors, we examined E2 Receptor alpha (ERα) phosphorylation as a 
function of exogenous E2 dose (0 – 1000 nM) and length of exposure (5 – 20 minutes). As early 
as 5 minutes after E2 exposure, epithelial cells showed a decrease in phosphorylated-ERα:ERα 
(Figure 2.3A), suggesting rapid receptor recycling after stimulation. Little ERα activation was 
observed at later time points (10 and 20 min; data not shown). These results suggest that the 
initial activation of ERα by E2 is rapid, occurring with 5 minutes of exposure within the CG 
scaffolds. We then looked at activation of ERK1/2, downstream of ERα in response to 
exogenous E2 dose (0 – 1000 nM) and exposure time (3 – 10 minutes, Figure 2.3B). While not 
significant, ERK1/2 phosphorylation (pERK:ERK) increased with E2 exposure (0.1 – 100 nM 
E2) and was highest at the shortest exposure time (3 min). However, exposure to exogenous E2 
did effect downstream VEGF production (Figure 2.3C). Endothelial epithelial cell (300,000 
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cells) seeded scaffolds were exposed to exogenous E2 (0 – 1000 nM) for 24 hours, with 
endogenous VEGF production quantified by ELISA. We observed an E2 dose dependent effect 
(p < 0.001) on VEGF production. While peak VEGF production was observed in response to 
1000 nM E2 (Figure 2.3C), subsequent coculture experiments used 10 nM E2 as it also induced 
significant VEGF production.  
Exogenous VEGF, but not E2, increases cell number and metabolic activity of endothelial cells 
cultured in CG scaffolds.  
To confirm that exogenous E2 does not induce the same proliferative response as VEGF, 
endothelial cell-seeded CG scaffolds (100,000 cells) were cultured in epithelial growth medium 
supplemented with either 10 nM E2 or 100 ng/mL VEGF for 48 hours (Figure 2.4). While 
epithelial growth medium was inadequate for sustaining long term endothelial cell cultures 
(Figure 2.5), it was sufficient for short term (<48 hours) cultures and was used to limit 
confounding growth factors that are present within complete endothelial growth medium. VEGF 
supplementation significantly increased both the number and metabolic activity of endothelial 
cells (p < 0.001) relative to unsupplemented control media while 10 nM E2 supplementation did 
not (p = 0.3 , p= 0.5, respectively).  
Conditioned media from epithelial cells with Exogenous E2 increases the metabolic response of 
endothelial cells.  
Given the observed effect of exogenous E2 on endometrial epithelial cells, the lack of effect of 
E2 on endothelial cells, and the effect of exogenous VEGF on endothelial cell culture, we 
examined whether CG scaffold culture would support epithelial cell-driven increases in 
endothelial cell activity. Epithelial cell seeded CG scaffolds were exposed to exogenous E2 (10 
nM) supplemented or unsupplemented epithelial growth media for 24 hours. Endothelial-seeded 
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CG scaffolds were subsequently cultured in epithelial cell conditioned media (+/- exogenous E2) 
for an additional 48 hours. The metabolic activity of Endothelial-seeded scaffolds cultured in 
media conditioned by E2 supplemented epithelial cells showed significantly (p < 0.05) increased 
metabolic activity while a non-significant increase in total endothelial cell number (Figure 2.6). 
Direct coculture of endometrial epithelial cells with endothelial cells in CG scaffolds.  
When homogeneously cultured in CG scaffolds, endothelial cells spread rapidly, showing an 
increased spindle-shaped morphology within 48 hours (Figure 2.7A), consistent with earlier 
results showing HUVEC spreading on CG scaffolds decorated with VEGF [46]. When HUVECs 
and endometrial epithelial cells were directly cocultured (1:1) in CG scaffolds in the presence of 
E2, epithelial cells showed spreading while endothelial cells remained primarily rounded (Figure 
2.7B).  
2.5 Discussion 
In this study, we sought to recapitulate aspects of intracellular signaling between endometrial 
epithelial cells (Ishikawas) and a non-endometrial endothelial cell population (HUVECs) within 
a three-dimensional CG scaffold. Endometrial angiogenesis is thought to be governed throughout 
the menstrual cycle by the dynamic actions of the sex steroid hormones E2 and progesterone. 
Herein, we focus on angiogenesis associated with high E2 levels, corresponding to endometrial 
conditions during the mid-late proliferative phase of the menstrual cycle. Previous work with 
artificially cycling rhesus macaques during this endometrial phase observed heightened 
endothelial proliferation with E2 [69, 138].  This suggests that exogenous E2 may play a direct 
role in pro-angiogenic processes and hence may be a novel pathway to explore in the 
development of biomaterial platforms. 
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The preliminary set of experiments was conducted to demonstrate that E2 acts directly on 
endometrial epithelial cells, resulting in an angiogenic supporting response. First, the addition of 
E2 to the cultures led to increased epithelial metabolism, indicating a change in cell processes 
that could be associated with changes in angiogenic gene expression. Motivated by the metabolic 
results, we sought to show E2 activating signaling pathways within endometrial epithelial cells. 
Previous research has found ERα is important in E2 induced VEGFA expression within rat 
uterine epithelial cells [139]. Therefore, we first focused on the early phosphorylation of ERα. 
After 5 minutes of exposure, receptor activation was reduced and nearly indiscernible, 
suggesting a much earlier activation by exogenous E2. Previous work by Kazi et al. 
demonstrated that the activation of PI3K/AKT is important to VEGFA expression [139]. 
However, we chose to focus our effort on the early activation of ERK 1/2. While not directly 
linked to VEGF production, ERK 1/2 has also been linked to E2 receptor activation [140], 
making ERK 1/2 a good indicator of selective receptor activation in response to E2 presentation. 
Harrington et al. found that ERK 1/2 phosphorylation showed a temporal and soluble E2 dose-
dependent response. In our experiment, increases in exogenous E2 dose corresponded to rapid 
(<3 min) but non-significant increase of ERK 1/2 activation (Figure 2.3). This suggests that E2 
is activating signaling pathways that can lead to angiogenic signaling, though future efforts will 
explore a wider range of signaling pathways and earlier exposure times to better explore these 
phenomena. 
The results of homogenous cell and conditioned media experiments suggest that exogenous E2 
can rapidly (< 48 hrs) promote pro-angiogenic processes in endothelial cells through the action 
of endometrial epithelial cells. Endometrial epithelial cells demonstrated enhanced VEGF 
production in CG scaffolds in response to exogenous E2 (10, 1000 nM). While E2 did not affect 
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endothelial cells directly, exogenous VEGF or conditioned media from E2 stimulated epithelial 
cells promoted increases in endothelial metabolic health. Together these findings demonstrate 
that treatment of endometrial epithelial cells with E2 can induce changes in endometrial 
epithelial cells to facilitate an angiogenic-like response within an in vitro three-dimensional 
culture. Previous studies have found similar potential of endometrial epithelial cells in vivo [69, 
90, 141] as well as in two-dimensional cultures [83, 85], but not within fully three-dimensional 
biomaterial platforms.  
While we found E2 supplementation altered epithelial cell behavior, it was insufficient to 
increase epithelial cell population. This corresponds with previous findings that the proliferative 
effects of E2 required additional growth factors (e.g., IGF-1) present in serum [84]. These 
findings are consistent with our study that shows exogenous E2 supplementation of endometrial 
epithelial cells can induce angiogenic signaling (VEGF production) while not directly inducing 
epithelial proliferation.  
Endothelial cells were treated with exogenous E2 in order to determine whether E2 acts directly 
on endothelial cells in CG scaffolds. Changes in endothelial cell number and metabolism were 
insignificant with E2 supplementation (Figure 2.4). While previous studies showed exogenous 
E2 could promote endothelial cell proliferation in two-dimensional cultures, these experiments 
were performed in growth medium [142, 143] while the work described here used a minimal 
media formulation. The proliferative effects observed in earlier work are likely due to the actions 
of E2 working in conjunction with other growth factors. Previous research has shown that E2 can 
enhance VEGF induced proliferation in endometrial cells [144], making such studies in the CG 
scaffold an attractive next step. These differences in findings may also be due in part to 
differences in cell-cell and cell-ECM signaling between two-dimensional and three-dimensional 
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cultures which have also been shown to alter cellular proliferation in other cell types [145]. More 
importantly, the lack of endothelial (HUVEC) cell response to E2 within the scaffold suggests 
changes in endothelial proliferation observed with epithelial conditioned-media studies are 
mostly contributable to epithelial cell produced signals. 
While exogenous E2 showed negligible effect on endothelial cells within the scaffolds, 
exogenous VEGF did directly affect endothelial culture. Unlike E2, VEGF led to an increase in 
both metabolic activity and cell population. These results are unsurprising as VEGF is commonly 
used to drive angiogenic processes, including cell proliferation, in vitro [47, 135] and in vivo [47, 
146]. In vivo animal endometrial models have also shown that the proliferative benefits of E2 
are, in part, diminished by blocking the actions of VEGFA [147]. Therefore, either direct 
stimulation of endothelial cells by exogenous VEGF or increased endogenous VEGF production 
by endometrial epithelial cells as a result of E2 supplementation provide a means to promote 
angiogenic processes within the scaffold. Cocultures of endothelial and endometrial epithelial 
cells with E2 could be developed so that the E2 treatment would induce production of epithelial 
angiogenic signals such as VEGF in order to stimulate angiogenesis within endothelial cells.  
We hypothesized that endometrial epithelial cells treated with exogenous E2 could produce pro-
angiogenic factors such as VEGF to elicit an angiogenic like response in endothelial cells. To 
test this, endothelial cells were cultured in scaffolds with E2 supplemented media enriched by 
two-dimensional cultures of epithelial cells. The E2 supplemented media resulted in an increase 
in metabolic activity in comparison to epithelial enriched media alone (Figure 2.6). This result 
supports the angiogenic findings of Albrecht et al. who demonstrated an increase in vessel 
formation due to soluble factors production when the cells were indirectly cocultured with 
endometrial epithelial and stromal cells [85]. Additionally, we cocultured epithelial and 
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endothelial cells together in scaffolds with E2 supplemented media (Figure 2.7). Surprisingly, 
the endothelial cells appeared more spread when cultured alone then when cultured with 
endometrial epithelial cells. This suggests that while the endometrial epithelial cells are 
producing angiogenic factors, the direct coculture conditions used in this study (1:1 
epithelial:endothelial, seeding together) may attenuate such pro-angiogenic processes. Results 
from Duffy et al. provide important context [54, 58], as both the correct ratio of 
endothelial:stromal cells as well as optimization of the relative timeframe of seeding these two 
cell populations within a collagen biomaterial were required to support long-term angiogenic 
events. 
While these studies provide promising evidence that angiogenic events can be stimulated within 
CG scaffolds through the incorporation of endometrial epithelial cells with E2 supplementation, 
the experimental design is admittedly limited. Endometrial angiogenesis is regulated by the 
temporal presentation of E2 and progesterone. However, in this study, we focused solely on high 
E2 conditions. Additionally, multiple pro- and anti-angiogenic factors are regulated during 
endometrial angiogenesis including placenta like growth factor, epidermal growth factor, 
fibroblast growth factor, platelet-derived growth factor, transforming growth factor, and 
angiopoietins 1 and 2 [76, 81]. In the current research, we have focused on VEGF alone due to 
its prominence in angiogenic studies. Consideration should also be made for the use of 
adenocarcinoma cells which may have different angiogenic potential than healthy endometrial 
epithelial cells. 
2.6 Conclusion 
Given the significant need for new strategies to improve vascular ingrowth and drive 
formation of dense networks of mature vessels within biomaterials to meet significant 
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biotransport limitations, this work explored the use of endometrial-inspired signals on 
pro-angiogenic events within collagen biomaterials. We demonstrate exogenous E2 
activates endometrial epithelial cells, resulting in increased VEGF production. We 
showed exogenous E2 has little effect on non-endometrial endothelial cells while 
treatment with exogenous VEGF increased endothelial cell metabolism and cell number. 
Notably, exogenous E2 does result in epithelial cell secretion of sufficient VEGF to drive 
equivalent responses as exogenously added VEGF. These findings support the hypothesis 
that endometrial epithelial cells can induce neo-angiogenic processes within a CG 
scaffold currently under development for a range of tissue engineering applications. 
While efforts extending from these results can concentrate explicitly on refining the mode 
of E2 presentation as well as exploring alternative angiogenic processes through the 
introduction of additional angiogenic signals (e.g., progesterone), this work also supports 
future development of collagen biomaterials based three-dimensional models of 
endometrial physiology and pathology. 
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2.7 Figures 
 
Figure 2.1 Schematic of pro-angiogenic signaling pathways associated with estradiol acting on 
endometrial epithelial cells. 
  
43 
 
 
Figure 2.2 Effect of estradiol dose on endometrial epithelial cells in CG scaffolds. (A) 
Metabolic activity of epithelial cells and (B) total epithelial cell population over two week 
culture. Results normalized to the initial number of epithelial cells seeded into the scaffold. 
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Figure 2.3 Activation of endometrial epithelial cell signal transduction pathways and 
VEGF production in CG scaffolds response to exogenous E2. (A) Estrogen Receptor (ERα) 
activation at 5 min exposure to E2-supplemented media. (B) ERK 1/2 phosphorylation following 
5 min treatment with (0 – 1000 nM E2) or 3 – 10 min exposure at 10 nM E2. (C) VEGF 
production by epithelial cells was found to be E2 dose dependent. ^: significantly higher VEGF 
production over other treatments *: significantly higher VEGF production compared to control (0 
nM E2). 
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Figure 2.4 Effect of 48 hours exposure to estradiol or VEGF on endothelial cells in CG 
scaffolds. (A) Endothelial cell metabolic activity normalized to control. *: significantly higher 
metabolic activity over other treatments (B) Endothelial cell population as determined by 
Hoechst DNA assay normalized to control. *: significantly higher cell number over other 
treatments. 
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Figure 2.5 Two Week cultures of HUVECs within CG scaffolds with or without VEGF 
supplementation. This data shows that the HUVECs were able to maintain culture in the 
presence of growth media, but not with the 5% CS-FBS supplemented DMEM/F-12.   
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Figure 2.6 Effect of epithelial cell conditioned media on endothelial cells within CG 
scaffolds. (A) Metabolic activity of endothelial cells treated with epithelial enriched media with 
10 nM E2 supplementation normalized to epithelial conditioned media without E2. *: significant 
increase over epithelial enriched media without  E2 (B) Endothelial cell population as 
determined by Hoechst DNA assay normalized to epithelial conditioned media without E2. 
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Figure 2.7 Combined culture of endothelial cells with endometrial epithelial cells in CG 
scaffolds. (A) Near surface fluorescent image of endothelial cells cultured in CG scaffolds for 48 
hours (B) Near surface fluorescent image of endothelial cells (green) and epithelial cells (red) 
cultured in CG scaffolds for 48 hours. 
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CHAPTER 3: ANGIOGENIC POTENTIAL OF ENDOMETRIAL STROMAL CELLS IN 
CO- AND TRI- CULTURES. 
3.1 Chapter overview 
The focus of this chapter will be on an endometrial model using GelMA hydrogel platform. The 
incorporation of stromal cells to non-endometrial endothelial cell cultures with or in the absence 
of endometrial epithelial cells will be explored to improve vascular formation and maturation. 
Known angiogenic signals present within the endometrium will be applied to these cultures to 
demonstrate how their incorporation alters the angiogenic properties of the culture. The effect of 
steroid hormone stimulation to endometrial cells within the model will be assessed for alterations 
in angiogenic signaling. While Chapter 2 looked at the very early cellular response, this chapter 
will focus largely on neovascularization characteristics. 
3.2 Introduction 
Nutrient transport has long been identified as a key limitation for the field of tissue engineering 
[148, 149]. Physiologically, capillaries with a maximal spacing of 200 µm facilitate nutrient and 
waste transport within tissues [1, 2], suggesting the eventual need to generate similar vessel 
network densities in engineered biomaterials. While native pro-angiogenic processes can 
facilitate new vessel ingrowth within implanted biomaterials, the process can take weeks [10, 
148]. As a result, many biomaterials are either implanted in an acellular state or with a reduced 
density of encapsulated cells. Biotransport concerns can be particularly significant in the case of 
large hydrogel constructs or for highly metabolically active cells. While recent efforts using 
three-dimensional printing have demonstrated avenues to generate on-demand vessel 
architectures [150, 151], concerns with these approaches include the achievable network density 
as well as whether it is necessary to define network architecture and anastomosis sites as 
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opposed to provide signals to support in situ vessel formation. As a result, there is a need to 
identify approaches to facilitate the rapid development of vascular structures that can readily 
incorporate into existing host vasculature, as well as approaches to promote remodeling of the 
vessel network to achieve increased vessel network density. 
Tissue engineering efforts have increasingly explored a wide design parameter space regarding 
the use of biomaterial carriers (e.g., hydrogels, scaffolds), cells, and biomolecular cues in an 
attempt to improve in situ vascularization processes. For example, co-cultures of endothelial 
cells with primarily stromal cell population have been shown to stabilize newly formed 
endothelial tubes [120, 152]. Mesenchymal stem cells (MSCs) have also received special interest 
due to their potential to secrete pro-angiogenic factors that may enhance endothelial cell 
proliferation and migration in a manner similar to that seen in vivo with pericytes [37, 38, 53-56]. 
MSCs also offer the potential to differentiate into tissue-specific stromal cells for a wide variety 
of musculoskeletal tissues [153, 154]. However, a primary strategy for promoting pro-angiogenic 
or pro-vasculogenic responses remains delivery and presentation of biomolecule agonists and 
antagonists.  One common strategy, inspired by angiogenic processes in the body in response to 
sites of regional hypoxia, uses rapid release of VEGF to initiate vessel formation followed by a 
slower and/or delayed release of PDGF to recruit supporting cells to stabilize the endothelial 
structures [20, 59]. Davies et al. described combinations of rapid VEGF release and prolonged 
PDGF release via heparinized collagen scaffolds to increase arteriole ingrowth in vivo [59]. 
However, while VEGF on its own has been shown to significantly increase pro-angiogenic 
phenotype across a wide range of biomaterials [48, 49, 62, 155, 156], response typically requires 
high dosages and can often promote rapid formation of small and relatively immature vessels. As 
a result, recent efforts by Brudno et al. explored approaches to temporally regulate delivery of 
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both angiogenic agonists and antagonists, showing selective delivery of VEGF and Ang2 
followed by delayed release of PDGF and Ang1 promoted growth of dense, mature vascular 
networks [29]. These previous efforts now motivate additional bioinspired strategies to facilitate 
pro-angiogenic processes in biomaterials, some inspired by the dynamic set of cues required to 
promote vessel formation, growth, and maturation.  
The endometrium, the lining of the uterus and site of embryo implantation, is an intriguing 
candidate model for inspiring pro-angiogenic biomaterials. As opposed to cancer-inspired 
models for vascularization, the endometrium is the site of cyclical growth, maturation, and 
shedding of dense vessel structures over the course of each menstrual cycle [157]. Further, rapid 
changes in vessel architecture during and after embryo implantation take place in order to 
support the growing embryo until placentation is well developed at the end of the first trimester 
[75, 158].  The dynamics of endometrial vessel development, remodeling, and shedding are 
tightly regulated by temporally-varying levels of the sex hormones estradiol and progesterone 
[82]. Hormonal regulation of the endometrium motivates exploring the use of sex hormones and 
endometrial-derived cells a novel means to initiate and control pro-angiogenic processes in vitro. 
Recent efforts in our lab showed that soluble estradiol was sufficient to induce VEGF secretion 
by endometrial epithelial cells at a level sufficient to induce changes in human umbilical vein 
endothelial cells metabolic activity in a model collagen scaffold [159]. The open pore 
architecture of the collagen scaffold made it difficult to monitor subsequent vessel formation 
events. Here, we describe the use of estradiol and progesterone to alter endometrial epithelial and 
stromal cell activity, as well as subsequent endothelial cell vessel formation, within a 
methacrylamide-functionalized gelatin (GelMA) hydrogel recently described by our laboratory 
[160-163].  
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3.3 Materials and methods 
Methacrylamide-functionalized gelatin macromer synthesis  
Methacrylamide-functionalized gelatin (GelMA) was synthesized as previously described [161]. 
Briefly, Gelatin (Type A, 300 bloom from porcine skin) solution was dissolved in phosphate 
buffered saline (PBS) (Gibco, Grand Island, NY) to a concentration of 10 wt%, (60˚C, stirring). 
Methacrylic anhydride (MA) (Sigma-Aldrich, St. Louis, MO) was then added dropwise and 
allowed to react (60˚C, 1 hr). The mixture was diluted in PBS (60˚C) prior to dialysis (12,000 – 
14,000 M.W, Fisherbrand, Pittsburgh, PA) against distilled water to remove salts and excess MA. 
The GelMA was then lyophilized prior to use. Sufficient MA was added to generate a final GelMA 
macromer with 47-57% degree of MA functionalization, as verified via 1H NMR (Varian INOVA).  
Lithium acylphosphinate photoinitiator synthesis  
Lithium acylphosphinate (LAP) photoinitiator was synthesized as previously described [164]. 
2,4,6-trimethylbenzoyl chloride (Sigma Aldrich) was added in a dropwise manner to equimolar 
dimethyl phenylphosphonite (Sigma Aldrich) at room temperature under continuous stirring and 
argon. A precipitate was formed by addition of fourfold excess of lithium bromide in 2-butanone 
(Sigma–Aldrich) and heating to 50˚C. The mixture was returned to room temperature prior to 
filtration and then washed 3 times in 2-butanone to remove unreacted lithium bromide. Excess 
solvent was subsequently removed by vacuum. 
Cell culture  
Endometrial epithelial cells, Ishikawa 3-H-12 cells, and hTERT immortalized human 
endometrial stromal cells, T HESCs, were cultured in DMEM/F-12 medium supplemented with 
5% in-house carbon stripped FBS (Invitrogen, Carlsbad, CA) as well as 100 U/mL:100 μg/mL 
penicillin:streptomycin (Invitrogen) and 2 mM L-glutamine (Invitrogen) (37˚C, 5% CO2). At 
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confluence, cells were trypsinized and passaged (1.5x10
6
 epithelial cells or 2.5x10
5
 T HESCs per 
T 75 flask), cryopreserved, or seeded into hydrogels. Human Umbilical Vein Endothelial Cells 
(HUVECs) (Invitrogen) were seeded at 2.5x10
5
 cells per T 75 flask in phenol red free EBM 
(Lonza) supplemented with EGM-2 SingleQuots (Lonza) (37˚C, 5% CO2). HUVECs were used 
at passage 4 for all experiments.  
GelMA hydrogel synthesis and culture 
A GelMA solution (4 wt %) with 0.1 wt % LAP photoinitiator was prepared in Endothelial Basal 
Medium (EBM) (Lonza) (60˚C). Cells were suspended in the GelMA solution prior to photo-
polymerization. The cell-hydrogel suspension was pipetted (40 µl) into the wells (5 mm 
diameter, 2 mm thick) in a Teflon mold attached to a glass slide with binder clips. The cell-
impregnated hydrogel suspension was then exposed to UV light (10 mW/cm
2
, 365 nm, 30 s) 
[163] to form a polymerized hydrogel which was then extracted from the molds. Hydrogel 
specimens were incubated (37˚C, 5% CO2) in 48-well culture plates in phenol-red free EBM 
media supplemented with EGM-2 SingleQuots supplemented with in-house carbon-stripped FBS 
(replaced every two days) [165]. Additionally, some experiments utilized epithelial cells pre-
seeded into wellplate before adding the hydrogel specimens (identified in the Results).  For 
experiments reporting the effect of sex steroid hormone and VEGF, media was supplemented 
with E2 (10-1000 nM; Sigma), P4 (1000 nM; Sigma) or VEGF (100 ng/mL; ProSpec). 
Profiling pro-angiogenic gene expression  
Cell-seeded hydrogels were generated using endometrial epithelial or endometrial stromal cell (5 
MM cells/mL); after 1 day in growth media to allow for initial cell-matrix interactions, the 
culture media was replaced with media supplemented with no E2/P4, 1 µM E2, or 1 µM P4, and 
maintained for up to 7 days. RNA was isolated from epithelial or stromal cell-laden hydrogels (n 
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= 4 hydrogels per cell/treatment/time) using an RNeasy Plant Mini kit (Qiagen, Valencia, CA), 
then quantified via a NanoDrop Lite (Thermo Scientific, Waltham, MA) [166].  RNA was then 
reverse transcribed with a QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA) using a 
Bio-Rad S1000 thermal cycler. Real-time PCR was performed with an Applied Biosystems 
7900HT Fast Real-Time PCR System (Carlsbad, CA) to measure gene expression levels for 
ANG1, ANG2, VEGF, and MMP11 with ACTB as a housekeeping gene (Table 2.1). Sequence 
Detection Systems software v2.4 (Applied Biosystems, Carlsbad, CA) was used to complete 
analysis. Results are expressed as fold changes relative to expression levels of cells with two 
days of control treatment. 
Quantifying VEGF secretion  
For experiments quantifying VEGF secretion as a function of E2 or P4 supplementation, cell-
seeded hydrogels were generated using endometrial epithelial (1 MM cells/mL) or endometrial 
stromal cell (2 MM cells/mL); after 1 day to allow for initial cell-matrix interactions, normal 
culture media was replaced with growth media where VEGF aliquots were omitted. Stromal and 
epithelial cell seeded hydrogels (n=6) were subsequently grown for 4 days with daily media 
changes in either VEGF-free media, 1 µM E2 supplemented VEGF-free media, 1 µM P4 
supplemented VEGF-free media, or 1 µM E2 plus 1 µM P4 supplemented VEGF-free media. 
Conditioned media at day 4 was collected and subsequently frozen (-80 ˚C) until analysis. The 
concentration of secreted VEGF was determined via the human VEGF ELISA duoset kit (R&D 
systems, Minneapolis, MN) using an F200 spectrophotometer (Tecan, Männedorf, Switzerland). 
Quantifying cell number and metabolic activity 
The number of endometrial epithelial and stromal cells encapsulated within the hydrogels were 
determined via DNA quantification (n = 6) [136]. Briefly, cell-seeded hydrogels were digested in 
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papain solution (Sigma Aldrich) (60˚C, 24 hours), with DNA then tagged via Hoechst 33528 
(Invitrogen). Fluorescent intensity of each sample was measured using a F200 spectrophotometer 
(Tecan) at 360(35)/465(35) nm (excitation/emission) and compared to a standard curve of known 
numbers of cells. The total metabolic activity within gels was assessed by a non-destructive 
alamarBlue assay as previously described [136, 137]. Hydrogels were rinsed in PBS then 
incubated at 37˚C in alamarBlue (Invitrogen) under mild shaking. The metabolic reduction of 
resazurin to the fluorescent byproduct resorufin was measured on a F200 spectrophotometer 
(Tecan) at 540(52)/580(20) nm (excitation/emission). Relative metabolic activity was determined 
by comparing the measured fluorescent intensities against a prepared standard curve generated 
via known numbers of cells.  
Analysis of vessel networks  
Cell-seeded hydrogels of increasingly cellular complexity were used to quantify spontaneous 
vessel network formation within the hydrogel [40]. GelMA hydrogels were seeded with either: 
1MM cells/mL endothelial cells (HUVECs); a total of 3MM cells/mL of HUVECs and 
endometrial stromal cells at a 2:1 HUVEC:stromal cell ratio previously reported to enhance 
vessel network formation [40]; or 4MM cells/mL of HUVECs, endometrial stromal cells, and 
endometrial epithelial cells at a 2:1:1 HUVEC:stromal:epithelial cell ratio. Hydrogels were 
maintained in growth or VEGF supplemented media for 7 or 10 days. Spontaneous vessel 
network formation within the hydrogel was analyzed as previously described [40]. Hydrogels 
were fixed in 10% Formalin (20 min, RT), blocked with 2% BSA (Sigma-Aldrich) and 0.1% 
Tween (Fischer Scientific), then incubated overnight in 1:200 mouse anti-human CD31 antibody 
(Dako, Carpinteria, CA, USA) followed by 1:500 Alexa Fluor 488-conjugated goat anti-mouse 
IgG (Invitrogen), all at 4˚C. Vessel networks were imaged via fluorescent microscopy (Leica 
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DMI4000B fluorescence microscope, Qimaging camera) at 4x and 10x, with six images per 
sample side analyzed via AngioTool in order to quantify average and total vessel length, vessel 
area, and total vessel junctions per field of view [167]. 
Statistical methods 
Statistical analyses were performed using SPSS software (IBM). Statistical significance was 
assumed at p < 0.05 unless otherwise stated. Error bars are reported as standard error of the mean 
unless otherwise noted. Main effects were assessed with ANOVAs with Tukey post hoc tests.  
VEGF gene expression within epithelial cells and differences between mono-, co-, and tri-
cultures with or without VEGF were evaluated further using 1-way ANOVAs at each time point.   
3.4 Results 
Hormone supplementation alters angiogenic gene expression in endometrial epithelial cell laden 
hydrogels but not endometrial stromal cells laden hydrogels.  
Expression profiles of three pro-angiogenic (ANG1, ANG2, VEGF) genes were examined in 
endometrial epithelial cell seeded GelMA hydrogels as a function media supplementation 
(Control growth media; 1µM E2 added; 1µM P4 added). Expression of ANG2 in endometrial 
epithelial cells, typically upregulated at sites of vascular remodeling [76, 77], was hormone 
dependent (p = 0.028) (Figure 3.1). Here, 1µM E2 induced significantly higher ANG2 
expression levels than 1 µM P4 supplementation (p = 0.04), and trended towards higher 
expression compared to the non-supplemented control (p = 0.064). Endometrial epithelial cells 
also showed a significant increase in VEGF expression with time (p < 0.001 for all time 
comparisons); however P4 supplemented media led to consistently significantly lower VEGF 
gene expression compared to E2-supplemented media (p= 0.001) or control media (p = 0.012). 
No observable trend in response to time or hormone supplementation was observed for ANG1, 
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typically associated with vessel maturation [76, 77] . In contrast, while expression of ANG1 and 
VEGF increased significantly with time at day 7 (p < 0.01) in endometrial stromal cells within 
the GelMA hydrogel, neither E2 nor P4 supplementation significantly altered angiogenic (ANG1, 
ANG2, VEGF) or stromal remodeling (MMP11) gene expression profiles (Figure 3.2).  
Endometrial epithelial cells produced more VEGF than stromal cells. 
We subsequently quantified the effect of hormone supplementation on the number, metabolic 
activity, and VEGF protein secretion of epithelial and stromal cells within the GelMA hydrogel. 
By day 4 in culture, significant differences were observed between endometrial stromal and 
endometrial epithelial cells in GelMA hydrogels. Notably, while hormone supplementation did 
not alter responses for each cell type, endometrial epithelial cells showed significantly (p < 
0.001) increased proliferation, reduced (p < 0.001) metabolic activity per cell, but most notably 
enhanced (p < 0.001) VEGF secretion into the media (Figure 3.3). 
Exogenous VEGF and endometrial stromal cells, but not endometrial epithelial cells, improves 
vascularization in co-cultures with endothelial cells.  
To confirm the angiogenic potential of co-cultures of endometrial epithelial and stromal cells 
with non-endometrial endothelial cells, GelMA hydrogel were seeded with HUVECs alone, 
HUVECs plus endometrial stromal cells, or HUVECs plus endometrial stromal cells and 
endometrial epithelial cells. Specimens were either maintained in conventional growth or VEGF 
supplemented (100 ng/mL) media for up to 10 days. Visible differences in vasculature were 
apparent between all culture conditions (Figures 3.4 and 3.5). Mean metrics of vascular network 
complexity were acquired from measurements taken from each side of the hydrogel. Notably, 
addition of large dosages of soluble VEGF significantly (p ≤ 0.001) increased the area, number 
of junctions, total vessel length and average vessel length. Further, the addition of endometrial 
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stromal cells led to an increase in vessel area, total length, and average length over HUVEC 
cultures alone (Figure 3.5, p < 0.05). Additionally, direct addition of endometrial epithelial cells 
to form a tri-culture adversely affected metrics of vessel formation.  
E2 supplementation did not alter endothelial cell organization. 
We subsequently examined the potential influence of exogenous estradiol (0 – 1µM) on network 
formation in GelMA hydrogels containing co-cultures of endothelial cells and endometrial 
stromal cells (Figure 3.6). Here, metrics of vessel formation showed no effect of estradiol 
concentration on vessel area, number of junctions, as well as total and average vessel length 
(Figure 3.7). 
3.5 Discussion 
In this study, we sought to leverage endometrial physiology to explore the vascularization of 
biomaterials in vitro. Few studies have previously sought to study the effects of sex hormones on 
endometrial angiogenesis in vitro [85, 95, 111]. While these studies sought to understand specific 
endometrial angiogenic phenomena, they did not try to use endometrial-inspired signals to 
promote pro-angiogenic processes in biomaterial constructs in order to overcome their inherent 
diffusion limitations. Additionally, none of these studies used a three-dimensional biomaterial 
culture platform to explore the potential to translate the concept for regenerative medicine 
applications. This project builds on previous effort by our laboratories to investigate the effects 
of estradiol on pro-angiogenic signaling on co-cultures of endometrial epithelial and non-
endometrial endothelial cells in a model collagen scaffold [159]. Here, we explore how 
endometrial stromal cells and endometrial epithelial cells may aid vessel formation by non-
endometrial endothelial cells in a gelatin-based hydrogel biomaterial. A primary motivator of the 
transition from a collagen-based scaffold with pores of order 150µm in size to a (gelatin-based) 
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hydrogel was the potential to more rapidly visualize de novo formation of vessel networks (as an 
early marker of angiogenesis) within the hydrogel network (4-7 days) as compared to porous 
scaffold networks (10 days) [58, 168]. 
Endometrial stromal cells, like mesenchymal stem cells, have the potential for use in tissue 
engineering applications [169-172]. HESCs offer a further advantage in regulating vessel 
formation as their vascular promoting factors have been shown to be regulated by sex hormone 
treatments. Pro-angiogenic factors within the endometrium, particularly VEGF and the 
angiopoeitins, have been found to vary temporally and spatially, [76, 147]. Previous research by 
Tsuzuki et al. found that estrogen treatment of isolated HESCs led to decreased ANG1 gene 
expression and increased VEGF production while medroxyprogesterone acetate (MPA; used as a 
progesterone mimetic) reduced ANG2 gene expression and VEGF production [92]. These finding 
suggest that E2 and P4 could be used in a coordinated manner in a tissue engineering setting to 
regulate vasculogenic processes within co-cultures of HESCs and endothelial cells. However, 
our research using a GelMA platform found angiogenic gene expression profiles in endometrial 
stromal cells were not significantly altered baseline by either E2 or P4 hormonal 
supplementation. The lack of a response to E2 or P4 may be due in part to the physical 
characteristics of the hydrogel itself. Endometrial stromal cells were able to significantly contract 
the GelMA hydrogel, likely reducing nutrient transport and thus resulting in a hypoxic 
environment and resultant pro-angiogenic responses that masked the effect of exogenous sex 
hormones at the dosage tested. While sufficient to induce a response in open-cell collagen 
scaffolds [159], future experiments will pursue an expanded dose range and hydrogels more 
resistant to contraction-based remodeling. Effects may also be observed for endometrial stromal 
cells under different culture conditions such as a lower seeding density. 
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While we hypothesized that endometrial stromal cells could be used to stabilize endothelial tube 
formation and provide angiogenic cues to promote angiogenesis, we were also interested in 
determining whether endometrial epithelial cells could provide additional pro-angiogenic signals 
within the GelMA hydrogel. Previous efforts in our laboratory using collagen scaffolds showed 
that VEGF within conditioned media from endometrial epithelial cells exposed to E2 in the 
scaffold were able to alter the metabolic response of endothelial cells within the scaffold. 
Similarly, increased VEGF expression or production has also been shown for epithelial cells in a 
wide range of two-dimensional and three-dimensional in vitro cultures as well as via an in vivo 
model in baboons [85, 92]. Our observed increase of VEGF and Ang1 expression within 
epithelial cultures with E2 treatment agrees with others’ findings that soluble pro-angiogenic 
signals can be produced by endometrial epithelial cells [85]. In contrast to endometrial stromal 
cells in GelMA, we observed temporal and hormone dependent changes in gene expression for 
endometrial epithelial cells in the GelMA hydrogel. Further, while endometrial stromal cells 
appear to contribute to significant hydrogel contraction, no obvious signs of hydrogel contraction 
were observed as a result of endometrial epithelial cell culture.  
While hormone supplementation of our three-dimensional epithelial cultures altered gene 
expression of angiogenic proteins, no alterations in VEGF production were found in either 
epithelial or stromal cultures. Previous research with two-dimensional cultures of endometrial 
stromal cells demonstrated that VEGF production was increased by E2 supplementation, while 
MPA or P4 attenuated the response [83, 92, 173]. Classen-Linke et al. also reported that E2 
increased VEGF production in endometrial epithelial and fibroblasts [174]. They also found 
MPA increased VEGF secretion in epithelial cells while decreasing secretions in fibroblasts. 
While ewe previously reported that E2 supplementation of endometrial adenocarcinoma cells 
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increased VEGF production in a collagen scaffolds [159], the lack of a response observed here 
suggests that the need to further optimize the GelMA hydrogel to endometrial cell culture. Future 
experiments will target control changes in hydrogel wt%, degree of functionalization, and 
photoinitiator concentration in order to tests a wider library of hydrogel environments [160, 161]. 
Further, the actions of estradiol may be masked by the state of hypoxia within the hydrogel itself, 
a function of both initial hydrogel properties and subsequent remodeling or contraction [84]. 
Future experiments which explore the coordinated effect of hypoxia and the presence of 
hormone-based angiogenic signals may provide valuable insight [84, 175] . 
We subsequently examined the ability for HUVECS to form vessel networks within the GelMA 
hydrogel as a function of endometrial cell co-culture. Previous efforts using HUVECs in other 
biomaterials have shown incorporation of VEGF can improve vessel network formation [46, 48, 
62]. Here, we showed that while VEGF improves endothelial cell network formation, the 
incorporation of endometrial stromal cells also improved vessel formation. These results are 
consistent with previous work using MSCs as a stromal cell population [54]. Importantly 
however, it suggests that endometrial stromal cells can be used as an alternative to MSCs in 
developing vascularized biomaterials. Having found that endometrial stromal cells could 
improve endothelial cell network formation, we subsequently sought to assess whether addition 
of E2 could promote an increase in network formation. Our findings that E2 supplementation in 
the presence of endometrial stromal cells did not improve vascular network formation are 
consistent with results from indirect co-cultures of endothelial cells and endometrial stromal cells 
that found no change in endothelial tube formation, even in the presence of E2 [85].  
These findings led us to investigate whether addition of endometrial epithelial cells to the co-
culture of endometrial stromal cells and HUVECs could promote vessel network formation. We 
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had previously shown that endometrial epithelial cells in three-dimensional biomaterial culture 
produce endogenous VEGF in response to E2 that was sufficient to enhance the activity of 
endothelial cultures [159]. While epithelial cells were found to alter angiogenic gene expression 
to hormone supplementation, the addition of epithelial cells to generate tri-cultures with 
endothelial cells and endometrial stromal cells led to diminished metrics of vessel network 
formation. These findings within a gelatin hydrogel are similar to observations we made using an 
open-cell porous collagen scaffold where direct co-cultures of endothelial cells with endometrial 
epithelial cells led to reduced bioactivity of the endothelial cells [159]. These findings suggest 
that while endometrial epithelial cells are capable of generating pro-angiogenic factors in 
response to exogenous E2 stimulation, direct contact between the epithelial and endothelial cells 
is detrimental. Ongoing efforts are exploring the use of stratified hydrogel cultures where 
endometrial epithelial cells and co-cultures of endothelial and endometrial stromal cells can be 
maintained, a degree of complexity that mirrors the native stratification in the endometrium [71]. 
3.6 Conclusion 
Tissue engineering approaches present the exciting opportunity to develop models that explore a 
wider range of natively angiogenic tissues as a means towards uncovering new routes to promote 
angiogenesis within biomaterials. Here we explored the degree to which concepts associated 
with a physiological angiogenic process that occurs rapidly and cyclically in the endometrium 
can be translated to support early angiogenic events within a gelatin hydrogel. We find that 
endometrial stromal cells are capable of promoting vessel network formation by a non-
endometrial derived endothelial cell population (HUVECs). Further, while E2 hormone 
supplementation enhances pro-angiogenic gene expression profiles in endometrial epithelial cell 
laden hydrogels, direct co-culture of endometrial epithelial cells and endothelial cells interferes 
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with network formation and necessitates development of stratified biomaterials for future studies. 
Together, these findings suggest the endometrium may present a particularly valuable model 
system in the context of developing novel pro-angiogenic strategies for tissue engineering 
biomaterials.  
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3.7 Figures and tables 
 
Figure 3.1 Hormone effects on angiogenic gene expression of endometrial epithelial cells in 
GelMA.  Endometrial epithelial response to 1 μM E2 or 1 μM P4 for (A) ANG1, (B) ANG2, 
(C) and VEGF as expression relative to day 1 control. *: significantly different time point #: 
significantly different from control within time point &: significantly different from estradiol 
within time point  
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Figure 3.2 Hormone effects on angiogenic gene expression of endometrial stromal cells in 
GelMA. Endometrial stromal response to 1 μM E2 or 1 μM P4 for (A) ANG1, (B) ANG2, 
(C) VEGF, (D) and MMP11 as expression relative to day 1 control. *: significantly different time 
point. 
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Figure 3.3 Alterations in endometrial epithelial and endometrial monocultures and VEGF 
production within GelMA hydrogels in response to 4 days of hormone treatment. (A) Cell 
population as determined by Hoechst DNA and normalized to cells seeded (B) Metabolic activity 
determined by alamarBlue (C) VEGF production per cell. 
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Figure 3.4 Images of endothelial cells within, mono-, co-, and tri-cultures following 10 days 
of 100 ng/mL VEGF treatment. Endothelial cells were stained for CD31 and imaged at 10x 
using fluorescent microscopy. 
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Figure 3.5 Assessment of endothelial tube formation. Mono-, co-, and tri-cultures of 
endothelial cells and endometrial cells. Hydrogel images were evaluated for (A) total vessel 
area, (B) total junctions, (C) total vessel area, (D) and average vessel area per image. *: 
significantly different culture type &: significantly different than endothelial monoculture within 
treatment #: significantly different than endothelial and stromal co-culture within treatment. 
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Figure 3.6 Images of endothelial and endometrial stromal cell cocultures following 7 days 
of (0-1) μM E2 treatment. Endothelial cells were stained for CD31 and imaged at 10x using 
fluorescent microscopy. 
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Figure 3.7 Assessment of endothelial and endometrial stromal cell cocultures l cells and 
endometrial cells. Hydrogel images were evaluated for (A) total vessel area, (B) total junctions, 
(C) total vessel area, (D) and average vessel area per image.  
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Table 3.1 PCR primer sequences 
 
Transcript Sequence Reference 
ANG1 Forward: 5’- CAGCGCCGAAGTCCAGAAAAC -3’ 
Reverse: 5’- CACATGTTCCAGATGTTGAAG -3’ 
[92] 
ANG2 Forward: 5’-GTCCACCTGAGGAACTGTCT-3’  
Reverse: 5’-TTGTGACAGCAGCGTCTGTA-3’ 
[92] 
ACTB Forward: 5’-AGGCACCAGGGCGTGAT-3’ 
Reverse: 5’-GCCCACATAGGAATCCTTCTGAC-3’ 
[176] 
MMP11 Forward: 5’-ATTTGGTTCTTCCAAGGTGCTCAGT-3’ 
Reverse: 5’-CCTCGGAAGAAGTAGATCTTGTTCT-3’ 
[177] 
VEGF Forward: 5’-CAGGACCATGAACTTTCTGC-3’ 
Reverse: 5’-CCTCAGTGGGCACACACTCC-3’ 
[92] 
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CHAPTER 4: INCORPORATING ENDOMETRIAL INSPIRED ANGIOGENIC CUES 
TO ENHANCE ANGIOGENIC EVENTS WITHIN A BIOMATERIAL 
4.1 Chapter overview 
The preceding two chapters communicated our progress in developing angiogenic models that 
utilize endometrial cells and cues, namely E2 and P4. This chapter will focus on our efforts to 
incorporate angiogenic signals within the two biomaterials to cultivate techniques that, for the 
purpose of this thesis, focus on vascular promoting biomimetic constructs. These methods, 
however, can be used more broadly for the design of other instructive biomaterials. The chapter 
begins with a brief introduction to previously-developed techniques for presenting biomolecules 
within biomaterials and how they were applied to the angiogenic factor VEGF. The chapter then 
focuses on the under-realized idea of incorporating steroids (for this research the sex steroid 
hormone E2). Covalent incorporation of E2 and the nuances associated with this method are 
discussed. Finally, a method employing a protein that readily and preferentially binds sex 
steroids is herein proposed and pursued. 
4.2 Introduction 
Instructive biomaterials guide cells to certain phenotypes and behaviors through any of a variety 
of means, including composition of the tissue analog and its mechanical properties, addition of 
cell types to provide cell-cell interactions as well as paracrine signaling, and direct 
supplementation of biologically significant signals (e.g. growth factors, integrins, and cytokines). 
A large body of research has focused on the latter, developing techniques to directly incorporate 
biological cues into instructive biomaterials to increase their efficacy [8, 19, 178-180]. These 
efforts extend to biomaterial vascularization work [1, 8, 15]. Our work here will focus in part on 
one powerful angiogenic promoter, VEGF, and different methods for presenting biological cues. 
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The simplest method to promote cellular activity by biological signals is through soluble 
supplementation like that used for VEGF in Chapters 2 and 3. While this method is 
straightforward in vitro, soluble presentation of factors requires continual supplementation over 
time due to the short half-lives of these signals. The issues are more pronounced in vivo, where 
diffusion of the supplemented factors requires high concentrations of factors to maintain the 
desired signal within the target tissue, which can lead to undesirable side-effects. High dosages 
of VEGF, for example, can result in abnormal vessel function and promotion of tumor growth 
among other issues and can even lead to loss of limb [19, 180]. Hence, there is a strong 
motivation to explore alternative methods to incorporate biologically-relevant signals. 
Biological cues are also incorporated by methods that temporarily (non-covalent attachment, 
embedding within a degradable polymer, or use of degradable linkers) or permanently fix the 
signal (via covalent bonding) within the biomaterial, allowing for spatial and temporal regulation 
[8, 178, 179]. These methods aid in increasing the efficacy while reducing the quantity of factor 
needed by controlling where and when the factor is presented, thus reducing or eliminating the 
need for continual supplementation. Utilizing soluble VEGF supplementation in conjunction 
with a transient immobilization technique and alginate gels to temporally and spatially regulate 
VEGF concentration, Silva and Mooney demonstrated angiogenic sprouting could be altered 
[47].   Additionally, researchers have exploited the inherent VEGF binding potential of certain 
ECM components such as fibronectin and heparin to regulate VEGF presentation and endothelial 
response [55, 180-184]. VEGF signaling by this method can further be manipulated by varying 
VEGF isoforms which bind differently to extracellular matrix [28, 185]. Finally, to prolong the 
angiogenic activity, methods have been pursued to covalently bind VEGF to biomaterials [46, 
61, 186].  
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Whereas VEGF incorporation into biomaterials has been readily explored, there has been little 
effort with E2. Only a small number of studies exist that have used E2 as a biological signal for 
regenerative medicine applications. These include the incorporation of E2 into medical devices 
(wound dressings and stents) as well as nano and micro particles to direct MSCs towards 
osteogenic differentiation [187-190].  Incorporation of E2 into biomaterial constructs could 
further be used for to direct endometrial inspired angiogenesis as well as cardiac [191] and 
neural health [192]. While studies on the cellular effects of E2 within biomaterials are limited, 
for decades researchers have focused on controlling the release of E2 from degradable polymers 
for pharmacological applications including menopause and osteoporosis [193-196]. Additionally, 
insoluble forms of E2 have been developed that alter the biological signaling capabilities by 
preventing cellular uptake [197]. While these studies could help instruct the development of E2 
incorporation within three-dimensional biomaterials, they lack a means for long term 
presentation or a means to harness endogenous E2. We therefore sought an alternative method 
utilizing SHBG to regulate E2 that is biologically relevant. 
This chapter first explores the incorporation of the proteoglycan heparin within the CG scaffolds 
as a means to use charge-charge interactions to transiently sequester VEGF within the scaffold 
network in order to improve cell bioactivity. The chapter then shifts to focus on methods to 
present E2 within a biomaterial via two distinct methods, a covalent method where E2 is bound 
to bovine serum albumen and a transient method using sex hormone binding globulin (SHBG) to 
sequester E2 within a biomaterial.  
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4.3 Materials and methods 
CG scaffold fabrication 
CG scaffolds were fabricated as previously described [125, 134]. 0.5 wt% CG slurry was 
prepared by homogenizing fibrillar collagen (Collagen Matrix, Franklin Lakes, NJ; Sigma 
Aldrich, St. Louis, MO) and heparin from porcine intestinal mucosa (Sigma Aldrich) in 0.05 M 
acetic acid (Acros Organic, NJ) and stored at 4˚C [6]. The degassed suspension was pipetted into 
an aluminum mold and cooled at a rate of 1 ˚C/min to -40˚C followed by subsequent sublimation 
of ice crystals (0˚C, 200 mTorr).  
CG scaffold crosslinking 
Scaffold sheets were crosslinked and sterilized via a dehydrothermal crosslinking (105˚C, 24 
hours, 0.5 mmHg) [6]. Biopsy punches (Integra-Miltex, York, PA) were used to cut experimental 
scaffolds (6 mm dia.; 3 mm thick). Prior to use, scaffolds were hydrated in ethanol, then water 
before undergoing further crosslinking via carbodiimide chemistry. Scaffolds were crosslinked 
(room temperature, 1.5 hrs) in a solution of 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC) (Sigma Aldrich) and N-hydroxysulfosuccinimide (NHS) (Sigma Aldrich) 
at a molar ratio of 5:2:1 EDC:NHS:COOH. The scaffolds were then washed in PBS and stored at 
4˚C until use. 
Epithelial and endothelial cell culture  
Endometrial epithelial cells, Ishikawa 3-H-12 cells, were cultured in DMEM/F-12 medium 
supplemented with 5% in-house carbon stripped FBS (Invitrogen, Carlsbad, CA), 100 U/mL: 
100 μg/mL penicillin/streptomycin (Invitrogen), 2 mM L-glutamine (Invitrogen) (37˚C, 5% 
CO2). At confluence, cells were trypsinized and passaged (1.5x10
6
 cells per T 75 flask), 
cryopreserved, or seeded into scaffolds. Human Umbilical Vein Endothelial Cells (HUVECs) 
76 
 
(Invitrogen) were seeded at 2.5x10
5
 cells per T 75 flask pre-coated with gelatin (Sigma Aldrich) 
and fibronectin (Sigma Aldrich) in Medium 200 (Invitrogen) supplemented with Low Serum 
Growth Supplement (LSGS) (Invitrogen) and 100 U/mL: 100 μg/mL penicillin/streptomycin 
(Invitrogen) (37˚C, 5% CO2). HUVECs were used at passage 4 for experiments. Cells were 
seeded into hydrated scaffolds using a static seeding method [127, 136]. Cell seeded scaffolds 
were then cultured (37C, 5% CO2) for up to 14 days with media replacement on days 3, 6, 10, 
and 13. For some experiments, culture media was supplemented for some experiments with 
soluble E2 (1-1000 μM; Sigma) or VEGF (100 ng/mL; ProSpec). Additionally, for studies 
examining the effect of factors secreted by epithelial cells, condition media was collected from 
epithelial seeded scaffolds and applied to endothelial-seeded scaffolds to assess the effects of 
epithelial secreted factors. 
Cell number and metabolic activity quantification  
The total number of cells within each scaffold was determined via DNA quantification [136]. 
DNA was tagged with Hoechst 33528 (Invitrogen) following scaffold and cellular digestion in a 
papain solution (Sigma Aldrich) (60˚C, 24 hours). Normalized fluorescent intensity was 
measured using a F200 spectrophotometer (Tecan) 360(35)/465(35) nm (excitation/emission) to 
determine cell number with a standard curve of known cell numbers and normalized fluorescent 
intensities. The total metabolic activity of cell seeded scaffolds was monitored via a non-
destructive alamarBlue assay [136, 137]. Scaffolds were rinsed in PBS and incubated at 37˚C in 
alamarBlue (Invitrogen,) under mild shaking. The metabolic reduction of resazurin to the 
fluorescent byproduct resorufin by cells was measured on a F200 spectrophotometer (Tecan) at 
540(52)/580(20) nm (excitation/emission). Relative metabolic activity was then determined by 
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comparing the resulting normalized fluorescent intensities with a prepared standard curve of 
known cell numbers and normalized fluorescent intensities.  
VEGF quantification in conditioned media 
Conditioned media was collected from epithelial cell-seeded scaffolds after 24 or 48 hours, 
aliquoted, then frozen (-20 ˚C). The concentration of secreted VEGF was determined via the 
ELISA duoset kit (R&D systems, Minneapolis, MN) per manufacturer’s instructions. 
Western blot analysis of receptor and signaling pathway activation 
For analysis of receptor and signaling pathway activation, cells were first transferred to 
unsupplemented DMEM/F-12 media for 20 hours to create a baseline. Epithelial cells were then 
seeded into the scaffold and maintained for 4 hours in unsupplemented DMEM/F-12 media to 
allow for sufficient cell attachment within the matrix. Cell-seeded scaffolds were then transferred 
to 1.8 mL microcentrifuge tubes. Scaffolds were stimulated with 25 μL of desired E2 
supplemented media for a set reaction time (3-20 min). Immediately at the end of the reaction 
time, 100 μL of cold RIPA buffer was added to each tube. Scaffold specimens were vortexed for 
20 minutes then frozen (-20˚C) for subsequent analysis. Protein concentration was determined by 
BCA assay (Bio-Rad) to ensure equal loading of samples. For analysis, samples were diluted in 
equal volumes of Laemmli buffer 2x with 2% β-mercaptoethanol (BioRad), heat-treated for 10 
minutes at 95˚C, and loaded onto SDS-PAGE (10% separating) (1 hour, 150 V). Protein was 
transferred onto nitrocellulose membranes via a Trans-Blot SD (BioRad) (15 minutes, 15 V). 
The membranes were blocked with 5% milk in 0.1% Tween-20 in TBS for 30 minutes at room 
temperature before overnight incubation with primary antibodies β-actin, (p44/42 MAPK, P-
p44/42 MAPK (T202/Y204), Estrogen Receptor α (D8H8), and Phospho-Estrogen Receptor α 
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(S104/106) (Cell Signaling, Beverly, MA). Blots were imaged using ImageQuant LAS 4010 (GE 
Healthcare Life Sciences, Pittsburgh, PA). Protein bands were quantified using ImageJ software. 
Methacrylamide-functionalized gelatin macromer synthesis  
Methacrylamide-functionalized gelatin (GelMA) was synthesized as previously described [161]. 
Briefly, Gelatin (Type A, 300 bloom from porcine skin) solution was dissolved in phosphate 
buffered saline (PBS) (Gibco, Grand Island, NY) to a concentration of 10 wt%, (60˚C, stirring). 
Methacrylic anhydride (MA) (Sigma-Aldrich, St. Louis, MO) was then added dropwise and 
allowed to react (60˚C, 1 hr). The mixture was diluted in PBS (60˚C) prior to dialysis (12,000 – 
14,000 M.W, Fisherbrand, Pittsburgh, PA) against distilled water to remove salts and excess 
MA. The GelMA was then lyophilized prior to use. Sufficient MA was added to generate a final 
GelMA macromer with 47-57% degree of MA functionalization, as verified via 
1
H NMR (Varian 
INOVA).  
Lithium acylphosphinate photoinitiator synthesis  
Lithium acylphosphinate (LAP) photoinitiator was synthesized as previously described [164]. 
2,4,6-trimethylbenzoyl chloride (Sigma Aldrich) was added in a dropwise manner to equimolar 
dimethyl phenylphosphonite (Sigma Aldrich) at room temperature under continuous stirring and 
argon. A precipitate was formed by addition of fourfold excess of lithium bromide in 2-butanone 
(Sigma–Aldrich) and heating to 50˚C. The mixture was returned to room temperature prior to 
filtration and then washed 3 times in 2-butanone to remove unreacted lithium bromide. Excess 
solvent was subsequently removed by vacuum. 
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GelMA hydrogel synthesis 
A GelMA solution (4 wt %) with 0.1 wt % LAP photoinitiator was prepared in PBS (60˚C). 
Cells were suspended in the GelMA solution prior to photo-polymerization. The cell-hydrogel 
suspension was pipetted (40 µl) into the wells (5 mm diameter, 2 mm thick) in a Teflon mold 
attached to a glass slide with binder clips. The hydrogel suspension (with/without E2 and/or 
SHBG) was then exposed to UV light (10 mW/cm
2
, 365 nm, 30 s) [163] to form a polymerized 
hydrogel which was then extracted from the molds. Hydrogel specimens were incubated (37˚C, 
5% CO2) in 48-well culture plates in PBS. 
E2 controlled release studies 
Sex hormone binding globulin (Fitzgerald, Acton, MA, USA) with or without E2 (Sigma 
Aldrich) was incorporated into the hydrogel precursor suspension prior to UV crosslinking. The 
hydrogels were placed in PBS for varying lengths of time (1, 6, 12, 24 hrs) to allow for elution of 
E2 from the network. At the experiment endpoint, the hydrogels were subsequently heat treated 
in fresh PBS with intermittent vortexing (60˚C, 1 hr) to release the remaining bound E2, which 
was then quantified via Estradiol Parameter Assay Kit (R&D systems). 
Statistical methods 
Statistical analyses were performed using SPSS software (IBM). Statistical significance was 
assumed at p < 0.05 unless otherwise stated. Error bars are reported as standard error of the mean 
unless otherwise noted. GAG effects on proliferation and cell number during 2-week cultures of 
epithelial cells with E2 (n = 6), ANOVAs with Tukey post hoc tests were used. E2-BSA and E2 
dose effects on ERα phosphorylation (n = 4), ERK 1/2 phosphorylation (n = 4), were assessed 
with ANOVAs. Carbodiimide immobilization of E2-BSA was evaluated by linear correlation. 
The effect of soluble versus EDC immobilized BSA-E2 conjugates on epithelial cell metabolic 
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activity and VEGF production was evaluated via ANOVA (n = 6). Release of E2 from GelMA 
gels laden with or without SHBG was determined via ANOVA with Tukey post hoc (n=5).  
4.4 Results 
Endothelial population and metabolic activity is higher in CG scaffolds with Heparin. 
Three media, an endothelial growth medium (LSGS), an epithelial growth medium supplemented 
with 5% CS-FBS, and the epithelial growth medium supplemented with 5% CS-FBS and 100 
ng/mL VEGF were explored to evaluate their ability to maintain endothelial cells within CG 
scaffolds short term (1 or 4 days).  Unsurprisingly, while VEGF improved both the metabolic 
activity and cell population compared to the epithelial growth medium alone, LSGS was the best 
at maintaining the endothelial culture (Figure 4.1). More importantly, we sought to determine 
whether replacing chondroitin sulfate with heparin within the scaffolds sulfate could improve 
cultures viability.  Heparin increased the number of endothelial cells both at days 1 and 4. Over 
the experiment, heparin trended toward increasing metabolic activity (p= 0.069). However, when 
the metabolic activity was normalized to cell population as determined by Hoechst DNA, there 
was no difference between heparin and chondroitin sulfate (p= 0.385), suggesting that heparin 
increased cell population but did not affect metabolic activity. 
Immobilization of E2 within the scaffold network has a negative effect on epithelial metabolic 
activity and VEGF production. 
To examine the effects of E2 presentation within the scaffold, E2-BSA conjugate was 
immobilized within the scaffold network (0 – 1000 nM E2) via carbodiimide cross-linking 
(Figure 4.2A). The metabolic activity and VEGF production of endometrial epithelial cells 
(300,000 cells seeded/scaffold) was examined in response to matrix-immobilized or soluble E2. 
Addition of soluble E2 to the media, in this case, led to a non-significant (p = 0.14) increase in 
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epithelial cell metabolic activity versus epithelial culture media alone (Figure 4.2B). However, 
epithelial cells were found to have a significantly higher metabolic activity when supplemented 
with the soluble versus the matrix-immobilized E2 (p < 0.05). VEGF production was found to be 
marginally higher (p = 0.06) in response to soluble E2 versus unsupplemented media, while 
VEGF production was significantly (p <0.01) reduced for cultures with matrix-immobilized E2 
(Figure 4.2C). No change, however, was detected in early ERK 1/2 activation (Figure 4.3). 
These findings suggest for long term presentation to facilitate angiogenesis, E2 must be 
transiently immobilized within the scaffold. 
Incorporation of SHBG alters the retention and release of E2 from the GelMA hydrogel.  
We next examined an approach to alter the retention of E2 within the hydrogel network via the 
inclusion of sex hormone binding globulin (SHBG). Here, the heat treatment (60
o
C, 1 hours) 
sufficient to release E2 bound by SHBG did not affect the ability to measure total dose of E2 
remaining within the hydrogel network (Figure 4.4). However, covalent incorporation of the 
SHBG into the network via pegylation [163, 198] rendered SHBG unable to bind exogenous E2 
(Figure 4.5). However, SHBG added to the hydrogel precursor suspension prior to 
photoimmobilization significantly (p = 0.004) increased the capacity to retain E2 within the 
hydrogel over time (Figure 4.6). Examining E2 retention, while almost 85% of the initially 
loaded 1µM E2 dose was released from the GelMA network, retention was significantly (p ≤ 
0.005) higher at 6, 12, and 24 hours for the GelMA hydrogel also incorporating 1µM SHBG 
(Figure 4.6A). Here, greater than 30% of the E2 dose was still retained in the SHBG containing 
hydrogel after 24 hours. Further, increasing the dose of SHBG initially incorporated within the 
GelMA hydrogel (0 – 5µM) led to a significant (p < 0.001) increase in initial sequestration of E2 
(1µM dose for all conditions) within the network (Figure 4.6B). 
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4.5 Discussion 
Tissue engineering efforts commonly employ a wide range of biological cues, including 
cytokines, growth factors, siRNA, in order to direct a desired cellular response [8, 178]. We 
previously showed that VEGF supplementation altered endothelial behavior within CG scaffolds 
[159]. Chapter 3 went a step further, demonstrating that VEGF supplementation improved 
vascularization in cultures of HUVECs with or without endometrial stromal cells within GelMA 
hydrogels. These experiments, however, relied solely on soluble VEGF. To increase the efficacy 
of VEGF and other biological factors, we previously sought to immobilize a model protein, 
Concanavalin A, within the scaffold via both a conventional carbodiimide-based crosslinking 
method [61, 199] as well as a photolithographic technique to explore the patterning conditions 
that effected the covalently and non-specific binding of biological factors within CG scaffolds 
[133, 134].  We used this photolithographic technique to spatially pattern VEGF to direct 
angiogenic processes within monocultures of HUVECs [46]. The presence of immobilized 
VEGF resulted in higher spreading of the HUVECs (Figure 4.7) and deeper cell penetration into 
the scaffolds (Figure 4.8). These findings agreed with previous experiments that utilized 
covalently bound VEGF [61, 62, 135].  
An alternative approach is to modify the biomaterial to directly sequester VEGF. Our lab has 
previously demonstrated that the incorporation of heparin improves the binding of some growth 
factors and alters cellular behavior [132]. We therefore sought to improve the efficacy of VEGF 
within our CG scaffolds by replacing chondroitin sulfate with heparin. Our experiments found 
that heparin improved endothelial viability, but did not alter the overall metabolic activity of the 
endothelial cells. These two methods improved the efficacy of VEGF within CG scaffolds, as 
discussed in Section 1.6. However, the incorporation of one or even a few angiogenic factors 
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oversimplifies the complex processes that occur in physiological angiogenesis. Therefore we 
sought to develop a more regulated vascular response that controls expression of a host of 
angiogenic factors by using exogenous sex hormones and endometrial cells, as discussed in 
Chapters 2 and 3. To better utilize these signals, in this work we sought to develop a method 
that would allow us to control E2 presentation within the biomaterials. The first method sought 
to covalently bound E2 within the CG scaffolds (Figure 4.2).   
While the incorporation of growth factors such as VEGF into biomaterials via a variety of 
delivery and immobilization methods has been widely explored [8, 20, 200], there has been only 
a few studies examining controlled presentation of sex hormones such as E2. Notably, E2 has 
been incorporated into polymer coatings and fibers of medical devices (wound dressings and 
stents) as well as released from nano and micro particles to enhance MSC osteogenic 
differentiation [187-190] and for therapies associated with menopause and osteoporosis [193-
196].  Beyond the angiogenic application described in this work, technologies to control the 
presentation and release of E2 may have benefits for a broader range of biomedical application, 
notably cardiac [191] and neural regeneration [192]. 
Research on E2 signaling has focused largely on the actions of free E2 working through estrogen 
receptors. Previously, uterine cells showed differential responses to E2 depending on whether the 
E2 was able to be internalized by the cell [201]. Within the past decade, researchers have 
explored how covalently bound E2 alters the actions of E2, which allows extranuclear signaling 
to occur while inhibiting direct gene transcription [140, 197, 201, 202]. Alternatively, the 
estrogen receptors (ERs) have been modified to prevent nuclear activities in order to distinguish 
between nuclear and non-nuclear signaling [203]. In the current study, we used E2 immobilized 
on BSA to examine whether the mode of E2 presentation affected epithelial cell response. The 
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results showed immobilized E2 led to decreased epithelial metabolic activity and VEGF 
production compared to soluble E2 treatment. No change, however, was detected in early ERK 
1/2 activation (Figure 4.3). These findings suggest for long term presentation to facilitate 
angiogenesis, E2 must be transiently immobilized within the scaffold.  
As an alternative method to covalently bound E2, we utilized sex hormone binding globulin 
(SHBG) to control the sequestration and release of E2 within our gelatin hydrogel. This effort 
was inspired by recent efforts utilizing interactions associated with proteoglycans to regulate the 
sequestration and release of growth factors within biomaterials [132, 178, 204]. The small size of 
E2 led us to examine mechanisms by which bioavailability of sex hormones are regulated within 
the body. Although the majority of E2 in plasma is bound by albumin, E2 binds more readily to 
SHBG, with an association constant four magnitudes higher [205]. While SHBG is produced 
primarily in the liver, hormone responsive tissues within the body including the endometrium 
have also been shown to produce the glycoprotein [206-209]. SHBG is classically thought to 
regulate the levels of free sex steroids available for signaling [207]. However, SHBG can also be 
internalized by cells and may facilitate internalization of E2 as well [210].  
We sought to incorporate SHBG within the gelatin hydrogel in order to modify the 
bioavailability of E2. Excitingly, addition of SHBG within the hydrogel network demonstrated 
that SHBG can be used to regulate E2 availability. Firstly, the concentration of SHBG within the 
hydrogel could tune the total amount of E2 sequestered, providing a pathway to alter either the 
sequestration of exogenous E2 or E2 produced endogenously by cells within the hydrogel. 
Further, the presence of SHBG within the hydrogel network led to significantly increased 
retention of E2 within the hydrogel network, to the degree of a 6.2-fold increase in E2 retention 
after 24 hours in culture. We subsequently attempted to covalently bind SHBG within the 
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hydrogel network via PEG-NHS ester linker as we have previously used to immobilize stem cell 
factor [163]. However, the crosslinking reaction abrogated any E2, suggesting that either the 
PEG-functionalization or subsequent photoimmobilization steps interfered with the homodimeric 
structure of SHBG, inactivating the E2 binding site. Ongoing studies are therefore exploring 
alternative approaches for binding SHBG within biomaterials such as the incorporation of 
fibulin, which has been shown to bind SHBG natively [211, 212], or antibodies for SHBG into 
the constructs. 
4.6 Conclusion 
The development of instructive biomaterials for regenerative medicine requires techniques that 
optimize and regulate biological factor presentation in order to direct cell behavior. Here, we 
demonstrated how these techniques could be advantageously applied in the development of 
endometrial inspired angiogenic biomaterials in order to regulate the presentation of angiogenic 
factors such as VEGF. We further sought to control vascularization through regulating 
endogenous angiogenic factor presentation through the actions of E2.  To this end, we attempted 
both covalent and non-covalent methods. We demonstrated the need for unbound E2 in order to 
allow for genomic signaling for the production of angiogenic factors. We utilized SHBG for 
short term regulation of exogenous E2 supplementation, which will require further research into 
sequestration and effects of cellular behavior and angiogenesis. 
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4.7 Figures 
 
  
Figure 4.1 Effect of GAG and growth media on endothelial cell activity and number on 
short term culture. (A) Metabolic activity of endometrial endothelial cells cultured in scaffolds 
prepared with chondroitin sulfate or heparin and treated with soluble E2 or E2-BSA cross-linked 
to scaffolds via BP (nM of BSA-E2 loaded for immobilization).    
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Figure 4.2 Effect of E2 immobilization by EDC on angiogenic potential of endometrial 
epithelial cells. (A) Immobilization of E2-BSA into CG scaffolds quantified by MFI of 
secondary antibody to E2. (B) Metabolic activity of endometrial epithelial cells cultured in 
scaffolds treated with soluble E2 or E2-BSA cross-linked to scaffolds via BP (nM of BSA-E2 
loaded for immobilization). (C) VEGF produced by endometrial epithelial cells under different 
treatments. Dashed lines represent control.   
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Figure 4.3 Change in ERK1/2 activation due to E2 presentation (A) pERK:ERK (B) 
Representative western blots 
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Figure 4.4 Quantification of E2 in gel relative to E2 loaded into gel.  
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Figure 4.5 Effect of incorporation of SHBG and pegylated SHBG into hydrogels on E2 
uptake from solution. * : Significantly different from control (p <.05), p=.054 between 
SHBG and PEG-SHBG. 
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Figure 4.6 Effect of Sex Hormone Binding Globulin (SHBG) on the retention of 1 μM E2 
within GelMA hydrogels. (A) E2 remaining within hydrogel following elution in PBS for 6, 12, 
and 24 hours. (B) E2 retained in hydrogel following 1 hour elution as a function of SHBG 
loaded. #: Significantly different than SHBG hydrogels &: Significantly different than other 
timepoints *: Significantly different than other treatments. 
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Figure 4.7 Photoimmobilized VEGF leads to an activated HUVEC cell morphology. (A) 
Representative images of TRITC-phalloidin (actin, green) and DAPI (nucleus, blue) stained 
HUVECs seeded onto CG scaffolds containing benzophenone photoimmobilized VEGF exhibit 
an activated (spread) morphology. (B) Representative images of HUVECs seeded into scaffolds 
without photoimmobilized VEGF reveal cells remain in quiescent state with little elongation, 
branching or cell–cell contact. Images acquired 18 h post-seeding. (C) Calculated average area 
per cell, measured by dividing total actin stained area by the number of cell nuclei, comparing 
scaffolds with and without photoimmobilized VEGF. *: p < 0.05. 
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Figure 4.8 Photoimmobilized VEGF leads to greater HUVEC scaffold penetration depth. 
Representative cross-section of the pan side of CG scaffolds reveal differences in HUVEC 
penetration for (A) benzophenone immobilized VEGF vs. (B) unmodified CG scaffold. Dashed 
lines indicate the edges of the scaffold. (C) HUVEC penetration was significantly greater with 
VEGF photoimmobilization. *: p < 0.05. Images acquired 18 h post-seeding. 
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary 
In this work we sought to develop new methods to promote pre-vascularization of biomaterials. 
We described the development of pro-vascular endometrial models to explore how 
characteristics of natively angiogenic tissues behaved within a three-dimensional biomaterial 
culture environment in vitro. Using a model collagen-GAG (CG) scaffold, we first developed a 
model leveraging pro-angiogenic factor-producing endometrial epithelial cells which 
demonstrated that altering estradiol supplementation led to changes in VEGF production and 
subsequent changes in non-endometrial endothelial cell activity (Chapter 2). We then explored 
endometrial stromal cells in addition to epithelial cells for both their pro-angiogenic signals and 
stabilization of endothelial tubes with longer cultures in a model methacrylamide-functionalized 
gelatin (GelMA) hydrogel, allowing for easier visualization of tube formation (Chapter 3). 
While this effort found endometrial epithelial cells altered angiogenic gene expression in 
response to E2 and progesterone, we observed no changes in VEGF secretion, suggesting future 
opportunities to refine the hydrogel structural and mechanical properties to perhaps enhance 
VEGF production. In both the scaffolds and hydrogels, direct cocultures of endometrial epithelial 
cells with endothelial cells led to reduced metrics of vascular network formation. Endometrial 
stromal cells, which were previously shown to alter angiogenic signaling in the presence of E2 
and progesterone in two-dimensional cultures, did not respond to hormonal changes within the 
three-dimensional biomaterial cultures, but cocultures of endometrial stromal cells with 
endothelial cells improved endothelial tube formation. 
One of our main objectives was to develop a novel method to regulate vascular processes within 
biomaterials using endometrial cues. To this end, we utilized traditional as well as nature-
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inspired methods to sequester estradiol within the biomaterials to facilitate endometrial cell 
driven vascularization (Chapter 4). In previous collaboration with Dr. Bailey’s group at UIUC, 
we explored both covalent-immobilization as well as novel light-based photoimmobilization 
strategies to incorporation biomolecular cues within the biomaterial network to direct cell 
behavior [46, 133, 134]. Through this collaboration, we observed early pro-angiogenic responses 
by endothelial cells in response to VEGF incorporated into CG scaffolds via both transient and 
covalent sequestration methods [46]. Similarly, we sought to incorporate E2 covalently using E2 
immobilized on BSA, but found that E2 uptake into the cell was important for pro-angiogenic 
responses. As a result, we sought to non-covalently incorporate E2 within the GelMA hydrogel 
using an approach inspired by the means by which E2 is sequestered physiologically. This effort 
demonstrated the use of sex hormone binding globulin (SHBG) to sequester and prolong the 
release of E2 within the GelMA hydrogel network.  
5.2 Future directions 
This thesis provides a foundation for future efforts aiming to develop an endometrial model for a 
range of tissue engineering applications. Importantly, this work highlights many key challenges 
associated with developing an angiogenic tissue model and pre-vascularizing biomaterials, 
including: 
 Recreating complex physiological conditions in culture conditions that account for the 
diverse cell-cell and cell-matrix interactions within the native endometrium 
 Optimizing biomaterial properties (e.g., stiffness, density, chemistry) to provide an 
environment conducive to initial vascular network formation as well as subsequent vessel 
maturation  
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 Optimizing in vitro culture conditions (types, ratios, and density of cells; biomolecular 
supplementation) 
 Altering the mode (soluble, covalent immobilization, transient sequestration) of 
biomolecule presentation 
Efforts described in this thesis concentrated on exploring a number of biomaterial-based systems 
and to validate the concept of using co-cultures of endometrial derived cells to promote pro-
angiogenic behaviors in biomaterial cultures. 
Exploration of role of hypoxia on vascularization 
In our endometrial model, we focused on the role of sex hormones, estradiol and progesterone, as 
key regulators of endometrial angiogenesis, in line with traditional endometrial vascular research 
[69, 81, 82]. We demonstrated that endometrial epithelial cells were able to endogenously 
produce VEGF in response to exogenous E2. Opportunities exist in the future to explore the 
coordinated response to E2 and endometrial hypoxia. Hypoxia plays an important role in 
angiogenesis when tissues exceed the available oxygen from diffusion (due to growth or injury) 
[25, 26]. In the case of the endometrium, hypoxia is mostly associated with menstruation as well 
as during and following implantation [69, 77, 213]. HIF-1α, a significant factor of hypoxia, is 
important to the transcription of VEGF [84]. Further, while levels of hypoxia has been found to 
alter the expression of angiogenic factors by endometrial stromal cells in vitro, the potential for 
synergistic activation of these processes via E2 and hypoxia remains poorly defined [92].  
Therefore, significant future opportunities lie in the ability to leverage hypoxia to enhance the 
hormone-dependent response we observed within our models. For instance, models using 
hydrogel cocultures of endothelial cells with endometrial epithelial cells and/or stromal cells 
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could be leveraged to explore the dynamics between hypoxia and endometrial vascularization in 
vitro. Further experiments could explore temporal changes in hypoxic conditions, beginning 
under hypoxic conditions to simulate the perimenstrual phase and then adjusting to normoxia. 
Leveraging microfluidic devices for improving angiogenic endometrial culture in vitro 
In developing this first iteration of a GelMA hydrogel-based endometrial model, we tuned many 
system parameters (media formulation, total cells seeded, the ratio of endometrial cells to 
endothelial cells, and concentration of GelMA). These and other system parameters can be 
adapted further using microfluidic devices which are becoming more commonly employed in the 
field of tissue engineering. Our lab has developed a class of microfluidic device to generate 
spatially-graded hydrogel to alter hematopoietic stem cell fate and glioma tumor properties [214, 
215]. These devices allow for gradient formations of matrix, biological cues, and cell densities, 
suggesting the possibility of future endometrial inspired investigations that use these graded 
biomaterials to more rapidly explore a wide biomaterial design space. 
Our efforts in Chapters 2 and 3, consistent with earlier efforts that employed cultures of 
endometrial cells cultured on two-dimensional substrates [57, 85], found that endometrial 
epithelial cells can promote vascularization via production of soluble factors, and further that 
endometrial stromal cells support vascular endothelial organization. Notably, these efforts 
concentrated on constant levels of hormone supplementation. As a result, there are significant 
opportunities to explore the temporal presentation of supplemental hormones to mimic changes 
within the endometrium. For instance, microfluidic culture tools such as those recently described 
by Kamm et al. [216, 217] offer particular opportunities to regulate the temporal presentation of 
estradiol and progesterone within a hydrogel that also contains a polarized monolayer of 
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epithelial cells (Figure 5.1) as well as a separate hydrogel environment impregnated with 
endothelial cells and endometrial stromal cells.  
Incorporation of additional endometrial ECM features into biomaterials 
Along with changes in growth factor secretion, alterations to ECM composition may also 
contribute to the vascular development within the endometrium. Previous work by Kalluri et al. 
showed components of the basement membrane associated with mature vessels could support 
stability and quiescence whereas components of provisional matrix such as vitronectin, 
fibronectin, Col I, and thrombin promote endothelial proliferation [33]. During the endometrial 
cycle, endometrial cells first generate ECM to facilitate growth and then remodel the ECM to 
prepare for implantation. A thorough study on endometrial composition was conducted by Aplin 
et al. in 1988 in which endometrial specimens from different endometrial phases were 
photolabeled to identify changes in relative levels of various ECM constituents of the 
interstitium and the basement membranes of glands, vessels, and pericellular matrix of stromal 
cells [218]. The ECM components of vascular basement membranes appear fairly consistent 
throughout the endometrial cycle. The composition of the interstitium, however, varies. Iwahashi 
et al. also demonstrated changes in collagen ratios during the menstrual cycle within endometrial 
ECM [219]. Their results suggest that the ratio of Col III to Col I decreases during the 
endometrial cycle and into pregnancy from almost 5:4 to 5:2, while Col V increases. They also 
propose that changes in collagen are due to stromal cells. While Aplin et al. found that Col V 
was most visible during the early part of the endometrial cycle, Iwahashi et al. found that the 
actual levels increased throughout the cycle. This apparent mismatch could be due to the 
accessibility of Col V which is masked by Col I. Col V may be contribute to angiogenesis as it 
has a higher affinity to heparin/heparan sulfate than other collagens, suggesting it could be 
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important to the maintenance of angiogenic growth factors such as VEGF [219]. A study into the 
ECM composition of baboon endometria, a common endometrial model,  found that fibronectin 
was found in the stromal compartment, while Col IV and laminin were found mainly in the 
basement membranes of vessels and glands [220]. These findings suggest opportunities to alter 
the incorporation of endometrial ECM constituents to further direct endometrial angiogenesis. 
Use of primary cells either through biopsy or menstrual tissue 
In our research we used endometrial cell sources (an adenocarcinoma clone that expresses 
estrogen and progesterone receptors [221] as an epithelial cell model as well as an h-TERT 
immortalized HESC population [222]) that were hormone responsive and would have a more 
stable phenotype than primary cells. There are future opportunities to use cells freshly isolated 
from biopsies samples [223-225] or endometrial cells isolated from menstrual tissue [226, 227]. 
Menstrual tissue collection is less invasive than biopsies and hence may be easier to obtain, but 
in both cases intra and inter sample heterogeneity of primary cells would provide an additional 
level of complexity to explore [57].  
Inclusion of immune cells to regulate angiogenesis. 
This thesis showed that endometrial epithelial and stromal cells could be employed to promote 
endometrial-inspired angiogenesis processes in vitro. Immune cells are prevalent within the 
endometrium and are thought to play an important role during menstruation and implantation 
[228, 229]. As summarized by Ribatti and Crivellato, innate immune cells support angiogenesis 
through secretion of angiogenic factors and matrix metalloproteinases (MMPs) in inflammatory 
as well as tumor environments [230]. Angiogenic factor secretion has also been demonstrated 
with both endometrial neutrophils and uterine natural killer cells [231, 232]. Further, leukocyte 
populations vary throughout the endometrial cycle and is at their highest density during the late 
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secretory phase [228]. It is worth noting that immune cells may lack estrogen and progesterone 
receptors and therefore may not directly respond to sex steroids. Rather, chemokines within the 
endometrium recruit immune cells which then proliferate during the late secretory phase. 
Therefore, inclusion and regulation of immune cell populations in an in vitro model may offer 
unique opportunities to add further complexity to in vitro endometrial model cultures.   
5.3 Final thoughts 
In conclusion, this thesis provides a unique perspective towards approaches to generate 
biomaterials capable of supporting rapid vessel formation using a non-pathological angiogenic 
tissue model. This work highlights how the endometrium can provide new insights for the field 
of tissue engineering by leveraging physiologically-inspired strategies to overcome obstacles 
preventing of dense vessel networks.  
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5.4 Figure 
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      Preconditioning cells and endometrial stromal cells 
Figure 5.1 Microfluidic device experimental setup. 
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APPENDIX A: IN VITRO ENDOMETRIAL MODELS 
Endometrial Models (search terms: endometrium culture). Previous studies that utilized in vitro 
endometrial models within the past 10 years were identified through a PubMed search using the 
term “endometrium culture”.  The search was conducted during July 7-July 10, 2015. Studies 
were chosen based on the following criteria: 
1. Some form of endometrial physiology was being studied. 
(Endometrial cell adhesion outside of the endometrium as well as endometrial cells 
differentiated for other purposes such as nerve regeneration were not considered) 
2. At least one type of endometrial cell was used with or without other cells types. 
(Endometrial cells cultured with macrophages or adipose cells were considered) 
3. Cultures went beyond standard 2-D seeding to attempt to recreate some endometrial 
condition. 
(Endometrial cells cultured in 2-D with trophoblasts on top or stromal cells cultured in 2-D 
and decidualized were considered). 
4. Explants were not considered. 
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Table A.1 Endometrial Models for probing specific endometrial function 
Paper 3D? Material Cell Description of culture Motivation 
[233] No Flexible bottom well 
plates 
Human endometrial stromal 
cells 
Cells were seeded onto flex plates and then 
stretched following decidualization 
Mechanical stress on 
decidualization 
[234] Yes Col 1 matrix (rat 
tail)  
monkey mid-secretory stage 
endometrial stromal cells  
Unknown Effect of LIF on endometrial 
stromal cells 
[235] No? Matrigel Human endometrial epithelial Cultured on matrigel or culture plastic Effect of ECM on cells 
[236] No Laminin Col IV Primary human endometrial 
stromal cells 
2D cultures Autocrine/paracrine 
regulation of stromal 
remodeling 
[102] Yes Col 1 porcine gels  Endometriotic cyst stromal 
cells, eutopic endometrial 
stromal cells with 
endometriosis, and normal 
endometrial stromal cells 
Embedded in collagen gels Contractility during 
decidualization 
[237] No? Collagen I, IV, 
Matrigel fibronectin, 
laminin, gelatin 
Canine uterine glands and 
stromal cells from tissue 
Cells seeded onto ECM components Study endometrial cyclic 
events in vitro 
[107] Yes Collagen Primary rabbit endometrial 
epithelial and stromal cells 
Stromal cells were suspended in collagen 
type 1 from rat tails with matrigel with 
epithelials seeded on surface 
Endometrial model 
[225] Yes FN modified 
alginate beads 
Primary human endometrial 
stromal cells 
Stromal cells encapsulated in beads Demonstration of perfusion 
culture system of stromal 
cells 
[238] No FN modified wells Primary human endometrial 
stromal cells 
Seeded into wells FN mediated adhesion of 
stromal cells 
[239] No Coverslips RL95-2 and JAr spheroids Jar spheroids on RL95-2 monolayers sLeX/L-selectin mediates 
adhesion 
[240] Yes* Matrigel inserts RL95-2, isolated endometrial 
stromal and epithelial cells 
Cells were cocultured on matrigel inserts Exploration of endometrial 
function 
[122] Yes Collagen I hydrogels T HESCs HESCs were suspended within the gel 
during gelation 
Regulation of stromal 
function leading to 
menstruation 
[99] Yes N/A N/A  Review article 
[241] No microplates Primary HEECs and 
HTR8sv/neo cells 
HTR8sv/neo cells were seeded on HEEC 
monolayers treated with conditioned media 
to determine adhesive capabilities 
Adhesion and receptivity 
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Table A.1 (cont.) 
Paper 3D? Material Cell Description of culture Motivation 
[103] Yes N/A N/A Multiple described Review article on epithelial 
cultures 
[242] No? Matrigel Canine uterine glands and 
stromal cells from tissue 
Cells seeded onto Matrigel Effects of sex steroids on 
canine epithelial/stromal 
coculture system 
[243] Yes Basement 
membrane 
(Matrigel) 
Murine endometrial epithelial 
cells isolated from biopsies 
Spherical structures formed in basement 
membrane suspension 
E2 priming of endometrial 
epithelial cells 
[244] Yes Temperature-
responsive cell 
culture dish 
(UpCell®) 
Murine (mouse and rat) 
endometrial cells 
Endometrial cell sheets Uterine tissue reconstruction 
[110] Yes Collagen/Matrigel 
Hydrogel 
Ishikawas and H-tert 
immortalized HESCs 
Cells seeded separately or together directly 
in hydrogels 
Studying Endometrial Cell-
Cell interactions 
[245] Yes Agarose Isolated bovine endometrial 
stromal and epithelial cells 
Spheroids on Agarose Study of bovine 
endometrium 
[246] No Culture Plastic Ishikawas, HESCs, adipocytes 2D cultures Cross-talk between the 
endometrium and adipose 
tissue effect on receptivity 
[159] Yes Col I scaffolds Ishikawas with HUVECs Cells were seeded into scaffolds Angiogenesis 
[247] Yes Electrospun PGA 
scaffolds 
Early-luteal phase bovine 
endometrial epithelial and 
stromal cells 
Scaffolds were seeded with stromal cells 
and later epithelial cells 
Endometrial model for 
studying endometrial 
function 
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Table A.2 Endometrial Models for pathogenic or diseased tissue 
Paper 3D? Material Cell Description of culture Motivation 
[100] Yes Gels from collagen 
type I purified from 
porcine tendons 
Human endometrial stromal 
cells and endometriotic stromal 
cells 
Endometrial or endometriotic stromal cells 
were embedded into gels 
Differences in contraction 
due to endometriosis 
[248] Yes Collagen coated 
microcarrier beads 
HEC1a, HeLa, and Chlamydia 
trachomatis serovar E 
Cells were seeded onto beads and 
Chlamydia introduced 
Chlamydia growth rate 
dependence on cell type 
[249] No Collagen coated 
microcarrier beads 
HEC-1B (and HeLa cells) Cells grown on beads Effect of polarization on 
Chlamydia trachomatis 
serovar L2 growth 
[104] No? Matrigel Mouse epithelial cells Cells were grown on culture plastic with 
matrigel supplementation in solution to 
form 3D gland structures 
Cancer 
[101] Yes  EM-E6/E7/TERT and EM-PR Spheroids Endometrial inflammatory 
diseases 
[250] 2D/3
D 
Basement 
membrane 
Ishikawa, RL95-2, KLE, EN-
1078D  
Spherical structures formed in basement 
membrane suspension 
Anti-cancer therapy studies 
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Table A.3 Endometrial Models for implantation and pregnancy 
Paper 3D? Material Cell Description of culture Motivation 
[251] Yes Fibrin matrices human endometrial 
microvascular endothelial cells 
and trophoblast cells (for 
conditioned media 
Cells were seeded onto matrices and 
allowed for invasion and vessel formation 
with conditioned media 
Estrogen and dioxin in 
endometriosis 
 
[252] No Culture dishes Endometrial stromal cells and 
trophoblasts 
Trophoblasts on stromal cells Ishikawa invasion 
[108] Yes Col I (bovine), 
Matrigel 
Stromal and epithelial cells 
isolated from human 
endometrial biopsies,  
blastocysts 
Stromal cells embedded in Col I, coated in 
matrigel and seeded with epithelial cell 
layer 
HIV/epithelial toxicity 
[98] 2D/ 
3D 
N/A N/A Multiple described Invasion 
[253] No? Matrigel Immortalized human 
endometrial endothelial cells 
and trophoblast cells 
Trophoblasts cells seeded onto endothelial 
cells seeded onto matrigel 
Implantation 
[254] No Col I treated 
membrane 
Murine blastocysts and 
endometrial epithelial cells 
isolated from mouse uterine 
Ishikawas were attached to Col 1 coated 
membranes prior to blastocyst introduction 
Development of single 
embryo coculture array 
[109] Yes Col I (bovine), 
Matrigel 
Stromal and epithelial cells 
isolated from human 
endometrial biopsies 
Stromal cells embedded in Col I, coated in 
matrigel and seeded with epithelial cell 
layer 
Development of a 
trophoblast cell line to study 
invasion 
[255] No  hTERT-EECs Ishikawas and murine blastocysts Toll-like receptor 5 on 
attachment 
[256] No  RL-95, HEC-1A, and BeWos BeWos seeded onto monolayers of RL-95 
or HEC-1As 
Implantation (invasion) 
[257] No coverslips hESCs with murine hatched 
blastocysts 
Blastocyst on hESC monolayers Macrophage contribution to 
receptivity 
[258] No  Ishikawas and JAr spheroids JAr spheroids with 2D Ishikawa culture Wnt-signaling on 
implantation 
[259] No  hESCs hESC monolayers Embryo-maternal crosstalk 
[260] No Well plates Ishikawas and murine 
blastocysts  
Blastocysts with 2D Ishikawa cultures Early implantation model 
[261] No Well plates hESCs and blastocysts Blastocysts with hESC monolayers Implantation 
[262] Yes  AC1-M59 and decidua parietalis 
from elective abortions 
Spheroids from decidua explants or 
trophoblast cells 
Study oxidative stress 
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Table A.3 (cont.) 
Paper 3D? Material Cell Description of culture Motivation 
[123] Yes* Culture plastic hESCs, RL95-2 Monolayer of HESCs with RL95-2 
monolayer on top 
Receptivity 
[263] No  AC-1M88and ESC Trophoblast spheroids with ESC 
monolayers  
Implantation model 
[264] No Well plates Murine endometrial cells and 
blastocysts 
Endometrial cells were cultured in 
wellplates with blastocysts attached to 
surface 
AEBSF effect on cell 
adhesion 
[265] No  Ishikawa and JAr JAr spheroids on Ishikawa monolayers Implantation 
[266] No  HTR-8 and ESC Trophoblast spheroids with ESC 
monolayers 
Implantation model 
[267] No Well plates Lines BeWo, RL95-2, and AN3-
CA 
BeWo spheroids with RL95-2 and AN3-
CA on wellplates 
Development of 
highthroughput screening of 
embryo attachment 
[268] No Glass slides Sw.71, hESC ECC-1 Sw.71 spheroids with hESC or ECC-1 
grown on glass slides 
Implantation model 
[269] Yes  Human decidual and placental 
tissues taken from 6-8 week 
terminations 
Explant cocultures Regulation of invasion by 
CsA 
[270] No Culture plastic Bovine trophoblast cells and 
EECs 
Trophoblast cell spheroids and EEC 2D 
cultures 
Studying implantation 
[271] No Culture plastic RL95-2 and BeWo 
choriocarcinoma cells 
BeWo spheroids and RL95-2 2D cultures Implantation (CypA 
induction) 
[272] No  BeWo and Jeg-3, Ishikawa 
and RL95-2 
BeWo and Jeg-3 spheroids with Ishikawa 
or RL95-2 monolayers 
Implantation 
[273] No  Ishikawas (H-L-12) and JAR JAR spheroids seeded onto confluent 
Ishikawa cultures 
Epithelial-Mesenchymal 
transition during 
implantation 
[274] Yes Fibrin-agarose gel 
matrix 
Human endometrial stromal and 
epithelial cells (primary and cell 
lines)ESCs, human trophoblast 
Jar cells 
Stromal cells suspended in gel, epithelial 
cells on surface with Jar cells attaching to 
epithelial cells 
Implantation 
[275] Yes Human amnion 
membrane/ wire 
mesh 
Murine endometrial explants 
and blastocysts 
Explants were placed on mesh or on 
amnion on top of mesh 
Studying early implantation 
[276] No Culture plates Ishikawa and murine blastocysts  Blastocysts on Ishikawas monolayers Implantation 
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Table A.3 (cont.) 
[277] No  Bovine embryos and luteal cells Cocultured Embryo-maternal 
interactions 
[278] No Culture plates Jeg-3 spheroids and RL95-2 
endometrial cells 
Spheroids with 2D endometrial cells Effect of PFOA on 
implantation 
[124] Yes Fibrin-agarose gel 
matrix 
Immortalized HESCs, human 
trophoblast Jar cells, Ishikawas 
Stromal cells suspended in gel, epithelial 
cells on surface 
Implantation 
[279] No Matrigel Coated 
coverslips 
Ishikawas with 2-cell mouse 
embryos and 5 day human 
trophoblasts  
Ishikawas were seeded onto matrigel 
coated coverslips with murine  embryos, 
human trophoblasts, OPN coated beads, or 
BSA coated beads 
Role of osteopontin-integrin 
αvβ3 interaction at 
implantation 
[280] No Culture Plastic Stromal cells isolated from 
endometrial biopsies during 
early proliferative phase 
2D cultures Effect of BPA endometrial 
exposure on placenta 
signaling  
[281] No Culture plastic ECC-1s and GFP expressing 
Sw.71 cells 
ECC-1 monolayers with Sw.71 on top Effect of hCG on 
implantation 
[282] No Matrigel coated well 
plate 
Human Endometrial Endothelial 
Cell line and HTR8  
Endothelial cells were seeded onto 
matrigel and allowed to form tubes prior to 
trophoblast cell seeding 
Effect of Lipoxin on 
trophoblast migration and 
endothelial interaction  
[223] Yes Collagen Stromal and epithelial cells 
isolated from human 
endometrial biopsies, human 
embryos 
Stromal cells suspended in gel, epithelial 
cells on surface 
Effect of ulipristal acetate on 
implantation 
[283] Yes Basement 
membrane 
HEC-1-A, RL95-2, Ishikawa Spherical structures formed in basement 
membrane suspension 
Effect of epithelial junctions 
on trophoblast-endometrial 
interactions 
[284] No Culture Plastic Ishikawas with murine 
blastocysts 
Ishikawas seeded on plastic with 
blastocysts placed in media on top 
IGF-1 role in blastocyst 
attachment 
[285] Yes Bovine Col I 
With Advanced 
Biomatrix 
Coated with 
Basement 
Membrane extract 
Isolated human endometrial 
epithelial and stromal cells 
Stromal cells in gel with epithelial cells 
seeded on top 
Effect of Mifepristone on 
implantation 
[286] No Culture Plastic Ishikawas and JAr spheroids Ishikawas seeded onto plastic with JAr 
spheroids in medium 
Paeonia lactiflora on 
trophoblast adhesion 
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Table A.4 Transwell experiments (mainly invasion, migration assays) 
Paper 3D? Material Cell Description of culture Motivation 
[287]   Human endometrial stromal cells, 
HMrSV5 (HPMC, a human peritoneal 
mesothelial cell line), U937 
Multiple designs estrogen and dioxin is 
involved in the 
pathogenesis of 
endometriosis 
 
[288] No Matrigel coated inserts Ishikawa FPS Ishikawas seeded into insert with FPS 
conditioned media in otherc 
compartment 
PGF2α-F-prostanoid- 
signaling on Ishikawa 
FPS invasion 
[289]   Endothelial and stromal cells isolated 
from human endometrial biopsies 
Stromal cells on inserts with 
endothelial cells in well 
Effect of cadmium 
chloride on 
angiogenesis 
[290] No Laminin coated inserts HEC-1A cells, 2 × 105 ME-180, SiHa 
or CaSki cells or 3 × 105 Ect1/E6E7, 
End1/E6E7 or VK2/E6E7 with IL-2 
stimulated PBMCs 
Epithelial cells in insert with PBMCs 
on bottom of well 
HIV/epithelial toxicity 
[291] No? Matrigel Primary ESCs or St-T1b and AC-1M88 1 or multiple cell types seeded onto 
matrigel insert 
Invasion 
[292] No  U937 cells (macrophage line) to 
endometrial stromal cells (ESCs) and/or 
human pelvic mesothelial cells 
U937 on insert Recruitment of 
Macrophages by 
RANTES in 
endometriosis 
[293] No Matrigel coated inserts Porcine epithelial and stromal cells 
isolated from uterine horns 
Epithelial cells seeded onto matrigel 
coated inserts with stromal cells 
seeded into well plates. 
Implantation 
[294] No  Macacque macrophages (peripheral and 
decidual) and trophoblasts 
Macrophages or trophoblast 
leukocytes were seeded on top of 
insert with the other cell in the bottom 
Effects that decidual 
macrophages have on 
trophoblasts that 
peripheral macrophages 
don’t 
[295] No Matrigel coated inserts hESCs and derived trophoblast cell 
lines from hESCs 
Trophoblast cells added to inserts with 
hESC monolayer on matrigel with 
trophoblast conditioned media 
Development of a 
trophoblast cell line to 
study invasion 
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Table A.4 (cont.) 
Paper 3D? Material Cell Description of culture Motivation 
[296] No  RL95-2 with BeWo RL95-2 in bottom with BeWo seeded 
in to 
hormonal regulation of 
Gal-3 in trophoblasts 
and the effect on 
endometrial cells 
[297]  Matrigel coated inserts Caprine immortalized EEC and ESCs Epithelial cells seeded onto matrigel 
coated inserts with stromal cells 
seeded into 24-well plates. 
Studying immune 
interactions for animals 
with non-invasive 
placentation 
[298]  Matrigel coated inserts Trophoblast Cells Decidualized stromal 
cells from abortions 
Trophoblasts seeded in bottom 
chamber while decidualized stromal 
cells were seeded onto inserts 
Implantation (invasion) 
[299] No  Human uterine endometrial carcinoma 
RL95-2, Ishikawa, and U937 
Epithelial cells on insert with U937 on 
bottom 
Macrophage 
contribution to 
receptivity 
[300] No Collagen  invasion 
transwells 
hESCs and cytotrophoblastic cell line 
JEG-3 
hESCs were seeded into top chamber 
with FBS supplemented media below, 
JEG-3s seeded into top chamber with  
Inhibition of Histone 
Deacetylase Activity on 
ECM remodeling and 
embryo implantation 
[224] No Matrigel Coated inserts Isolated human endometrial epithelial 
and fibroblast celsl 
Epithelial cells on insert with 
fibroblasts on bottom of well 
Epithelial and 
Fibroblast interactions 
[301]   Mid secretory phase ESCs and 
HTR8/SVneo cell line 
ESC monolayer on matrigel insert 
with trophoblast cells seeded on top 
Modulation of TIMP-1 
by hCG and effect 
Invasion 
[302] No Transwell T-HESC and AC-1M88 trophoblast 
cells 
Individual cell types seeded into insert. 
In some instances, other cell type 
seeded into bottom of well 
HESC-trophoblast 
mutual stimulation of 
chemotactic migration 
[303] No Transwell inserts and 
culture plastic 
Ishikawa, RL95-2 and HEC-1B with 
primary stromal cells from endometrial 
carcinoma samples 
Cancer cells in insert with stromal in 
wells or stromals treated with enriched 
media by cancer cells  
 
[304]  Variety of inserts, some 
with matrigel 
The endometrial epithelial and stromal 
cells were isolated from the horn 
ipsilateral to the corpus luteum 
Epithelial cells seeded onto matrigel 
coated inserts with stromal cells 
seeded into well plates. 
Model to study 
endometrial epithelial 
cells in 3D state 
(vectoral secretion) 
[305] No  Primary HESCs and St-T1b with AC-
1M88 or first trimester villous explant 
Stromal cells on insert with 
conditioned media in bottom chamber 
Stromal cell motility 
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Table A.4 (cont.) 
Paper 3D? Material Cell Description of culture Motivation 
[306] No Matrigel coated inserts Ishikawa, HEC-1B, and human 
embryonic kidney 293 T cells 
Cells were seeded in upper chamber 
with FBS supplementation in the 
bottom 
TrkB-STAT3-miR-204-
5p regulation of 
carcinoma proliferation 
and invasion 
[307] No Inserts with or without 
matrigel 
Ishikawas and KLEs transfected with 
ERα and ERβ expression vectors 
Cells were seeded in upper chamber 
with FBS supplementation in the 
bottom 
Upregulation on ERs on 
migration, invasion, and 
proliferation 
[308] No Matrigel coated inserts Ishikawa, 
Hec-1A, and osteoblastlike 
osteosarcoma cell line MG63 
Endometrial cancer cells seeded into 
top chamber with MG63s in bottom 
Inhibition of invasion 
by Kisspeptin-10 
[309] No Inserts with or without 
matrigel 
Ishikawas and KLE Cells seeded onto insert Effect of MPA 
signaling pathway on 
tumors 
[310] No ECM coated inserts Ishikawas and SHT-290  Ishikawas seeded onto inserts with or 
without SHT-290s in bottom chamber 
Effect of progesterone 
on estrogen influenced 
Chlamydia infection 
[311] No Some with matrigel 
coated inserts 
Ishikawa and HEC1B In suspension in top chamber Effect of Piwil1 on 
endometrial cancer stem 
like properties  
[114] No Some with matrigel 
coated inserts 
HEC1-A, ECC1, Spec-2, RL95-2, 
AN3CA, and KLE 
Seeded onto insert Effect of biglycan on 
endometrial cancer 
migration and invasion 
[312] Yes* Matrigel coated 
Millicell inserts 
Stromal and epithelial cells isolated 
from bovine uterine removed at days 1-
4 of estrous cycle 
Epithelial cells seeded onto matrigel 
coated inserts with stromal cells 
seeded into 24-well plates. 
Vectoral secretion of 
inflammatory markers 
(IL-6) by epithelium 
[313] No ECM coated inserts Endometrial cells with BeWo cells Endometrial cells were seeded onto 
inserts 
BPA on BeWo invasion 
[314] No Matrigel coated inserts HEC1a HEC1a on insert in serum free media 
with FBS supplemented media in 
bottom chamber  
IL-11Rα on tumor 
growth and metastasis 
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APPENDIX B: EXPERIMENTAL PROTOCOLS 
B.1 CG Suspension Preparation Protocol  
Reference: [6, 136, 315, 316] 
Reagents  
 Purified Fibrillar Collagen (Collagen Matrix); store at 4ºC  
 Chondroitin sulfate sodium salt from shark cartilage (Sigma-Aldrich C4384); store at 4ºC  
 Heparin sodium salt from porcine intestinal mucosa (Sigma-Aldrich H3149); store at 4ºC 
 Glacial acetic acid (Sigma-Aldrich 71251)  
 Ethylene glycol (VWR BDH1125-4LP)  
 Deionized water  
Equipment and Supplies  
 Recirculating chiller (Fisher Isotemp Model 900)  
 Rotor-stator (IKA 0593400)  
 Disperser (IKA 3565001)  
 Jacketed beaker (Ace Glass 5340-115)  
 Freeze-dryer (VirTis Genesis)  
 Beakers  
 Parafilm  
 Spatula 
 
Procedure  
*This procedure describes how to make 300 mL of 0.5% CG suspension. Scale collagen and 
GAG content appropriately to create different volumes of suspension.  
1. Fill recirculating chiller with a 50/50 mix of ethylene glycol and deionized water, making 
sure that the cooling coils are completely immersed in the liquid. Set the recirculating 
chiller to 4ºC. 
2. Attach recirculating chiller to jacketed beaker so that the coolant enters at the jacketed 
beaker’s base and exits at the beaker’s top. Allow for the temperature to equilibrate to 
4ºC, about 30 minutes. Maintaining this temperature is important, as it will prevent the 
collagen from denaturing during the blending process.  
3. Prepare a 0.05 M solution of acetic acid by adding 0.87 mL of glacial acetic acid to 300 
mL of deionized water.  
4. Weigh 1.5 g of collagen and add to the jacketed beaker.  
5. Pour 250 mL of the 0.05 M acetic acid into the jacketed beaker. 
6. Assemble the rotor-stator and attach it to the disperser. Lower the rotor-stator into the 
suspension. The rotor-stator should be vertical and centered in the beaker.  
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7. Blend the suspension at 15,000 rpm for 90 min at 4ºC. The height of the rotor-stator may 
need to be adjusted during the blending process: If the rotor-stator is positioned too high, 
the holes on its side will be visible; if it is too low, the suspension will bubble 
excessively. Periodically check to see if the rotor-stator is clogged with collagen; remove 
clogs with a spatula as needed. 
8. Add 50 mL of 0.05 M acetic acid to a 50 mL centrifuge tube. Weigh out 0.133 g of 
chondroitin sulfate or Heparin (GAG) and add to the centrifuge tube. Vortex until the 
GAG is fully dissolved. Let the GAG solution rest in the refrigerator (4ºC) for at least 10 
minutes.  
9. Add the GAG solution drop-wise to the collagen suspension while it is being mixed at 
15,000 rpm at 4ºC. Periodically manually stir in any GAG that remains on the surface of 
the suspension using a spatula. It may be necessary to stop and unclog the rotor-stator 
with a spatula during this process.  
10. Once all of the GAG solution has been added, blend at 15,000 rpm for 90 min at 4ºC. 
Periodically check to ensure the rotor-stator is lowered to the correct depth, as the 
suspension will gradually become less viscous and creep up the sides of the jacketed 
beaker. Periodically check to see if the rotor-stator is clogged; remove clogs with a 
spatula as needed.  
11. Store the suspension for at least 18-22 h at 4ºC.  
12. Degas the suspension to remove any air bubbles prior to use. It is recommended to degas 
approximately 20 mL at a time, until the solution starts to boil. To minimize suspension 
loss during the degassing process, cover the beaker with slit Parafilm. 
13. Store the suspension at 4ºC. Periodically check the CG suspension; if not homogenous, 
re-blend at 15,000 rpm for at least 30 min at 4ºC. 
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B.2 DHT Crosslinking Protocol  
Reference :[6, 317] 
Supplies and equipment  
 Sterile air filter (Millipore SLGP033RS) 
 Vacuum oven (Welch Vacuum, Fisher 13-262-52) 
 Welch DirecTorr Gold synthetic pump oil (Fisher 01-184-105) 
Procedure  
*Note: Periodically check vacuum pump oil levels. Change oil at least once every 6-12 months. 
Change sterile air filter on ‘Purge’ line regularly. 
1) Turn on vacuum oven and set the temperature to 105ºC.   
2) Once vacuum oven has reached temperature set point, place scaffolds in opened 
aluminum pouches carefully inside the oven. Close the oven door.  
3) Close the ‘Purge’ valve, located on the lower right face of the vacuum oven. Completely 
open the ‘Vacuum’ valve.   
4) Turn on the vacuum pump and make sure vacuum is pulled to a sufficiently low level (< 
1 in Hg). Allow scaffolds to crosslink for 24 hours. 
5) After crosslinking is complete, turn off the vacuum pump, close the 'Vacuum' valve, open 
the 'Purge' valve, then carefully remove scaffolds from the oven. Quickly seal the 
aluminum pouches, taking care to ensure that the aluminum pouches are sufficiently 
“puffed” so that the scaffolds will not be crushed during storage. Store sealed pouches 
with scaffolds (now sterile) in desiccator until time of use. 
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B.3 Scaffold Cutting and Hydration 
Reference: [136, 316-318] 
Reagents  
 Sterile phosphate-buffered saline (PBS) 
 200 proof (100%) ethanol 
Equipment and Supplies 
 50 mL centrifuge tubes (Fisher 14-432-22) 
 Dual range balance (Mettler Toledo XS105) 
 6 mm biopsy punches (Fisher NC9551417) 
 Pasteur pipettes 
Procedure  
* Note: all steps should be performed in the laminar flow hood unless otherwise noted.  
1. Prior to cutting scaffolds, ensure that all materials (including gloves) are completely dry.  
2. Cut scaffolds from scaffold sheets using a biopsy punch. Ensure that the biopsy punch is 
oriented perpendicular to the scaffold sheet. Holding the top of the biopsy punch, gently 
spin the biopsy punch downward to cut through the sheet, applying pressure at the end 
only if necessary. If the scaffold remains lodged in the biopsy punch, gently poke it out 
using a Pasteur pipette. Place cut scaffolds in labeled pre-weighed 50 mL conical tubes. 
3. If scaffolds are to be EDC’d, weigh scaffolds prior to hydration. 
4. Hydrate cut pieces in 100% ethanol overnight. (Do not hydrate scaffolds for BP) 
5. Rinse scaffolds PBS for 1 hour, then let soak in PBS for 24 hours prior to crosslinking. 
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B.4 EDC Crosslinking Protocol  
Reference: [136, 316-318]  
Reagents  
 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC, Sigma-Aldrich 
E7750); store at -20ºC 
 N-hydroxysulfosuccinimide (NHS, Sigma-Aldrich H7377); store in desiccators 
 Sterile phosphate-buffered saline (PBS) 
Equipment and Supplies  
 6-well plates (Fisher 08-772-1B) 
 50 mL centrifuge tubes (Fisher 14-432-22) 
 Syringe and syringe filter (Fisher 148232A) 
 MTS 2/4 digital microtiter shaker (IKA 3208001) 
 Dual range balance (Mettler Toledo XS105) 
 
Procedure  
1. Note: all steps should be performed in the laminar flow hood unless otherwise noted.  
2. Determine the EDC and NHS concentrations to be used in the crosslinking solution. The 
calculations shown below are done with a 5:2:1 EDC:NHS:COOH molar ratio, where 
COOH is carboxylic acid groups in CG material based on a conversion factor of 1.2 
mmol COOH per gram of collagen (Olde Damink, Dijkstra et al. 1996). The mass of 
EDC and NHS required can be calculated as follows: 
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5. Mix the EDC and NHS in PBS. Approximately 1 mL of solution will be needed per 3 
scaffold pieces (6 mm diameter, 3 mm thick). 
6.  In the laminar flow hood, sterile filter the solution and add to 6-well plates. One can 
crosslink up to 6 scaffolds per well. If volume is insufficient to cover scaffolds, add 
additional PBS, keeping the volume constant for all wells. 
7. Add scaffolds to crosslinking solution and place well plate on digital microtiter shaker in 
37ºC incubator. Allow scaffolds to crosslink under moderate shaking for 1 hour 30 
minutes. Crosslinking time should be increased for less permeable constructs and higher 
solids content scaffolds. 
8. Remove EDC/NHS solution and rinse scaffolds in sterile PBS under moderate shaking 
for 1 hour. 
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9. Remove PBS wash solution and replace with fresh PBS. Rinse under moderate shaking 
overnight. 
10. Store in fresh sterile PBS at 4ºC until use. 
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B.5 EDC Protein Crosslinking Protocol  
Reference: [133, 199, 317, 318]  
 
Reagents  
 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC, Sigma-Aldrich 
E7750); store at -20ºC 
 N-hydroxysulfosuccinimide (NHS, Sigma-Aldrich H7377); store in desiccators 
 Sterile phosphate-buffered saline (PBS) 
 200 proof (100%) ethanol 
 Protein to be immobilized 
- β-Estradiol 6-(O-carboxy-methyl)oxime: BSA (BSA-E2, Sigma-Aldrich  E5630); 
store aliquots at -20ºC 
- Sex Hormone Binding Globulin (SHBG; Fitzgerald 30-AS40) 
 
Equipment and Supplies 
 24-well plates (Fisher 08-772-1) 
 Clear 96-well plate (Fisher 12-565-66)  
 50 mL centrifuge tubes (Fisher 14-432-22) 
 Syringe and syringe filter (Fisher 148232A) 
 MTS 2/4 digital microtiter shaker (IKA 3208001) 
 Dual range balance (Mettler Toledo XS105) 
 Tweezers 
 
Procedure  
1. Note: all steps should be performed in the laminar flow hood unless otherwise noted.  
2. Prior to cutting scaffolds, ensure that all materials (including gloves) are completely dry.  
3. Cut scaffolds from scaffold sheets using a biopsy punch. Ensure that the biopsy punch is 
oriented perpendicular to the scaffold sheet. Holding the top of the biopsy punch, gently 
spin the biopsy punch downward to cut through the sheet, applying pressure at the end 
only if necessary. If the scaffold remains lodged in the biopsy punch, gently poke it out 
using a Pasteur pipette. Place cut scaffolds in labeled pre-weighed 50 mL conical tubes. 
4. Weigh scaffolds prior to hydration. 
5. Hydrate cut pieces in 100% ethanol overnight. 
6. Rinse pieces in PBS for 1 hour, then let soak in fresh PBS for 24 hours prior to 
crosslinking. 
7. Prepare protein solutions in PBS 
8. Determine the EDC and NHS concentrations to be used in the crosslinking solution. The 
calculations shown below are done with a 5:12.5:1 EDC:NHS:COOH molar ratio, where 
COOH is carboxylic acid groups in CG material based on a conversion factor of 1.2 
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mmol COOH per gram of collagen (Olde Damink, Dijkstra et al. 1996). The mass of 
EDC and NHS required can be calculated as follows: 
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11. Mix the EDC and NHS in PBS. 150 uL of solution will be needed per 3 1X scaffold piece 
(6 mm diameter, ~3 mm thick). 
12.  In the laminar flow hood, sterile filter the solution and add 150 uL crosslinking solution 
per well for a 96-well plates. If volume is insufficient to cover scaffolds, add additional 
PBS, keeping the volume constant for all wells. 
13. Add scaffolds to crosslinking solution and place well plate on digital microtiter shaker at 
room temperature. Allow scaffolds to crosslink under moderate shaking for 20 minutes. 
14. Pipette 100 uL of protein solution to wells of separate 96 well plate  
15. After 20 minutes of shaking, remove scaffolds from EDC solution and dab on plate lid to 
remove excess solution. 
16. Transfer each scaffold to individual wells of a 96 well plate, assuring that scaffolds are 
oriented properly in each well. 
17. Place well plae on shaker at room temperature for 1 hour. 
18. Pipette 1 mL PBS per well into 24 well plates 
19. Remove scaffolds from 96 well plate and place in wells of 24-well plates.   
20. Allow sample to rinse under moderate shaking at room temperature for 1 hour  
21. Remove wash solution and replace with 1 mL fresh PBS solution per well. Rinse under 
moderate shaking at room temperature overnight. 
22. Store in fresh sterile PBS at 4ºC until use or analysis. 
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B.6 Analysis of Digested Scaffolds of Protein Immobilization by EDC 
Reagents  
 Papain buffer (100 mL); store at 4ºC 
o 100 mL PBS  
o 1 mL 0.5 M EDTA (pH = 8.0, Sigma-Aldrich EDS); store at 4ºC  
 Papain from Carica papaya (Sigma-Aldrich 76218); store at -20ºC 
 Bovine Serum Albumin 
 PBS 
 Primary antibodies 
- Estradiol antibody 
- Sex Hormone Binding Globulin (SHBG) antibody (Biotin)  (antibodies-online.com 
ABIN738773); store at 4ºC 
 Secondary antibodies 
- Alexafluor 488 anti-mouse IgG (H+L) antibody (Invitrogen A11059); store at 4ºC  
- Streptavidin AlexaFluor 488 (Invitrogen S32354); store at 4ºC  
 
Supplies and equipment  
 Black 96-well plates (Fisher 14-245-177)  
 Clear 96-well plates (Fisher 12-565-66)   
 Clear 24 well plate (Fisher 08-772-1) 
 Vortex (Fisher 02-215-365)  
 Water bath (60oC, Fisher 15-460-2SQ)  
 Fluorescent spectrophotometer (Tecan F200)  
 Microcentrifuge tubes (1.5 mL)  
 Conical centrifuge tubes (15 and 50 mL) 
 Kimwipes 
 Sterile blunt-nosed tweezers 
 
Procedure  
1. Prepare a 2% BSA solution by dissolving BSA in PBS and vortexing 
2. Dilute 10 μL of primary antibody per 5 mL BSA solution (need 150 μL per scaffold) 
3. Pipette 150 μL into wells of clear 96-well plate 
4. Dab scaffolds dry using Kimwipe and place in individual wells with dye solution 
5. Place plate covered on shaker at room temperature under low shaking for 1 hour 
6. Transfer scaffolds into a 24 well plate with 1 mL of PBS per well. 
7. Rinse scaffolds on shaker at room temperature under moderate shaking for 1 hour 
8. Dilute 2.5 μL secondary antibody per 5 mL BSA solution (need 150 μL per scaffold) 
9. Pipette 150 μL into wells of black 96-well plate 
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10. Dab scaffolds dry using Kimwipe and place in individual wells with dye solution 
11. Place plate covered with foild on shaker at room temperature under low shaking for 1 
hour 
12. Transfer scaffolds into a 24 well plate with 1 mL of PBS per well. 
13. Cover plate with foil 
14. Rinse scaffolds on shaker at room temperature under moderate shaking for 1 hour 
15. Prepare papain solution by adding 2.4 mg of papain to 1 mL of papain buffer.  Let 
solubilize in 60ºC water bath for ~10 minutes. Vortex thoroughly to mix. 
16. Pipette 250 μL of papain solution into each labeled 1.5 mL microcentrifuge tube.  
17. Dab blank scaffolds dry on Kimwipe and place in 1.5 mL microcentrifuge tubes with 
papain solution 
18. Place tubes in 60ºC water bath for 1 hour or until scaffolds are digested. 
19. Allow samples to cool to room temperature  
20. Vortex each tube thoroughly. 
21. Pipette 100 μL from each tube into a black 96-well plate. 
22. Immediately read plate on Tecan F200 fluorometer. Load protocol. For AlexaFluor 488 
use: excitation: 485 (20 nm bandwidth) and emission: 535 (25 nm bandwidth)  
23. Determine amount of protein immobilized by subtracting the blank and using the curve 
determined by the standard 
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B.7 Gelatin Methacrylate (GelMA) synthesis protocol  
Reference: [161]   
Reagents  
 Porcine Gelatin Type A, 300 bloom (Cat #G2500, Sigma Aldrich, St. Louis, MO)  
 Methacrylic anhydride (Cat #64100, Sigma Aldrich, St. Louis, MO)  
 PBS 
 
Supplies and equipment  
 Dialysis tubing (12,000 – 14,000 MW) (Cat #21-152-8, Fisher Scientific, Pittsburgh, PA) 
 Magnetic stirrer/hotplate  
 Lyophilizer 
 
Procedure  
1. Prepare a 10% (w/v) solution of gelatin in PBS and stir at 60°C until the gelatin has fully 
dissolved. 
2. Add Methacrylic anhydride dropwise, stirring the solution continuously.  
20%  methacrylic anhydride (v/v) yields roughly 85% degree of functionalization 
10% methacrylic anhydride (v/v) yields roughly 60% degree of functionalization  
 
3. Allow the reaction to run for 1 h. 
4. Dilute the reaction with five-fold volume of dH2O. 
5. Pre-soak dialysis tubing in water for 20 min.  
6. Clip one end of the tubing with the heavier clips and pipette the reaction solution. Leave 
enough space for expansion due to dialysis. Clip the top end and place the tubing in 
water. 
7. Dialyze for a minimum of 7 days, changing water daily and maintaining the solution at 
60°C with constant stirring.  
8. After dialysis, pipette the solution into 50 mL conical tubes and freeze at -20 °C, 
followed by lyophilization until all the water has been removed. Store the dried GelMA 
for future use. 
9. Check degree of functionalization via NMR spectroscopy. 
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B.8 Lithium acylphosphinate (LAP) photoinitiator protocol 
Reagents  
 2,4,6-trimethylbenzoyl chloride (Cat #682519, Sigma Aldrich, St. Louis, MO)  
 dimethyl phenylphosphonite (Cat #149470, Sigma Aldrich, St. Louis, MO)  
 lithium bromide (Cat #213225, Sigma Aldrich, St. Louis, MO) 
 2-butanone (Cat #360473, Sigma Aldrich, St. Louis, MO) 
 
Supplies and equipment  
 Dialysis tubing (12,000 – 14,000 MW) (Cat #21-152-8, Fisher Scientific, Pittsburgh, PA) 
 Magnetic stirrer/hotplate  
 Schlenk line with Argon gas 
 
Procedure  
1. 2,4,6-trimethylbenzoyl chloride was added drop wise to an equimolar amount of 
continuously stirred dimethyl phenylphosphonite at room temperature and under argon. 
2. The reaction mixture was stirred for 18 hours after which a fourfold excess of lithium 
bromide in 2-butanone was added and heated to 50 °C to form a solid precipitate. 
3. The mixture was cooled to ambient temperature then filtered and washed 3 times with 2-
butanone to remove unreacted lithium bromide. 
4. Excess solvent was subsequently removed by vacuum, leaving behind a white residue 
which is LAP. 
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B.9 GelMA cell tissue protocol 
 
Reagents  
 GelMA (See B.7) 
 LAP photoinitiator (See B.8)  
 PBS 
 Cells and cell mediums (See B.14-B.16) 
 
Supplies and equipment  
 UV Lamp 
 Teflon molds (autoclaved)  
 Glass slides (autoclaved) 
 Binder clips (autoclaved) 
 1CC syringes with needles 
 1.5 mL microcentrifuge tubes (autoclaved) 
 Spatula (autoclaved) 
 Forceps (autoclaved) 
 Ultra-low attachment well plates 
 Scintillation vials 
 
Procedure  
1. Assemble molds by placing Teflon mold on top of glass slide and securing the four sides 
with binder clips. 
2. UV sterilize the molds and the GelMA in a scintillation vial for 30 min. 
3. Add phenol red free EBM to the GelMA to create a 7% (w/v) solution. Be sure to 
subtract out the volume of the GelMA from the total volume. 
4. Heat the mixture at 60 °C until all the GelMA is dissolved and the foam has subsided. 
Place in the incubator at 37 °C until further use. 
5. For cellular gels, resuspend cells in appropriate volumes of phenol red free EBM. 
(Calculate using the desired cell concentration per gel, the desired final concentration (ie 
5% GelMA), the current volume and the volume of LAP for 0.1% final concentration 
6. Prepare a 5% stock solution of LAP in sterile PBS. 
7. In 1.5 mL conical tubes, mix the components to yield a 5% GelMA, 0.1% PI solution. 
Adjust to final volume using EBM if necessary. 
8. For cellular gels, add cell solution to the mixture and mix well 
9. Pipette the pre-polymer solution into the wells and place under UV light for 30 seconds 
(10 mW/cm2). 
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10. To remove gels, loosen mold by first removing binder clips then pipetting sterile PBS 
onto each gels and along edges of mold to facilitate separation. Gently separate the mold 
from the glass slides. To detach gels from glass gently roll a needle between the glass and 
the gel. Use a spatula to transfer gels to ultralow attachment 24 well plates with 2 mL of 
phenol red free EGM-2 per scaffold. 
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B.10 Fibrin gel protocol 
Reagents  
 Fibrinogen (See B.7) 
 Thrombin (50 U/mL stock solution prepared in H2O)  
 DPBS (or FBS free medium) 
 Cell solutions 
 
Supplies and equipment  
 48 well tissue culture plate 
 1.5 mL microcentrifuge tubes (autoclaved) 
 15 mL conical tube 
 
Procedure  
1. In a 15 mL conical tube, combine fibrinogen and DPBS (or medium) for the desired 
concentration and gel volume (10 mg/mL) 
2. Warm the mixture in the water bath, mixing by inversion every 10 min, until the 
fibrinogen goes into solution. 
3. Prepare cell pellet with desired number of cells in 1.8 mL conical tubes (spin down 
cell solution at 1000 (<100 g) RPM for 2 min, rotate 180 degrees and spin down 
again at 1000 RPM for 2 min, rotate 90 degrees and spin down 2.5 min at 1500 RPM. 
Aspirate off supernatant 
4. Resuspend cell pellet in desired volume of fibrinogen solution. 
5. Quickly add thrombin (final concentration of 2 U/mL) and quickly pipette. 
6. Pipette 100 uL of solution into each well, running pipette along the edge of each well 
to insure gel contact with well walls. 
7. Let gels sit for 5 min in hood at room temperature. 
8. Transfer gels to incubator for 30 min to complete reaction. 
9. Add desired volume of supplemented media to each well (300-400 uL)  
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B.11 Immunofluorescent staining of GelMA 
Reagents  
 PBS 
 Formalin 
 PBST 
o PBS 
o 0.1% Tween 
 PBS + 0.5% Tween 
 2% Abdil 
o PBS 
o 0.1% Tween 
o 2% BSA (w/v) 
 CD 31 Primary antibody 
 Secondary antibody 
 DAPI 
Supplies and equipment  
 MTS 2/4 digital microtiter shaker (IKA 3208001) 
 
Procedure  
1. Wash gels with PBS 3 times briefly.  
2. Fix the gels in formalin for 15 min. 
3. Wash gels with PBS 3 times briefly.  
4. Permeabilize in PBS+ 0.5% Tween for 15 min (minimum). 
5. Wash gels in PBST for 5 min, 3 times. 
6. Block gels with 2% abdil for 1 hour (minimum). 
7. Dilute the primary antibody in 2% abdil (for CD31 use 1:200). 
8. Incubate gels in primary antibody overnight at 4°C. 
9. Wash gels with PBST for 20 min, 4 times. 
10. Dilute the secondary antibody in 2% abdil (for Alexafluor use 1:500). 
11. Incubate gels in secondary antibody overnight at 4°C. 
12. Wash gels with PBST for 20 min, 4 times. 
13. If desired, incubate gels in DAPI (1:300 dilution in PBS) for 30 min. 
14. Wash with PBST. 
128 
 
15. Image with fluorescent microscope. 
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B.12 Incubator disinfection protocol  
Reagents  
 Steris staphene spray (Fisher 14-415-15)  
 70% ethanol  
Procedure  
1. Shut off the CO2 tanks and turn off the incubator.  
2. Prepare the sterile hood by covering the inside with bench-coat.  
3. Cover the chemical fume hood with fresh bench-coat.  
4. Disassemble all removable parts from the incubator chamber. Spray all pieces from the 
incubator inside the chemical fume hood with staphene. Spray the inside of the inside of 
the incubator with staphene. Let stand for 15 min with the incubator door cracked open 
~2 in.  
5. Spray the inside of the incubator with 70% ethanol. Wipe off the excess staphene with 
paper towels.  
6. Spray all internal pieces of the incubator in the chemical fume hood with 70% ethanol 
and wipe off the excess staphene. Spray each part generously with ethanol again and 
place into the sterile hood to dry. Do not wipe anything down. Allow all parts to air dry 
for 15-30 min.  
7. Spray the inside of the incubator with 70% ethanol and allow all parts to dry for 15-30 
min; do not wipe anything down.  
8. Reassemble all internal pieces of the incubator, taking care to move each piece from the 
sterile hood to the incubator as quickly as possible.  
9. Spray the inside of incubator again with 70% ethanol. Shut the foot and allow all parts to 
dry; do not wipe anything down. 
10. Turn on the incubator power and open the valves on the CO2 tanks. Allow the incubator 
to ventilate with the CO2 on for 24 h before using again. 
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B.13 Carbon Stripping FBS Protocol  
Reagents  
 HI FBS (Invitrogen 16140-071); store at -20ºC  
 Dextran from Leuconostoc spp. (Sigma-Aldrich 31390);  
 Activated Charcoal (Sigma-Aldrich C3345)  
 Ethylene glycol (VWR BDH1125-4LP)  
Equipment and Supplies  
 Recirculating chiller (Fisher Isotemp Model 900)  
 1L Jacketed beaker (Ace Glass 5340-118)  
 500 mL bottle (autoclaved) 
 Stir bar 
 Hotplate/stirrer (VWR VMS-C4) 
 Spatula 
 Centrifuge (Eppendorf Centrifuge 5430 R) 
 500 mL Stericup (Fisher SCGPU05RE) 
 50 mL conical tubes 
Procedure  
*This procedure describes how to make 400 mL of carbon stripped FBS. Scale FBS, dextran, and 
charcoal appropriately to strip the desired volume.  
1. Fill recirculating chiller with a 50/50 mix of ethylene glycol and deionized water, making 
sure that the cooling coils are completely immersed in the liquid. Set the recirculating 
chiller to 4
o
C. 
2. Attach recirculating chiller to jacketed beaker so that the coolant enters at the jacketed 
beaker’s base and exits at the beaker’s top. Allow for the temperature to equilibrate to 
4ºC, about 30 minutes. Maintaining this temperature is important, as it will prevent the 
collagen from denaturing during the blending process. 
3. Place jacketed beaker on stir plate. 
4. Combine 1.1 g Dextran, and 10.9 g activated charcoal (10:1 ratio (wt %)) in 500 mL 
beaker. Add stir bar and replace lid. 
5. In hood add 400 mL of HI FBS (30 mg of carbon/dextran mixture per mL FBS) to bottle 
and replace lid. Combine mixture through gentle shaking or using a spatula (in hood). 
6. Place bottle in jacketed beaker with ~100 mL of tap water. 
7. Turn on stir plate and slowly raise the stir rate until the stirring is sufficient to move the 
fluid, but not high enough that the spin bar no longer spins properly. 
8. Allow the mixture to stir overnight at 4ºC. 
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9.  Pipette FBS/carbon/dextran mixture into 50 mL conical tubes and spin down for 15 min 
at max speed of centrifuge. 
10.  In hood, filter supernatant through .22 μM vacuum filter (stericup). 
11. Aliquot 25 mL carbon stripped FBS into 50 mL conical tubes and store at -20ºC until use. 
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B.14 Ishikawa culture protocol  
Reagents:  
 Complete Ishikawa media (500 mL); store at 4ºC  
o 470 mL phenol red-free DMEM/F-12 (Based on Invitrogen Catalog Number: 
21041-025, order from Sandy McMasters at SCS Media Facility); store at 4ºC  
o 25 mL carbon stripped fetal bovine serum; store at -20ºC  
o 5 mL penicillin-streptomycin (Invitrogen 15140-122); store at -20ºC  
 0.5% Trypsin-EDTA, no phenol red (Invitrogen 15400-054); store at -20ºC 
 Trypan blue (Sigma-Aldrich T8154)  
 DMSO (Fisher D128-500)  
 Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
Supplies and equipment  
 Hausser phase contrast hemacytometer (Fisher 02-671-5)  
 Tabletop centrifuge (VWR 53513-812)  
 Optical microscope (Leica Microsystems DMIL LED)  
 Water bath (37ºC, Fisher 15-474-35)  
 Sterile pipettes (5, 10, 25 mL)  
 Pasteur pipettes 
 T75 tissue culture flasks  
Procedure 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted.  
 
Ishikawa thawing procedure  
1. Place complete Ishikawa media in water bath and warm to 37ºC.  
2. Thaw frozen cell vials in 37ºC water bath for about 1 min.  
3. Transfer the thawed cells and freezing media to a 15 mL centrifuge tube. Add 8.5 mL 
complete Ishikawa media.  
4. Gently re-suspend the cells in the diluted media and pellet the cells at 200 g for 7 min.  
5. Resuspend the cells in a small volume of media. 
6. Mix 10 μL of the cell suspension with 90 μL of Trypan blue. Pipette several times to mix 
the stain and cell suspension. 
7. Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension 
into each side of the hemacytometer.  
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8. Cell counts are performed in as many of the nine separate regions per side of the 
hemacytometer as is feasible (Typically four corners and center). Average number of 
cells per region is used to calculate the total cell population. For this calculation, the 
dilution factor is typically 10 (1:9 ratio of cell suspension to Trypan blue).  
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume)  
9. Seed the cells at the required density (1.5 million cells per T 75 flask). Use around 6-7 
mL media for a T75. 
10. Place the flask(s) into the incubator overnight. 
11. Replace the media (10-15 mL/flask) the next day. 
12. Check the confluence every 24 h and feed cells every other day and the day before 
passaging. 
Ishikawa feeding procedure  
13. Warm complete Ishikawa media in water bath to 37ºC.  
14. When the media is warm, wipe dry with paper towel and spray with 70% ethanol before 
placing in the sterile hood.  
15. Remove all old media from each T75 flask, taking care not to scrape the cells with the 
Pasteur pipette. 
16. Add 10-15 mL of complete Ishikawa media. Return the T75 flasks to the incubator and 
feed every other day. Adjust volume of media accordingly for different sized flasks.  
Ishikawa passaging procedure  
1. Warm complete Ishikawa media, sterile PBS, and 5 mL phenol red free trypsin-EDTA 
per T75 flask to be passaged in water bath to 37ºC.  
2. When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray 
with 70% ethanol before placing in the sterile hood.  
3. Remove all old media from each T75 flask, taking care not to scrape the cells with the 
pipette tip.  
4. Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. 
Swirl gently to remove any excess media from the cells. Adjust volumes of PBS, media, 
and trypsin accordingly for different sized flasks.  
5. Remove the PBS and add 5 mL of trypsin per T75 flask. Return the flasks to the 
incubator for 5 min to allow for the cells to detach from the tissue culture plastic (flasks 
will require harsh tapping). Tap the sides of the flasks until the cells detach. 
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6. Add 10 mL of complete Ishikawa media to each flask to neutralize the trypsin and to 
flush cells off of the tissue culture plastic.  
7. Remove the trypsinized cell solution from the flask and put into a conical tube. 
Centrifuge the cells at 200 g for 7 min.  
8. Resuspend the cell pellet in a small volume of media. 
9. Mix the 10 μL cell suspension aliquot with 90 μL of Trypan blue. Pipette several times to 
mix the stain and cell suspension.  
10. Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension 
into each side of the hemacytometer.  
11. Cell counts are performed in as many of the nine separate regions per side of the 
hemacytometer as is feasible (Typically four corners and center). Average number of 
cells per region is used to calculate the total cell population. For this calculation, the 
dilution factor is typically 10 (1:9 ratio of cell suspension to Trypan blue).  
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume)  
12. Add additional media to dilute cells to desired concentration. 
13. Seed the cells at the required density (1.5 million cells per T75). Use around 6-7 mL for a 
T75.  
14. Place the flask(s) into the incubator. 
15. Replace the media with fresh media the following day. 
16. Check the confluence every 24 h and feed cells every other day  
Ishikawa freezing procedure  
1. Complete steps 1-8 on Ishikawa passaging procedure. 
2. Calculate volumes of complete Ishikawa media, carbon stripped FBS, and DMSO needed 
to freeze 5 x 10
6
 cells per 1.5 mL (freezing media: 50% complete Ishikawa, 40% FBS, 
10% DMSO).  
3. Add additional Ishikawa media required (minus the amount added for resuspending the 
cell pellet), followed by carbon stripped FBS, and DMSO. 
4. Aliquot cells into 1.5 mL cryogenic tubes and place in -20ºC freezer for 1 h.  
5. Place cryogenic tubes in -80ºC freezer. Cells can be stored here for up to 6 months. For 
longer-term storage, keep cells at -80ºC for at least 24 h and then carefully move to liquid 
nitrogen storage in IGB.  
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B.15 T HESC culture protocol  
Reagents:  
 Complete HESC media (500 mL); store at 4ºC  
o 470 mL phenol red-free DMEM/F-12 (Based on Invitrogen Catalog Number: 
21041-025, order from Sandy McMasters at SCS Media Facility); store at 4ºC  
o 25 mL carbon stripped fetal bovine serum; store at -20ºC  
o 5 mL penicillin-streptomycin (Invitrogen 15140-122); store at -20ºC  
 0.5% Trypsin-EDTA, no phenol red (Invitrogen 15400-054); store at -20ºC 
 Trypan blue (Sigma-Aldrich T8154)  
 DMSO (Fisher D128-500)  
 Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
Supplies and equipment  
 Hausser phase contrast hemacytometer (Fisher 02-671-5)  
 Tabletop centrifuge (VWR 53513-812)  
 Optical microscope (Leica Microsystems DMIL LED)  
 Water bath (37ºC, Fisher 15-474-35)  
 Sterile pipettes (5, 10, 25 mL)  
 Pasteur pipettes 
 T75 tissue culture flasks 
Procedure  
*Note: all steps should be performed in the laminar flow hood unless otherwise noted.  
 
HESC thawing procedure  
1. Place complete HESC media in water bath and warm to 37ºC.  
2. Thaw frozen cell vials in 37ºC water bath for about 1 min.  
3. Transfer the thawed cells and freezing media to a 15 mL centrifuge tube. Add 8.5 mL 
complete Ishikawa media.  
4. Gently re-suspend the cells in the diluted media and pellet the cells at 130 g for 10 min.  
5. Resuspend the cells in a small volume of media. 
6. Mix 10 μL of the cell suspension with 90 μL of Trypan blue. Pipette several times to mix 
the stain and cell suspension. 
7. Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension 
into each side of the hemacytometer.  
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8. Cell counts are performed in as many of the nine separate regions per side of the 
hemacytometer as is feasible (Typically four corners and center). Average number of 
cells per region is used to calculate the total cell population. For this calculation, the 
dilution factor is typically 10 (1:9 ratio of cell suspension to Trypan blue).  
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume)  
9. Seed the cells at the required density (0.25-0.3 million cells per T 75 flask). Use around 
6-7 mL media for a T75. 
10. Place the flask(s) into the incubator overnight. 
11. Replace the media (10-15 mL/flask) the next day. 
12. Check the confluence every 24 h and feed cells every other day and the day before 
passaging. 
HESC feeding procedure  
13. Warm complete HESC media in water bath to 37ºC.  
14. When the media is warm, wipe dry with paper towel and spray with 70% ethanol before 
placing in the sterile hood.  
15. Remove all old media from each T75 flask, taking care not to scrape the cells with the 
Pasteur pipette. 
16. Add 10-15 mL of complete HESC media. Return the T75 flasks to the incubator and feed 
every other day. Adjust volume of media accordingly for different sized flasks.  
HESC passaging procedure  
1. Warm complete HESC media, sterile PBS, and 3 mL phenol red free trypsin-EDTA per 
T75 flask to be passaged in water bath to 37ºC.  
2. When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray 
with 70% ethanol before placing in the sterile hood.  
3. Remove all old media from each T75 flask, taking care not to scrape the cells with the 
pipette tip.  
4. Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. 
Swirl gently to remove any excess media from the cells. Adjust volumes of PBS, media, 
and trypsin accordingly for different sized flasks.  
5. Remove the PBS and add 3 mL of trypsin per T75 flask. Return the flasks to the 
incubator for 5 min to allow for the cells to detach from the tissue culture plastic (flasks 
will require harsh tapping). Tap the sides of the flasks until the cells detach. 
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6. Add a minimum of 6 mL of complete HESC media to each flask to neutralize the trypsin 
and to flush cells off of the tissue culture plastic.  
7. Remove the trypsinized cell solution from the flask and put into a conical tube. 
Centrifuge the cells at 200 g for 7 min.  
8. Resuspend the cell pellet in a small volume of media. 
9. Mix the 10 μL cell suspension aliquot with 90 μL of Trypan blue. Pipette several times to 
mix the stain and cell suspension.  
10. Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension 
into each side of the hemacytometer.  
11. Cell counts are performed in as many of the nine separate regions per side of the 
hemacytometer as is feasible (Typically four corners and center). Average number of 
cells per region is used to calculate the total cell population. For this calculation, the 
dilution factor is typically 10 (1:9 ratio of cell suspension to Trypan blue).  
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume)  
12. Add additional media to dilute cells to desired concentration. 
13. Seed the cells at the required density (0.25-0.3 million cells per T75). Use around 6-7 mL 
for a T75.  
14. Place the flask(s) into the incubator. 
15. Replace the media with fresh media the following day. 
16. Check the confluence every 24 h and feed cells every other day  
HESC freezing procedure 
1. Complete steps 1-8 on HESC passaging procedure. 
2. Calculate volumes of complete Ishikawa media, and DMSO needed to freeze 5 x 106 
cells per 1.5 mL (freezing media: 95% complete HESC media and 5% DMSO).  
3. Add additional Ishikawa media required (minus the amount added for resuspending the 
cell pellet), followed DMSO. 
4. Aliquot cells into 1.5 mL cryogenic tubes and place in -20ºC freezer for 1 h.  
5. Place cryogenic tubes in -80ºC freezer. Cells can be stored here for up to 6 months. For 
longer-term storage, keep cells at -80ºC for at least 24 h and then carefully move to liquid 
nitrogen storage in IGB.  
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B.16 HUVEC culture protocol  
Reagents:  
 Complete endothelial media (500 mL); store at 4ºC  
o 480 mL phenol red-free Media 200 (Invitrogen M-200PRF-500); store at 4ºC  
o 10 mL Low Serum Growth Supplement (LSGS, Invitrogen S-003-10); store at -
20ºC  
o 5 mL penicillin-streptomycin (Invitrogen 15140-122); store at -20ºC  
o 5 mL L-glutamine (Invitrogen 25030-081) 
 0.5% Trypsin-EDTA, no phenol red (Invitrogen 15400-054); store at -20ºC 
 Trypan blue (Sigma-Aldrich T8154)  
 DMSO (Fisher D128-500)  
 Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
Supplies and equipment  
 Hausser phase contrast hemacytometer (Fisher 02-671-5)  
 Tabletop centrifuge (VWR 53513-812)  
 Optical microscope (Leica Microsystems DMIL LED)  
 Water bath (37ºC, Fisher 15-474-35)  
 Sterile pipettes (5, 10, 25 mL)  
 Pasteur pipettes 
 T75 tissue culture flasks  
Procedure 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted.  
 
HUVEC thawing procedure  
1. Place complete endothelial media in water bath and warm to 37ºC. 
2. Thaw frozen cell vials in 37ºC water bath for about 1 min. 
3. Transfer the thawed cells and freezing media to a 15 mL centrifuge tube. Add 8.5 mL 
complete endothelial media. 
4. Gently re-suspend the cells in the diluted media and pellet the cells at 200 g for 7 min. 
5. Resuspend the cells in a small volume of media. 
6. Mix 10 μL of the cell suspension with 90 μL of Trypan blue. Pipette several times to mix 
the stain and cell suspension.  
7. Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension 
into each side of the hemacytometer.  
8. Cell counts are performed in as many of the nine separate regions per side of the 
hemacytometer as is feasible (Typically four corners and center). Average number of 
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cells per region is used to calculate the total cell population. For this calculation, the 
dilution factor is typically 10 (1:9 ratio of cell suspension to Trypan blue).  
 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume)  
9. Seed the cells at the required density (1.5 million cells per T 75 flask) into 
fibronectin/gelatin coated flasks. Use around 6-7 mL complete endothelial media for a 
T75. 
10. Place the flask(s) into the incubator overnight. 
11. Replace the media (15-20 mL complete endothelial media/flask) the next day. 
12. Check the confluence every 24 h and feed cells every other day and the day before 
passaging. 
HUVEC feeding procedure  
13. Warm complete Ishikawa media in water bath to 37ºC. 
14. When the media is warm, wipe dry with paper towel and spray with 70% ethanol before 
placing in the sterile hood. 
15. Remove all old media from each T75 flask, taking care not to scrape the cells with the 
Pasteur pipette.  
16. Add 15-20 mL of complete endothelial media. Return the T75 flasks to the incubator and 
feed every other day. Adjust volume of media accordingly for different sized flasks.  
HUVEC passaging procedure  
1. Warm complete endothelial media, sterile PBS, and 1.5 mL phenol red free trypsin-
EDTA per T75 flask to be passaged in water bath to 37ºC.  
2. When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray 
with 70% ethanol before placing in the sterile hood. 
3. Remove all old media from each T75 flask, taking care not to scrape the cells with the 
pipette tip.  
4. Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. 
Swirl gently to remove any excess media from the cells. Adjust volumes of PBS, media, 
and trypsin accordingly for different sized flasks.  
5. Remove the PBS and add 1.5 mL of trypsin per T75 flask and let sit 1 min. Tap the sides 
of the flasks until the cells detach. 
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6. Add 6 mL of complete endothelial media to each flask to neutralize the trypsin and to 
flush cells off of the tissue culture plastic. 
7. Remove the trypsinized cell solution from the flask and put into a conical tube. 
Centrifuge the cells at 200 g for 7 min.  
8. Resuspend the cell pellet in a small volume of media. 
9. Mix the 10 μL cell suspension aliquot with 90 μL of Trypan blue. Pipette several times to 
mix the stain and cell suspension.  
10.  Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension 
into each side of the hemacytometer.  
11. Cell counts are performed in as many of the nine separate regions per side of the 
hemacytometer as is feasible (Typically four corners and center). Average number of 
cells per region is used to calculate the total cell population. For this calculation, the 
dilution factor is typically 10 (1:9 ratio of cell suspension to Trypan blue).  
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume)  
12. Add additional media to dilute cells to desired concentration.  
13. Seed the cells at the required density (1.5 million cells per T75) into fibronectin/gelatin 
coated flasks. Use around 6-7 mL for a T75. 
14. Place the flask(s) into the incubator. 
15. Replace the media with fresh media the following day. 
16. Check the confluence every 24 h and feed cells every other day  
 
HUVEC freezing procedure  
1. Complete steps 1-8 on HUVEC passaging procedure. 
2. Calculate volumes of complete endothelial media, carbon stripped FBS, and DMSO 
needed to freeze 5 x 10
6
 cells per 1.5 mL (freezing media: 50% complete endothelial 
media, 40% FBS, 10% DMSO).  
3. Add additional endothelial media required (minus the amount added for resuspending the 
cell pellet), followed by carbon stripped FBS, and DMSO. 
4. Aliquot cells into 1.5 mL cryogenic tubes and place in -20⁰C freezer for 1 h.  
5. Place cryogenic tubes in -80ºC freezer. Cells can be stored here for short term (2 weeks). 
For longer-term storage, keep cells at -80ºC for at least 24 h and then carefully move to 
liquid nitrogen storage in IGB. 
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B.17 Cell seeding on CG scaffolds protocol 
Reference: [136, 319] 
Reagents 
 Complete media (refer to B.14-B.16 protocols for cell recipes); store at 4ºC  
 Trypsin-EDTA (Invitrogen 25300-062); store at -20ºC 
 Trypan blue (Sigma-Aldrich T8154) 
 Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
Supplies and equipment 
 Ultra-low attachment 6-well plates (Fisher 07-200-601) 
 Hausser phase contrast hemacytometer (Fisher 02-671-5) 
 Tabletop centrifuge (VWR 53513-812) 
 Optical microscope (Leica Microsystems DMIL LED) 
 Water bath (37ºC, Fisher 15-474-35) 
 Sterile pipettes (5, 10, 25 mL) 
 Kimwipes 
 
Procedure 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted.  
1. At least 1 hour prior to seeding, transfer scaffolds from PBS into media to be used for 
seeding (use 1/2 mL per scaffold). 
2. Warm complete media, sterile PBS, and 1.5-5 mL trypsin-EDTA per T75 flask 
depending on cell type to be passaged (refer to B.14-B.16 protocols) in water bath to 
37ºC. 
3. When the media, PBS and trypsin are warm, wipe them dry with paper towel and spray 
with 70% ethanol before placing in the sterile hood. 
4. Remove all old media from each flask, taking care not to scrape the cells with the pipette 
tip. 
5. Add 10 mL of PBS per T75 flask and leave the PBS in the flask to rinse the cells for 30 s. 
Swirl gently to remove any excess media from the cells. Adjust volumes of PBS, media, 
and trypsin accordingly for different sized flasks. 
6. Remove the PBS and add required volume of trypsin per flask. For Ishikawas, return the 
flasks to the incubator for 5 min to allow for the cells to detach from the tissue culture 
plastic. Tap flasks until cells detach. 
7. Add 6-10 mL of complete cell media (refer to B.14-B.16 protocols) to each flask to 
neutralize the trypsin and to flush cells off of the tissue culture plastic. 
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8. Remove the trypsinized cell solution from the flask and put into a conical tube. 
Centrifuge the cells at 200 g for 7 min.  
9. Resuspend the cell pellet in a small volume of media. 
10. Mix the 10 μL cell suspension aliquot with 90 μL of Trypan blue. Pipette several times to 
mix the stain and cell suspension.  
11.  Place a cover slip on the hemacytometer and pipette 10 μL of the stain/cell suspension 
into each side of the hemacytometer.  
12. Cell counts are performed in as many of the nine separate regions per side of the 
hemacytometer as is feasible (Typically four corners and center). Average number of 
cells per region is used to calculate the total cell population. For this calculation, the 
dilution factor is typically 10 (1:9 ratio of cell suspension to Trypan blue).  
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume)  
13. Add additional media to dilute cells to desired concentration (usually 1-5 x 105 cells per 
10 μL.  
14. Carefully remove excess media from scaffolds with a Kimwipe and place 3-6 (typically 
6) scaffold pieces in each well of Ultra-low attachment 6-well plates. Do not overdry 
scaffolds as this will lead to reduced viability. 
15. Add 5 μL of cell suspension to each scaffold piece. Place scaffolds in incubator for 1 h. 
16. Remove scaffolds from incubator, flip over, add additional 5 μL of cell suspension to the 
other side of each scaffold, and return to incubate for additional 1 h. 
17. Carefully add 2 mL complete media per scaffold (or media with growth factors but 
without serum) to each well. Change media every 2-3 days over the course of the 
experiment. 
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B.18 AlamarBlue metabolic activity protocol 
Reference: [136, 137, 319] 
Reagents 
 Complete media (refer to B.14-B.16 protocols); store at 4ºC 
 AlamarBlue (Invitrogen DAL1100); store at 4ºC 
Supplies and equipment 
 24-well plates (Fisher 08-772-1) 
 96-well plates (Fisher 12-565-369) 
 MTS 2/4 digital microtiter shaker (IKA 3208001) 
 Water bath (37ºC, Fisher 15-474-35) 
 Fluorescence spectrophotometer (Tecan, RAL 104) 
Procedure 
*Note: all steps should be performed in the laminar flow hood unless otherwise noted. The  
volumes of reagents used are correct for 6 mm diameter, 3 mm thick scaffold pieces. Use control 
media being used for experiment. 
 
Generating standard curve procedure 
1. Warm media and AlamarBlue in water bath to 37ºC. 
2. Before starting an experiment, generate a standard curve with a known number of cells. 
The standard should have at least seven sample points: one well with media and 
AlamarBlue, and five wells with media, AlamarBlue, and a different number of cells 
(Ranging from 0.3125-5 times seeding density). 
3. Assuming 10 μL cell solution used for scaffold seeding, pipette 100 uL (10 times seeding 
density) cell solution and 800 μL of media and pipette to mix 
4. To the 2nd-5th well, pipette 450 μL media 
5. Starting with the 2nd well, perform half dilutions by transferring 450 μL from the 
preceding well (1
st
 to 2
nd
, 2
nd
 to 3
rd
, etc.) into to the current well and pipetting to mix. 
6. Transfer 450 μL from the 900 μL in the 5th well to the 6th well. 
7. Pipette 450 μL of media into the 7th well. 
8. Add 50 μL of AlamarBlue to each well. 
9. Incubate at 37ºC under gentle (~50 rpm) shaking for 0.5-1.5 h. During this time healthy 
cells convert the active ingredient in AlamarBlue (resazurin) to the highly fluorescent 
resorufin. Longer incubation times are necessary for smaller cell concentrations, but 
make sure not to incubate cells too long or all of the resazurin will be reduced to 
resorufin. 
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10. After incubation, pipette 100 μL in triplicate from each sample well into a clear 96-well 
plate. 
11. Measure fluorescence (excitation: 540 nm, emission: 580 nm) on the spectrophotometer 
in RAL 104 using the program ‘AlamarBlue F200’. Remember to reserve the F200 
machine on the Google Calendar prior to use. For each data point, adjust the fluorescence 
reading by subtracting the average reading from the background control. The standard 
curve is created by plotting cell number as a function of adjusted fluorescent intensity. 
Quantifying metabolic activity on scaffolds procedure 
1. For measuring cell metabolic activity on scaffolds, pipette 450 μL media into each well 
(one well for each scaffold piece plus the two control wells). Add 100 μL AlamarBlue to 
each well except for one negative control well. Adjust volumes for smaller/larger 
materials accordingly, keeping the 9:1 media: AlamarBlue® ratio constant. 
2. Remove scaffolds to be assayed and rinse in sterile PBS to remove excess media and 
unattached/dead cells. Add scaffolds to experimental wells and incubate at 37ºC under 
gentle (~50 rpm) shaking. The incubation time should be identical to the time used to 
make the standard curve. 
3. After incubation, pipette 100 μL in triplicate from each sample well into a 96-well plate. 
4. Measure fluorescence (excitation: 540 nm, emission: 580 nm) on the spectrophotometer 
in RAL 104 using the program ‘AlamarBlue F200’. Remember to reserve the F200 
machine on the Google Calendar prior to use. Subtract the background control from the 
data points and extrapolate adjusted fluorescent intensity on the standard curve to give 
metabolic activity. 
5. This assay is non-destructive, so scaffolds can continue to be cultured and analyzed at 
later time points or for DNA. 
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B.19 Hoechst DNA quantification protocol 
Reference: [136, 319, 320] 
Reagents 
 Hoechst dye buffer (500 mL); store at 4ºC for up to 3 months 
o 400 mL deionized water 
o 58.44 g sodium chloride (RAL storeroom) 
o 0.605 g Tris base (RAL storeroom) 
o 0.185 g disodium EDTA (Sigma-Aldrich E5134) 
o Adjust pH to 7.4, bring total volume to 500 mL, sterile filter before use 
 Papain buffer (100 mL); store at 4ºC 
o 100 mLsterile phosphate-buffered saline without Ca2+ or Mg2+ PBS 
o 1 mL 0.5 M EDTA (pH = 8.0, Sigma-Aldrich EDS); store at 4ºC 
o 79 mg cysteine-HCl (Sigma-Aldrich 00320) 
 Hoechst 33258 dye solution (1 mL); store at 4ºC for up to 6 months 
o 1 mL sterile water 
o 1 mg Hoechst 33258 dye (Invitrogen H1398); store at 4ºC 
 Papain from Carica papaya (Sigma-Aldrich 76218); store at -20ºC 
 Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
Supplies and equipment 
 96-well plates (Fisher 12-565-369) 
 Vortex (Fisher 02-215-365) 
 Water bath (60ºC, Fisher 15-460-2SQ) 
 Fluorescence spectrophotometer (Tecan, Room 104 RAL) 
 Microcentrifuge tubes (1.5 mL) 
Procedure 
*Note: steps 1-2 should be performed in the laminar flow hood. 
 
Standard Curve Procedure 
1. At the beginning of each experiment, a standard curve should be generated with a known 
number of cells. Make up active papain enzyme solution by dissolving 2.4 mg papain in 1 
mL papain buffer in the 60ºC water bath. 
2. In 1.5 mL microcentrifuge tube, spin down 50 μL of cell solution (5 times cell seeding 
volume) for 3 min at 12000 rpm. 
3. Remove supernatant and add 300 μL papain enzyme solution to tube. Pipette to 
resuspend cells. Allow to digest for 24 h in the 60ºC water bath. 
4. After 24 h, vortex cell lysate thoroughly.  
5. Prepare 1 mL of digest by dissolving 2.4 mg papain in 1 mL papain buffer in the 60ºC 
water bath. 
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6. Perform half dilutions to prepare standard (5x, 2.5x, 1.25x, 0.625x, 0.3125x cells seeded 
plus control). Label tubes for 2.5-.3125x points and add 150 μL of papain enzyme 
solution to each tube. Starting with the 2.5x sample, add 150 μL from the next higher 
concentration tube to the tube and vortex (150 μL from 5x into 2.5x, then 150 μL from 
2.5 x into 1.25x, etc.). 
7. Prepare Hoechst working dye solution by adding 0.5 μL dye solution to 5 mL Hoechst 
dye buffer. Vortex thoroughly. Prepare a second set of microcentrifuge tubes. To each 
tube add 600 μL of dye solution and 30 μL of corresponding cell lysate for a total volume 
of 630 μL. Vortex thoroughly. The Hoechst dye fluorescently binds to double-stranded 
DNA from the lysed cells, allowing quantification of DNA and thus cell number. 
8. Pipette 200 μL from each tube in triplicate into a black 96-well plate. 
9. Measure fluorescence (excitation: 360 nm, emission: 465 nm) on the spectrophotometer 
in RAL 104. Use the ‘DNA F200’ program and remember to reserve the F200 machine 
on the Google Calendar prior to use. For each data point, adjust the fluorescence reading 
by subtracting the reading from the blank control. The standard curve is created by 
plotting cell number as a function of adjusted fluorescent intensity. 
Cell Quantification Procedure 
*Note: step 2 should be performed in the laminar flow hood. 
1. For measuring cell number on scaffolds, pipette 300 μL of papain enzyme solution into 
microcentrifuge tubes (one for each scaffold plus controls: one tube containing a blank 
scaffold with no seeded cells as a background control). 
2. Remove scaffolds to be assayed and rinse in sterile PBS to remove excess media and 
unattached/dead cells. Add scaffolds to microcentrifuge tubes and incubate in 60ºC water 
bath for 24 h. Vortex occasionally to facilitate digestion of scaffold. 
3. After incubation, pipette 600 μL Hoechst working dye solution into new set of 
microcentrifuge tubes. 
4. Remove samples from water bath and vortex thoroughly. Add 30 μL from each tube to its 
corresponding tube containing working dye solution. Vortex thoroughly. 
5. Pipette 200 μL from each tube in triplicate from each sample well into a 96-well plate. 
6. Measure fluorescence (excitation: 360 nm, emission: 465 nm) on the spectrophotometer 
in RAL 104. Use the ‘DNA F200’ program and remember to reserve the F200 machine 
on the Google Calendar prior to use. For each data point, adjust the fluorescence reading 
by subtracting the reading from the background control. Adjusted fluorescent intensity 
can be extrapolated on the standard curve to give a cell number. 
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B.20 Cell tracker staining protocol 
Reagents:  
 Complete media (refer to B.14-B.16 protocols); store at 4ºC 
 Cell Tracker Red (Invitrogen CMTPX); store at -20ºC 
 Cell Tracker Green (Invitrogen CMFDA ); store at -20ºC 
 DMSO (Fisher D128-500) 
 Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
Supplies and equipment  
 15 mL conical tubes 
 Pasteur pipettes  
 Vortex (Fisher 02-215-365)  
Procedure 
*Note: all steps should be performed in the laminar flow hood in the dark unless otherwise 
noted. 
1. To conical tube labeled “Red”, pipette 7.29 mL of desired complete medium (refer to 
B.14-B.16 protocols) (Note: will need 5 mL of dye solution per flask). 
2. To 1 vial of red cell tracker, add 7.29 μL of DMSO.  
3. Dilute the cell tracker dye solution using 400 μL of medium from “Red” Conical tube 
and pipette to mix. 
4. Transfer dye into the “Red” 15 mL conical tube. Vortex to mix. 
5.  Retrieve a flask of cells (Ishikawas or HESCs) from the incubator. 
6.  Rinse the cell thoroughly with 10 mL of PBS. 
7. Aspirate of the PBS and add 5 mL of the cell tracker red solution. 
8. Return the flask to the incubator for half an hour. 
9. During the cell tracker red incubation, stain the HUVECs. 
10. To 15 mL conical tube labeled “Green”, add 10.76 mL of desired growth medium. 
11. To a vial of cell tracker green, add 10.76 μL of DMSO and pipette to suspend the dye. 
12. Add 400 μL of medium from the “Green” 15 mL conical tube to the cell tracker green 
vial and pipette to mix. 
13. Transfer dye into the “Green” 15 mL conical tube. Vortex to mix. 
14. Retrieve 2 flasks of HUVECs from the incubator. 
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15. Rinse each flask of cells thoroughly with 10 mL of PBS. 
16. Aspirate off PBS and add 5 mL of cell tracker green solution to each flask. 
17. Return the flasks to the incubator for half an hour. 
18. After cells have been stained with cell tracker for half an hour, begin passaging and 
scaffold seeding following the protocols (refer to B.14-B.16 protocols). (Be sure to 
continue the remainder of the experiment in the dark.) 
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B.21 Protein isolation protocol  
Reagents  
 RIPA buffer (500 mL)  
o 495 mL deionized water  
o 4.38 g sodium chloride (150 mM, RAL storeroom)  
o 5 mL Triton X-100 (1%, Sigma 93443-100ML)  
o 2.5 g sodium deoxycholate (0.5%, Sigma D6750-10G)  
o 0.5 g SDS (0.1%, Sigma L3771-25G)  
o 3.03 g Tris base (50 mM, RAL storeroom)  
o Adjust pH to 8.0 and store at 4°C  
 
 Protease inhibitor cocktail (Sigma P8340-1ML)  
 Phosphatase inhibitor cocktail 2 (Sigma P5726-1ML)  
 Phosphatase inhibitor cocktail 3 (Sigma P0044-1ML)  
 Ice  
 Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS)  
 
Supplies and equipment  
 Ice bucket  
 Microcentrifuge tubes  
 Vortex (Fisher 02-215-365)  
Procedure  
*Note: steps 2-3 should be performed in the laminar flow hood.  
1. Label microcentrifuge tubes for each sample. Prepare ~ 200 μL of ice-cold RIPA buffer 
per sample and add protease and phosphatase inhibitors (100x stocks) fresh to the buffer.  
2. Rinse scaffold pieces in PBS to remove dead and unattached cells. Place scaffolds in 
empty, labeled microcentrifuge tubes.  
3. Pipet 150-200 μL complete RIPA buffer onto each scaffold piece.  
4. Keep scaffolds on ice for 30 min, agitating with a pipet tip occasionally to aid buffer 
infiltration.  
5. After 30 min, remove scaffold from tubes, squeeze out excess liquid, and store lysates at -
80°C until use.   
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B.22 BCA protein quantification protocol  
Reference:  https://www.piercenet.com/instructions/2161296.pdf 
 
Reagents  
 Pierce BCA Protein Assay Kit (Fisher 23225, 23227) 
o BCA Reagent A 
o BCA Reagent B 
o Albumin standard Ampules 
 RIPA buffer 
 Ice  
 
Supplies and equipment  
 Ice bucket  
 50 mL conical tube 
  96-well plates (Fisher 12-565-369) 
 Vortex (Fisher 02-215-365)  
 Fluorescence spectrophotometer (Tecan, Room 104 RAL) 
Procedure 
1. Thaw lysate samples on ice  
2. Prepare the working reagent in a 50 mL conical tube by combining 50 parts BCA 
Reagent A to 1 part Reagent B and vortexing. (Will need 200 μL of WR per sample and 
standard replicate) 
200 μL * (# standards + # samples) (# replicates) 
3.  Prepare the standard using the following formulation recipe 
Vial 
RIPA Vol 
(μL) 
BSA Vol and 
Source (μL) 
[BSA] 
(μg/mL) 
A 0 300 stock 2000 
B 125 375 stock 1500 
C 325 325 stock 1000 
D 175 175 vial B 750 
E 325 325 vial C 500 
F 325 325 vial E 250 
G 325 325 vial F 125 
Blank 400 0 0 
4. Vortex and pipette 10 μL of each standard and sample replicate into a clear 96 well plate. 
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5. Pipette 200 μL of working reagent into each well containing a standard or sample 
replicate. (The first two columns of the plate should be used for the standard for a plate 
run with two replicates.) 
6. Gently shake plate side to side or place on plate shaker for 30 sec to mix 
7. Cover plate and place in incubator at 37°C for 30 min- 2 hours. 
8. Remove plate and cool to RT. 
9. Read the absorbance at 562 nm on the M200 plate reader in RAL 104. 
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B.23 Western Blotting  
Reference: http://gewesternblotting.com/resources/28999897AB-WB-HANDBOOK.pdf 
http://www.youtube.com/watch?v=XnEdmk1Sqvg 
http://www.labtricks.com/2010/01/24/how-to-run-an-sds-page-gel/  
Reagents  
 RIPA buffer: Need ~200uL per sample 
o 150 mM NaCl 
o 1% Triton X-100 (Sigma 93443) 
o 0.5% sodium deoxycholate (Sigma D6750) 
o 0.1% SDS (Bio Rad 161-0301) 
o 50 mM Tris (Fisher BP152-500) 
o pH = 8.0 
 
 Running buffer: Need ~700mL per gel (when running 1-2 gels) 
o 25 mM Tris base (Fisher BP152-500) 
o 192 mM glycine (ACROS 12007-0010) 
o pH ~ 8.3 
o 0.1% SDS (Bio Rad 161-0301) 
 
 Towbin’s electrotransfer buffer (10x): Need 100mL per gel 
o 25 M Tris base (Fisher BP152-500) 
o 192 M glycine (ACROS 12007-0010) 
 
 Transfer buffer: Need ~1L per gel 
o 20% Methanol (MACRON) 
o 10% 10x Towbin’s electrotransfer buffer 
o 70% Water 
 
 TBS-T  store at 4ºC 
o 20 mM Tris pH 7.5 (Fisher BP152-500) 
o 0.8% w/v NaCl 
o 0.1 % v/v Tween 20 (Fisher BP337-500) 
***Use ultrapure water and filter all buffers! 
 2x Laemmli buffer (BioRad 161-0737) 
o 2% β-mercaptoethanol (Sigma M7522) 
 
 Blocking Buffer 1 (TBS-T + 5% non-fat milk)  
o 100mL TBS-T 
o 5g non-fat milk powder 
 
 Blocking Buffer 2 (TBS-T + 5% Bovine Serum Albumin)  
o 100mL TBS-T 
o 5g BSA (Sigma A7906) store at 4ºC 
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 Combined protease/phosphatase inhibitors (x100) 
o Phosphatase Inhibitor Cocktail 2 (Sigma P5726); store at 4ºC 
o Phosphatase Inhibitor Cocktail 3 (SigmaP0044); store at 4ºC 
o Protease Inhibitor Cocktail (Sigma P8340); store at -20ºC 
 
 ddH2O or at least DI water 
 Protein ladder (GE Healthcare 28925341(RPN800E)); store at -20ºC 
 Primary antibody  
 Secondary antibody 
 Polyacrylamide gel (precast gels available at stockroom, otherwise make your own) 
 Ice 
 Ponceau S stain (Fisher Cat# K793-500mL) 
 Chemiluminescent substrate store at 4ºC 
o  SuperSignal West Femto Maximum Sensitivity Substrate (Fisher 34096) 
o SuperSignal West Pico Chemiluminescent Substrate (Fisher 34080) 
 Restore Western Blot Stripping Buffer (Fisher 21059) 
Supplies and equipment 
 Mini-Protean apparatus (BioRad) 
 Power Pac HC 250 V/3.0 A/300 W (BioRad) 
 Trans-Blot SD Semi-Dry Transfer Cell (BioRad) 
 ImageQuant (GE healthcare) 
 Water bath (95 ºC) ( Fisher Isotemp 102S)  
 Nitrocellulose membrane (GE Healthcare, 10600012) 
 Whatman paper 
 Plastic forceps 
 Gel-loading pipette tips 
 Blot containers (for blocking and staining) 
 Clean glass bucket/container (large enough to hold entire gel) 
 Plastic wrap (for imaging) 
 1.5 mL conical tubes 
 15 mL conical tubes 
 KimWipes 
Procedure 
Protein lysis, recovery, and quantification 
1. Pre-cool all reagents (tubes, RIPA buffer, inhibitors) by putting them on ice. 
2. Add inhibitors to the RIPA buffer (1:100 dilution). Prepare ~200uL buffer per sample. 
Keep on ice.  
3. Rinse your sample with PBS to remove dead and unattached cells. (x2) 
4. Lysis: Adjust the amount of buffer depending on how much protein you have in your 
sample. If you have a lot of cells, use 200uL or more. If you have very little cells, add 
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less. Remember, you can only load 10-20uL protein sample per lane. 
 Homogenization (for scaffolds and hydrogels only): 
o Use a Dounce homogenizer to grind scaffold/hydrogel. 
 Scaffold/Membrane/3D hydrogel: Place scaffold in RIPA buffer + inhibitors.  
 2D hydrogel: Pipette 200uL buffer onto the hydrogel. Lyophilize and resuspend 
later. Note) Use a small gel if you have a small number of cells. 
 Cell suspension: Add RIPA buffer + inhibitors. 
 Protein lyophilization: You can lyophilize your lysate and reconstitute in a 
smaller volume of sterile water.  
5. Keep on ice for 30 min with intermittent agitation/vortexing. 
6. Centrifuge at 15K RPM for 10min at 4°C.  
7. Quantify protein amount with BCA kit.  
8. Put on ice for immediate analysis or freeze at -80°C for later analysis. 
 
Day 1: Protein lysate gel electrophoresis, transfer, primary antibody 
1. Have buffers ready. 
2. Obtain precast gel from storeroom.Normally:10-12% acrylamide, however gradient gels 
and different gel percentages may be more applicable for particular target resolution 
(consult manufacturer) 
3. Prepare the heating block (95°C; water bath with beads and water). 
4. For -80°C lysates: Thaw them on ice. 
5. Add 1 part lysate (7.5-25 uL) to 1 part 2x Laemmli buffer (7.5-25 uL) in 1.5 mL 
centrifuge tube. Adjust the amount accordingly depending on how much protein you 
want to load. 
 Loading size: Typically 15-40uL lysate+Laemilii per lane. 
6. Heat tubes at 95°C in heating block for 5-10 min. 
7. Electrophoresis apparatus: 
 While tubes are heating, remove gel from fridge and rinse with water.  
 Take strip off bottom and place it to the front of electrophoresis apparatus.  
o If only running one gel, place a blank plastic cassette on the back side.  
 Clamp everything in properly. (Red-red; black-black) 
 Pour running buffer between cassettes until gel is immersed. 
 Fill container with running buffer to 2 or 4 gel marks (use 1 liter for 250 V 
transfer) 
 Remove comb from precast gels.  
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8. Take sample tubes. Spin down for a few seconds if you have solid pieces from 
hydrogels/scaffolds.  
9. Using gel-loading tips and 20 or 100 μL pipette, carefully load 15-40μL lysate/Laemmli 
mix into each lane (behind plate). Load 5uL (for 50 μL lanes, or 3μL (15 μL) ladder to 
one lane for reference. 
10. Run gel at 150V for ~1hr until all lysates (blue) arrive at the bottom. 
 Make sure your band doesn’t run off the gel 
 While waiting, prepare nitrocellulose membrane by cutting it to match gel size. 
 Also make sure transfer buffer is ready. 
11. Turn off power and rinse gel cartridge thoroughly with DI water. 
12. Carefully open gel cartridge using opening lever. For precast gels, crack open at 4 sides 
marked by arrowheads. 
13. Remove stacking gel and rinse with water. Cut off edges and lane dividers. 
14. Soak gels in buffer solution for 20-60 (30) min to equilibrate (may notice shrinkage) 
15. Cut membrane and filter paper to gel size and slide at a 45⁰ angle into transfer buffer 
solution to soak for 5-10 min (15-30 min according to manual) 
16. Remove safety cover and prepare gel sandwich as follows (roll out air bubbles between 
each layer): 
To bottom platinum anode place: 
 Pre-wet extra thick (or 2 thick or 3 thin) filter paper 
 Pre-wet membrane 
 Equilibrated gel 
 Pre-wet extra thick (or 2 thick or 3 thin) filter paper 
17. Place cathode onto the stack, pressing to engage the latches with the guide post without 
disturbing the filter paper stack 
18. Place the safety cover on the unit  
19. Set the transfer parameters as 10 V for 30 min or 15 V for 15 min with max current of 
5.5mA/cm
2 
(0.35A/gel) 
 While waiting, prepare blocking buffers (5g dry milk to 100mL TBS-T and 5g 
BSA to 100mL TBS-T) vortex thoroughly. 
20. Take apart assembly. Discard filter paper and gel (nothing should be left in the gel, 
indicating the transfer was successful). Nick membrane edge (top left corner) with 
scissors so you know which side the protein is on (this is the side of the membrane that 
faced the gel!) 
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21. Stain with Ponceau S (1x) to check protein bands (can be re-used). Bands may not 
appear. Rinse with TBS-T to remove stain. 
22. Cut membrane according to molecular weight of your protein(s) of interest and place 
each piece in a separate mini plastic container. 
23. Add 20-30mL blocking buffer 1 (milk) to container. Incubate for 30min on a shaker (~50 
rpm). 
 While waiting, prepare primary antibody solution in ~5mL blocking buffer.  
24. Add corresponding primary antibody in blocking buffer 2 (or as suggested by 
manufacturer) to each container. 
 Primary antibodies diluted in blocking buffer can be used again. Store at 4°C or -
20°C.  
25. Incubate overnight at 4°C or 2 hrs at RT on shaker. Keep remaining blocking buffer in 
fridge. 
Day 2 Secondary antibody, read blot using ECL (enhanced chemiluminescence) 
1. Wash membranes with TBS-T for 5min on shaker at RT (3x). 
 While waiting, prepare 5-10mL secondary antibody solution (1:2500 dilution) in 
TBS-T or blocking buffer 1 from fridge. 
 Make sure you use matching (anti-rabbit; anti-mouse, etc.) secondary antibody. 
2. Incubate in secondary antibody solution for 1hr at RT. 
 Make sure you use matching (anti-rabbit; anti-mouse, etc.) secondary antibody. 
3. Wash membranes with TBS-T for 5min on shaker at RT (3x). 
4. Now, go to IGB room 124D to use ImageQuant for ECL detection. 
 Make sure to bring: Your membranes in TBS-T, ECL reagents, 15mL conical 
tube, 1mL pipette with tips, plastic forceps, key to 124D. 
 Make sure your membranes stay hydrated until next step. 
 There should be plastic wrap and KimWipes in basement. 
5. Once in basement, mix ECL reagents (1:1; make 2mL per membrane) in 15 mL conical 
tubes.  
6. Place plastic wrap on a flat surface. Pick up your membrane with forceps then gently blot 
using KimWipes. Quickly do this for all membranes and pipette mixed ECL solution onto 
the membranes.  
7. Wrap it with saran wrap and keep it in drawer at least 2 minutes. 
8. Log into computer and start software. 
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9. Take membranes from the drawer.  
10. Prepare clean saran wrap on the side. Pick up your membrane with forceps and gently 
blot using KimWipes. Place membranes on the clean saran wrap and cover it. 
11. Place it in the detection chamber and detect. Expose for 30-60 sec first then adjust 
according to the output intensity (bands should not be completely black, some level of 
grey scale is needed for quantification).  
12. Save image.  
13. Post-analysis: Analyze band intensity using Gel Image Analyzer or ImageJ. 
Stripping (Standard): 
1. Incubate in stripping buffer for 5-15 min at RT. Use a volume that will cover the 
membrane. 
2. Discard buffer and add fresh stripping buffer for 10min at RT. 
3. Wash with TBS-T for 5min at RT. (3x) 
4. Ready for blocking stage. 
Notes: 
Loading controls (not detailed here) 
To obtain reliable information about the expression levels of proteins on western blots (i.e. for 
publication), it is necessary to use an appropriate loading control (beta-Actin, GAPDH, etc). 
 
For best results, it may be necessary to optimize all parameters including sample loading amount, 
antibody host species/concentrations, order of target probing and stripping, and the membrane 
type and blocking reagents. 
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Reagent Formulas 
RIPA: TOTAL 500mL 
pH = 8.0 NaCl 4.38g 
 Triton X-100 5mL 
 Sodium deoxycholate 2.5g 
 SDS 0.5g 
 Tris base 3.03g 
Running buffer (10x): TOTAL 1000mL 
Dilute 1:10 with ddH2O DI water 1000mL 
pH will be 8.3 Tris base 30.3g 
 Glycine 144g 
 SDS 10g 
Towbin’s electrotransfer buffer 
(10x): 
TOTAL 1000mL 
 DI water 1000mL 
 Tris base 30.3g 
 Glycine 144g 
Transfer buffer TOTAL 1000mL 
 DI water 700mL 
 Towbin’s buffer (10x) 100mL 
 Methanol 200mL 
TBS-T (10x): TOTAL 1000mL 
Dilute 1:10 with ddH2O DI water 990mL 
pH will be 7.5 Tris base 24.2g 
 NaCl 80g 
 Tween20 10mL 
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B.24 Western Blot quantification protocol  
Reference: http://www.lukemiller.org/ImageJ_gel_analysis.pdf 
Procedure 
1. Open the image file in ImageJ 
2. If the image isn’t already in 8-bit grayscale, convert to grayscale is to go to 
Image>Type>8-bit. 
3. If the bands are slanted, level them by selecting Image →Rotate→Arbitrairly… 
4. Choose the rectangular selection option from the toolbar and draw a rectangle around the 
band in the first lane. Click Ctrl+1 to set the first lane. 
Note: If your rectangle is taller than it is wide, ImageJ will assume your lanes run 
up and down, but if your rectangle is wider than it is tall, Image J will assume 
your lanes run up and down. The width of the selection is fixed for all lanes. It is 
important to get the shape and position of the first lane correct prior to setting it. 
5. Place the mouse over the “1” inside the rectangle, clicking and holding down while 
dragging the box to the second lane. Click Ctrl+2 (or Analyze→Gels→Select Next Lane) 
6. Place the mouse over the next rectangle band, clicking and holding down while dragging 
the box to the next lane. Again, click Ctrl+2. Repeat for any additional lanes. 
7. Upon dragging the rectangle over the last lane, click Ctrl+3 (or Analyze→Gels→Plot 
Lanes). The plots will open in a new window. 
8. Use the straight line tool to close the bottom of the first peak. 
9. Using the plot window, scroll down to the next peak (the hand tool is good for scrolling). 
Use the straight line tool to again close off the peak. Repeat for any additional peaks. 
10. Scroll back to the top and selecting the wand tool, click inside the peak. A new window 
will open with the value for the lane 
11. Scroll to the next peak and use the wand tool. The new value will be added to the table in 
the new window. Repeat until all peaks are measured. 
12. Peaks can be normalized to GAPDH bands. In the case of phosphorylated measurements, 
the peaks can be normalized to the unphosphorylated measurements. 
13. Copy the data from the table and paste into excel for further analysis. 
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B.25 RNA Isolation  
Reference: [58, 321] 
 
Reagents:  
 RNeasy Plant Mini Kit (Qiagen 74904) 
 β-mercaptoethanol (Sigma M7522-100ML) 
 70% ethanol (use RNase free water when making solution) 
 Sterile phosphate-buffered saline without Ca2+ or Mg2+ (PBS) 
 RNase-free water 
 Ice 
 
Supplies and equipment  
 2 mL RNase free non-graduated microcentrifuge tubes 
 RNase free pipette tips 
 Ice bucket 
 Kimwipes 
 Microcentrifuge 
 
Procedure 
Reagent prep (before starting) 
1. Lysis buffer: Add 10 μL β-mercaptoethanol (14.3 M) per 1 mL of Buffer RLT supplied 
with Qiagen kit. This solution can be stored at room temperature for 1 month. 
2. Buffer RPE: Add 4 volumes of 100% ethanol to the bottle of Buffer RPE supplied with 
Qiagen kit. 
RNA Extraction 
*All steps are performed at room temperature. Work quickly; limit the number of samples for 
RNA extraction to 18-24 in each sitting. RNase free tips should be used throughout. 
3. Label one microcentrifuge tube for each sample. 
4. Label one microcentrifuge tube for each sample. 
5. Put some ice (2nd floor RAL) in an ice bucket. 
6. Wash scaffolds in PBS three times, cut in half with razor blade, and then place in labeled 
tubes.  
7. Add ~ 500 µL of ice-cold lysis buffer to each tube and keep on ice for ~ 5 min, shaking 
tubes periodically to help the buffer infiltrate the scaffolds. Scale amount of lysis buffer 
appropriately. 
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8. Pipette lysate into a labeled QIAShredder column. Place scaffold pieces in column as 
well. Spin at 14,000 rpm for 2.5 min.  
9. Add equal volume of 70% ethanol to each sample and mix by pipetting up and down. 
10. Add half of the lysate + ethanol to labeled RNeasy column (with 2-mL collection tube). 
11. Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
12. Add the remaining lysate + ethanol to the column. 
13. Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
14. Add 700 μL Buffer RW1 to the column.  
15. Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
16. Pipet 500 μL Buffer RPE into the column. 
17. Centrifuge at 12,000 rpm for 30 s. Discard flow-through and replace column. 
18. Add another 500 μL Buffer RPE into the column. 
19. Centrifuge at 12,000 rpm for 2.5 min. Discard flow-through and place the column in a 
new 2 mL collection tube (supplied with kit).  
20. Centrifuge at 12,000 rpm for 2.0 min. 
21. Transfer the column to a new labeled, 1.5-mL collection tube. 
22. Pipet 30 μL RNase-free water into the column and wait 5 min. 
23. Centrifuge the RNeasy column at 12,000 rpm for 1.5 min. 
24. Store RNA at -80°C for later use or put on ice if directly proceeding to quantification, 
reverse transcription, and RT-PCR. 
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B.26 Reverse Transcription 
Reagents:  
 QuantiTect Reverse Transcription Kit (Qiagen 205313) 
 RNA samples 
 Ice 
Supplies and equipment  
 BIO-RAD S1000 ThermoCycler 
 Ice bucket 
 200 uL microcentrifuge tubes 
Procedure 
1. Turn on thermocycler to allow it time to warm up 
2. Put all samples, water, gDNA wipeout, Reverse Transcriptase, and Reverse Transcriptase 
Buffer on ice. 
3. Label 200 uL conical tubes with sample identifiers (1 per sample) 
4. Calculate the volume of RNA sample required for a 10 uL reaction: 
                                     
     
                                 
Note: 1.10 is for 10% excess 
Calculate the amount of water needed to be added to each RNA volume (6uL final 
volume) 
Note: If the total RNA volume necessary is above 6 uL, use only 6 uL. This will be 
corrected for using a house keeping gene (such as GAPDH) 
5. Pipette the required amount of water to each 200 uL conical tube 
6. Add 1 uL of gDNA wipeout  and mix (vortex or pipette)  each conical tube 
7. Add required RNA volumes to each tube, mix, and close lids 
8. Thermocycler should read “ block is idle”  
9.  Push handle back (away from you) and lift up to open the thermocycler 
10. Load samples 
11. To close lid, lower, pushing  lid away from you and let go when the lid has completely 
lowered to lock 
12. Tighten knob on lid clockwise until the inner lid touches the vessels (is hand tight) and 
then add ¼ turn because the conical tubes are capped (have lids) 
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13. Click Enter, select cav 1, enter again to select 
14. Change volume to 10 uL, hit enter and hit enter again (when run is highlighted) 
Note: to view current step click screen button (to left of screen) 
 
15. When screen reads “forever” open thermocycler (don’t change any settings) 
16. Master mix (make enough for at least n+2 reactions) 
17. Master mix for each sample: 2.5 uL of combined Reverse Transcriptase buffer (green) 
and primer mix (purple) + 0.5 uL Reverse Transcriptase (red) 
Note: Be sure to mix RT buffer and primer mix vials! 
18. Add 3 uL of master mix to each sample and reclose caps 
19. Close thermocycler. 
20. Press enter  
21. The thermocycler should read “Go to next step”. Select yes using arrows and click enter 
to begin cycle. 
22. When cycle is complete, remove samples and store at -20 C. 
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B.27 RT-PCR 
Reagents:  
 Forward and Reverse Primers (order from IDT) 
 cDNA samples 
 FastStart Universal SYBR Green Master (Rox) (Roche) 
 TE Buffer 
o 10 mM TrisHCl 
o 1 mM EDTA (E5134-50g, Sigma) 
 RNAse Free water 
 Ice 
Supplies and equipment  
 Applied Biosystems 7900HT Fast Real-Time PCR 
 Ice bucket 
 1 mL microcentrifuge tubes 
 Auto-pipetters 
Procedure 
1. Put samples and Primers on ice 
2. Label 1 mL tubes (1 tube per sample + 1 tube per primer set) 
3. For new primers, reconstitute primers in TE buffer to 100x  (30 uM) 
Note: cDNA should not be more than 10% of total volume 
Primer Preparation  
4. Label a 1mL microcentrifuge tube for each primer set. 
5. Calculate the necessary volume of SYBR green and primers (V=5.2uL*#cDNA 
samples*#replicates*110%; each replicate for a 10 uL reaction requires 5 uL of SYBR 
green, 0.1 uL forward primer, 0.1 uL of reverse primer)  
6. To use electronic auto-pipette, pick up pipette (it should automatically turn on). Set 
volume- it will automatically go to the max number of samples it can run. To change the 
number of aliquots, after the volume is entered, hit reset and use the arrows to lower to 
the desired aliquot and press left or right bottom button to pull up initial volume of 
solution to be dispensed. Press left or right button to release first aliquot. A single high 
beep indicates that there is still enough solution for another sample. A high/high/low beep 
indicates that there isn’t enough solution for another sample. After high/high/low, hit the 
reset button to expel remaining fluid back into the stock solution. Wait a second after the 
high/high beep prior to trying to pull up more liquid (will have a slight vacuum which 
will result in air bubbles/extra fluid etc.) 
7. To each primer tube, add required volumes of SYBR green 
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8. Vortex primers set and add required volumes of forward and reverse primers to 
corresponding primer tube. Pipette/vortex to mix 
Sample Preparation 
9. To the 10 uL of cDNA in each sample tube, add enough water to dilute to sample # used 
in reverse transcription calculations.  
4.8 uL*# of replicates*# of primers*1.10 -10 uL = volume of water 
Plate Preparation (assumes primers run vertically and samples run across) 
10. Starting with the first primer (alphabetically), vortex the sample and then pipette 5.2 uL 
into each well of the first 2-3 columns (depending on # of replicates) snaking the way 
down to the bottom of the plate 
11. Starting with the next primer in the next empty column repeat step 10 
12. Continue the process until all primers are added to the plate 
13. Starting in the first row, vortex the first cDNA sample and add 4.8 uL to each well 
14. Repeat step 14 for each additional sample, moving to a new row each time. 
15. Once all samples are pipetted, take a sealing cover. Remove paper back and place the 
paper side down onto the plate. Use a squeegee to ensure seal.  
16. Tear off side flaps and cover in aluminum foil (to carry over to IGB). 
17. Remove foil, and place plate sealed side up in Centrifuge.  
18. Spin plate for 3 min at 2000 RPM. 
19. Log on to computer and fill out log book. 
20. Click on SDS 2.3 icon on desktop. 
21. Click on new document and click ok. 
22. Click add detectors on bottom right side of screen and click sort by group and select or 
enter genes to be detected. Click ok to add. 
23. Highlight the samples in the first 3 columns and select  
24. On the Thermal cycle screen, click on the line on the far right step and then click the add 
dissociation step button (bottom of the screen). 
25. Change the reaction volume to 10 uL. 
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26. Click open/close to extend tray 
27. Place the plate so that the A1 corner matches up with A1 marker on the tray. 
28. Save file in Harley folder and then click start run and click ok. 
29. The machine should now start performing PCR. 
30. When run is complete, save document. 
31. On the thermal cycle screen, click open/close to remove plate. 
32. Place plate in biowaste. 
33. Click open/close to close machine. 
34. Exit out of the program. 
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